## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :		(11) International Publication Number: WO 98/14601
C12N 15/82, 9/10, 15/54, 15/62, C12Q 1/68, C12N 1/21, A01H 5/00	A1	(43) International Publication Date: 9 April 1998 (09.04.98)
(21) International Application Number: PCT/US  (22) International Filing Date: 30 September 1997 (30)  (30) Priority Data: 60/026,855 30 September 1996 (30.09.9)  (71) Applicant: EXSEED GENETICS L.L.C. [US/US Food Science Building, Iowa State University, A 50011–1061 (US).	30.09.9 6) ( S]; 15'	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML,
<ul> <li>(72) Inventors: KEELING, Peter; 3409 Oakland Street, A 50014 (US). GUAN, Hanping; 1608 Crestwoo Ames, IA 50010 (US).</li> <li>(74) Agents: WINNER, Ellen, P. et al.; Greenlee, Wi Sullivan, P.C., Suite 201, 5370 Manhattan Circle, CO 80303 (US).</li> </ul>	d Circ	e, With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

#### (54) Title: ENCAPSULATION OF POLYPEPTIDES WITHIN THE STARCH MATRIX

#### (57) Abstract

Hybrid polypeptides are provided formed with encapsulating regions from genes that encode for anabolic proteins. More particularly, the present invention relates to recombinant nucleic acid molecules that code for genes which encapsulate an attached protein within a matrix; preferably, these genes encapsulate a desired ("payload") polypeptide within starch, and more specifically within the starch granule matrix. Expression vectors comprising these recombinant nucleic acid molecules, and hosts therefor, and more specifically the starch-bearing portions of such hosts, transformed with such vectors, are also provided. Preferably, grain containing a foreign protein encapsulated within the starch is provided, useful to produce mammalian, fish and avian food. The invention also encompasses methods of producing purified protein from starch and particularly from starch granules, and industrial uses of such protein.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

1

#### ENCAPSULATION OF POLYPEPTIDES WITHIN THE STARCH MATRIX

#### CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to provisional patent application serial No. 60/026,855 filed September 30, 1996. Said provisional application is incorporated herein by reference to the extent not inconsistent herewith.

#### BACKGROUND OF THE INVENTION

## Polysaccharide Enzymes

5

10

15

20

25

Both prokaryotic and eukaryotic cells use polysaccharide enzymes as a storage reserve. In the prokaryotic cell the primary reserve polysaccharide is glycogen. Although glycogen is similar to the starch found in most vascular plants it exhibits different chain lengths and degrees of polymerization. In many plants, starch is used as the primary reserve polysaccharide. Starch is stored in the various tissues of the starch bearing plant. Starch is made of two components in most instances; one is amylose and one is amylopectin. Amylose is formed as linear glucans and amylopectin is formed as branched chains of glucans. Typical starch has a ratio of 25% amylose to 75% amylopectin. Variations in the amylose to amylopectin ratio in a plant can effect the properties of the starch. Additionally starches from different plants often have different properties. Maize starch and potato starch appear to differ due to the presence or absence of phosphate groups. Certain plants' starch properties differ because of mutations that have been introduced into the plant genome. Mutant starches are well known in maize, rice and peas and the like.

The changes in starch branching or in the ratios of the starch components result in different starch characteristic. One characteristic of starch is the formation of starch granules which are formed particularly in leaves, roots, tubers and seeds. These granules are formed during the starch synthesis process. Certain synthases of starch, particularly

2

granule-bound starch synthase, soluble starch synthases and branching enzymes are proteins that are "encapsulated" within the starch granule when it is formed.

5

10

15

20

25

The use of cDNA clones of animal and bacterial glycogen synthases are described in International patent application publication number GB92/01881. The nucleotide and amino acid sequences of glycogen synthase are known from the literature. For example, the nucleotide sequence for the *E. coli* glgA gene encoding glycogen synthase can be retrieved from the GenBank/EMBL (SWISSPROT) database, accession number J02616 (Kumar et al., 1986, J. Biol. Chem., 261:16256-16259). *E. coli* glycogen biosynthetic enzyme structural genes were also cloned by Okita et al. (1981, J. Biol. Chem., 256(13):6944-6952). The glycogen synthase glgA structural gene was cloned from *Salmonella typhimurium* LT2 by Leung et al. (1987, J. Bacteriol., 169(9):4349-4354). The sequences of glycogen synthase from rabbit skeletal muscle (Zhang et al., 1989, FASEB J., 3:2532-2536) and human muscle (Browner et al., 1989, Proc. Natl. Acad. Sci., 86:1443-1447) are also known.

The use of cDNA clones of plant soluble starch synthases has been reported. The amino acid sequences of pea soluble starch synthase isoforms I and II were published by Dry et al. (1991, Plant Journal, 2:193202). The amino acid sequence of rice soluble starch synthase was described by Baba et al. (1993, Plant Physiology, ). This last sequence (rice SSTS) incorrectly cites the N-terminal sequence and hence is misleading. Presumably this is because of some extraction error involving a protease degradation or other inherent instability in the extracted enzyme. The correct N-terminal sequence (starting with AELSR) is present in what they refer to as the transit peptide sequence of the rice SSTS.

The sequence of maize branching enzyme I was investigated by Baba et al., 1991, BBRC, 181:8794. Starch branching enzyme II from maize endosperm was investigated by Fisher and Shrable (1993, Plant Physiol., 102:10451046). The use of cDNA clones of plant, bacterial and animal branching enzymes have been reported. The nucleotide and amino acid sequences for bacterial branching enzymes (BE) are known from the literature. For example, Kiel et al. cloned the branching enzyme gene glgB from Cyanobacterium synechococcussy PCC7942 (1989, Gene (Amst), 78(1):918) and from Bacillus

stearothermophilus (Kiel et al., 1991, Mol. Gen. Genet., 230(12):136-144). The genes glc3 and ghal of *S. cerevisiae* are allelic and encode the glycogen branching enzyme (Rowen et al., 1992, Mol. Cell Biol., 12(1):22-29). Matsumomoto et al. investigated glycogen branching enzyme from *Neurospora crassa* (1990, J. Biochem., 107:118-122). The GenBank/EMBL database also contains sequences for the *E. coli* glgB gene encoding branching enzyme.

5

10

15

20

25

30

Starch synthase (EC 2.4.1.11) elongates starch molecules and is thought to act on both amylose and amylopectin. Starch synthase (STS) activity can be found associated both with the granule and in the stroma of the plastid. The capacity for starch association of the bound starch synthase enzyme is well known. Various enzymes involved in starch biosynthesis are now known to have differing propensities for binding as described by Mu-Forster et al. (1996, Plant Phys. 111: 821-829). Granule-bound starch synthase (GBSTS) activity is strongly correlated with the product of the waxy gene (Shure et al., 1983, Cell 35: 225-233). The synthesis of amylose in a number of species such as maize, rice and potato has been shown to depend on the expression of this gene (Tsai, 1974, Biochem Gen 11: 83-96; Hovenkamp-Hermelink et al., 1987, Theor. Appl. Gen. 75: 217-221). Visser et al. described the molecular cloning and partial characterization of the gene for granule-bound starch synthase from potato (1989, Plant Sci. 64(2):185192). Visser et al. have also described the inhibition of the expression of the gene for granule-bound starch synthase in potato by antisense constructs (1991, Mol. Gen. Genet. 225(2):289296).

The other STS enzymes have become known as soluble starch synthases, following the pioneering work of Frydman and Cardini (Frydman and Cardini, 1964, Biochem. Biophys. Res. Communications 17: 407-411). Recently, the appropriateness of the term "soluble" has become questionable in light of discoveries that these enzymes are associated with the granule as well as being present in the soluble phase (Denyer et al., 1993, Plant J. 4: 191-198; Denyer et al., 1995, Planta 97: 57-62; Mu-Forster et al., 1996, Plant Physiol. 111: 821-829). It is generally believed that the biosynthesis of amylopectin involves the interaction of soluble starch synthases and starch branching enzymes. Different isoforms of soluble starch synthase have been identified and cloned in pea (Denyer and Smith, 1992, Planta 186: 609-617; Dry et al., 1992, Planta Journal, 2: 193-

5

10

15

20

25

202), potato (Edwards et al., 1995, Plant Physiol 112: 89-97; Marshall et al., 1996, Plant Cell 8: 1121-1135) and in rice (Baba et al., 1993, Plant Physiol. 103: 565-573), while barley appears to contain multiple isoforms, some of which are associated with starch branching enzyme (Tyynela and Schulman, 1994, Physiol. Plantarum 89: 835-841). A common characteristic of STS clones is the presence of a KXGGLGDV consensus sequence which is believed to be the ADP-Glc binding site of the enzyme (Furukawa et al., 1990, J Biol Chem 265: 2086-2090; Furukawa et al., 1993, J. Biol. Chem. 268: 23837-23842).

In maize, two soluble forms of STS, known as isoforms I and II, have been identified (Macdonald and Preiss, 1983, Plant Physiol. 73: 175-178; Boyer and Preiss, 1978, Carb. Res. 61: 321-334; Pollock and Preiss, 1980, Arch Biochem. Biophys. 204: 578-588; Macdonald and Preiss, 1985 Plant Physiol. 78: 849-852; Dang and Boyer, 1988, Phytochemistry 27: 1255-1259; Mu et al., 1994, Plant J. 6: 151-159), but neither of these has been cloned. STSI activity of maize endosperm was recently correlated with a 76-kDa polypeptide found in both soluble and granule-associated fractions (Mu et al., 1994, Plant J. 6: 151-159). The polypeptide identity of STSII remains unknown. STSI and II exhibit different enzymological characteristics. STSI exhibits primer-independent activity whereas STSII requires glycogen primer to catalyze glucosyl transfer. Soluble starch synthases have been reported to have a high flux control coefficient for starch deposition (Jenner et al., 1993, Aust. J. Plant Physiol. 22: 703-709; Keeling et al., 1993, Planta 191: 342-348) and to have unusual kinetic properties at elevated temperatures (Keeling et al., 1995, Aust. J. Plant Physiol. 21 807-827). The respective isoforms in maize exhibit significant differences in both temperature optima and stability.

Plant starch synthase (and *E. coli* glycogen synthase) sequences include the sequence KTGGL which is known to be the ADPG binding domain. The genes for any such starch synthase protein may be used in constructs according to this invention.

Branching enzyme [α1,4Dglucan: α1,4Dglucan 6D(α1,4Dglucano) transferase (E.C. 2.4.1.18)], sometimes called Q-enzyme, converts amylose to amylopectin. A segment of a α1,4Dglucan chain is transferred to a primary hydroxyl group in a similar glucan chain.

5

10

15

20

25

Bacterial branching enzyme genes and plant sequences have been reported (rice endosperm: Nakamura et al., 1992, Physiologia Plantarum, 84:329-335 and Nakamura and Yamanouchi, 1992, Plant Physiol., 99:1265-1266; pea: Smith, 1988, Planta, 175:270-279 and Bhattacharyya et al., 1989, J. Cell Biochem., Suppl. 13D:331; maize endosperm: Singh and Preiss, 1985, Plant Physiology, 79:34-40; VosScherperkeuter et al., 1989, Plant Physiology, 90:75-84; potato: Kossmann et al., 1991, Mol. Gen. Genet., 230(12):39-44; cassava: Salehuzzaman and Visser, 1992, Plant Mol Biol, 20:809-819).

In the area of polysaccharide enzymes there are reports of vectors for engineering modification in the starch pathway of plants by use of a number of starch synthesis genes in various plant species. That some of these polysaccharide enzymes bind to cellulose or starch or glycogen is well known. One specific patent example of the use of a polysaccharide enzyme shows the use of glycogen biosynthesis enzymes to modify plant starch. In U.S. patent 5,349,123 to Shewmaker a vector containing DNA to form glycogen biosynthetic enzymes within plant cells is taught. Specifically, this patent refers to the changes in potato starch due to the introduction of these enzymes. Other starch synthesis genes and their use have also been reported.

## Hybrid (fusion) Peptides

Hybrid proteins (also called "fusion proteins") are polypeptide chains that consist of two or more proteins fused together into a single polypeptide. Often one of the proteins is a ligand which binds to a specific receptor cell. Vectors encoding fusion peptides are primarily used to produce foreign proteins through fermentation of microbes. The fusion proteins produced can then be purified by affinity chromatography. The binding portion of one of the polypeptides is used to attach the hybrid polypeptide to an affinity matrix. For example, fusion proteins can be formed with beta galactosidase which can be bound to a column. This method has been used to form viral antigens.

Another use is to recover one of the polypeptides of the hybrid polypeptide.

Chemical and biological methods are known for cleaving the fused peptide. Low pH can be used to cleave the peptides if an acid-labile aspartyl-proline linkage is employed between the peptides and the peptides are not affected by the acid. Hormones have been

6

cleaved with cyanobromide. Additionally, cleavage by site-specific proteolysis has been reported. Other methods of protein purification such as ion chromatography have been enhanced with the use of polyarginine tails which increase overall basicity of the protein thus enhancing binding to ion exchange columns.

5

10

A number of patents have outlined improvements in methods of making hybrid peptides or specific hybrid peptides targeted for specific uses. US patent 5,635,599 to Pastan et al. outlines an improvement of hybrid proteins. This patent reports a circularly permuted ligand as part of the hybrid peptide. This ligand possesses specificity and good binding affinity. Another improvement in hybrid proteins is reported in U.S. patent 5,648,244 to Kuliopulos. This patent describes a method for producing a hybrid peptide with a carrier peptide. This nucleic acid region, when recognized by a restriction endonuclease, creates a nonpalindromic 3-base overhang. This allows the vector to be cleaved.

15

An example of a specifically targeted hybrid protein is reported in U.S. patent 5,643,756. This patent reports a vector for expression of glycosylated proteins in cells. This hybrid protein is adapted for use in proper immunoreactivity of HIV gp120. The isolation of gp120 domains which are highly glycosylated is enhanced by this reported vector.

20

U.S. patent 5,202,247 and 5,137,819 discuss hybrid proteins having polysaccharide binding domains and methods and compositions for preparation of hybrid proteins which are capable of binding to a polysaccharide matrix. U.S. patent 5,202,247 specifically teaches a hybrid protein linking a cellulase binding region to a peptide of interest. The patent specifies that the hybrid protein can be purified after expression in a bacterial host by affinity chromatography on cellulose.

25

The development of genetic engineering techniques has made it possible to transfer genes from various organisms and plants into other organisms or plants. Although starch has been altered by transformation and mutagenesis in the past there is still a need for further starch modification. To this end vectors that provide for encapsulation of desired

WO 98/14601

5

10

15

20

25

PCT/US97/17555

7

amino acids or peptides within the starch and specifically within the starch granule are desirable. The resultant starch is modified and the tissue from the plant carrying the vector is modified.

#### SUMMARY OF THE INVENTION

This invention provides a hybrid polypeptide comprising a starch-encapsulating region (SER) from a starch-binding enzyme fused to a payload polypeptide which is not endogenous to said starch-encapsulating region, i.e. does not naturally occur linked to the starch-encapsulating region. The hybrid polypeptide is useful to make modified starches comprising the payload polypeptide. Such modified starches may be used to provide grain feeds enriched in certain amino acids. Such modified starches are also useful for providing polypeptides such as hormones and other medicaments, e.g. insulin, in a starch-encapsulated form to resist degradation by stomach acids. The hybrid polypeptides are also useful for producing the payload polypeptides in easily-purified form. For example, such hybrid polypeptides produced by bacterial fermentation, or in grains or animals, may be isolated and purified from the modified starches with which they are associated by art-known techniques.

The term "polypeptide" as used herein means a plurality of identical or different amino acids, and also encompasses proteins.

The term "hybrid polypeptide" means a polypeptide composed of peptides or polypeptides from at least two different sources, e.g. a starch-encapsulating region of a starch-binding enzyme, fused to another polypeptide such as a hormone, wherein at least two component parts of the hybrid polypeptide do not occur fused together in nature.

The term "payload polypeptide" means a polypeptide not endogenous to the starchencapsulating region whose expression is desired in association with this region to express a modified starch containing the payload polypeptide. When the payload polypeptide is to be used to enhance the amino acid content of particular amino acids in the modified starch, it preferably consists of not more than three different types of amino acids selected from the group consisting of: Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val.

5

When the payload polypeptide is to be used to supply a biologically active polypeptide to either the host organism or another organism, the payload polypeptide may be a biologically active polypeptide such as a hormone, e.g., insulin, a growth factor, e.g. somatotropin, an antibody, enzyme, immunoglobulin, or dye, or may be a biologically active fragment thereof as is known to the art. So long as the polypeptide has biological activity, it does not need to be a naturally-occurring polypeptide, but may be mutated, truncated, or otherwise modified. Such biologically active polypeptides may be modified polypeptides, containing only biologically-active portions of biologically-active polypeptides. They may also be amino acid sequences homologous to naturally-occurring biologically-active amino acid sequences (preferably at least about 75% homologous) which retain biological activity.

15

10

The starch-encapsulating region of the hybrid polypeptide may be a starch-encapsulating region of any starch-binding enzyme known to the art, e.g. an enzyme selected from the group consisting of soluble starch synthase I, soluble starch synthase II, soluble starch synthase III, granule-bound starch synthase, branching enzyme I, branching enzyme IIa, branching enzyme IIBb and glucoamylase polypeptides.

20

When the hybrid polypeptide is to be used to produce payload polypeptide in pure or partially purified form, the hybrid polypeptide preferably comprises a cleavage site between the starch-encapsulating region and the payload polypeptide. The method of isolating the purified payload polypeptide then includes the step of contacting the hybrid polypeptide with a cleaving agent specific for that cleavage site.

25

This invention also provides recombinant nucleic acid (RNA or DNA) molecules encoding the hybrid polypeptides. Such recombinant nucleic acid molecules preferably comprise control sequences adapted for expression of the hybrid polypeptide in the

9

selected host. The term "control sequences" includes promoters, introns, preferred codon sequences for the particular host organism, and other sequences known to the art to affect expression of DNA or RNA in particular hosts. The nucleic acid sequences encoding the starch-encapsulating region and the payload polypeptide may be naturally-occurring nucleic acid sequences, or biologically-active fragments thereof, or may be biologically-active sequences homologous to such sequences, preferably at least about 75% homologous to such sequences.

5

10

15

20

25

Host organisms include bacteria, plants, and animals. Preferred hosts are plants. Both monocotyledonous plants (monocots) and dicotyledonous plants (dicots) are useful hosts for expressing the hybrid polypeptides of this invention.

This invention also provides expression vectors comprising the nucleic acids encoding the hybrid proteins of this invention. These expression vectors are used for transforming the nucleic acids into host organisms and may also comprise sequences aiding in the expression of the nucleic acids in the host organism. The expression vectors may be plasmids, modified viruses, or DNA or RNA molecules, or other vectors useful in transformation systems known to the art.

By the methods of this invention, transformed cells are produced comprising the recombinant nucleic acid molecules capable of expressing the hybrid polypeptides of this invention. These may prokaryotic or eukaryotic cells from one-celled organisms, plants or animals. They may be bacterial cells from which the hybrid polypeptide may be harvested. Or, they may be plant cells which may be regenerated into plants from which the hybrid polypeptide may be harvested, or, such plant cells may be regenerated into fertile plants with seeds containing the nucleic acids encoding the hybrid polypeptide. In a preferred embodiment, such seeds contain modified starch comprising the payload polypeptide.

The term "modified starch" means the naturally-occurring starch has been modified to comprise the payload polypeptide.

WO 98/14601

A method of targeting digestion of a payload polypeptide to a particular phase of the digestive process, e.g., preventing degradation of a payload polypeptide in the stomach of an animal; is also provided comprising feeding the animal a modified starch of this invention comprising the payload polypeptide, whereby the polypeptide is protected by the starch from degradation in the stomach of the animal. Alternatively, the starch may be one known to be digested in the stomach to release the payload polypeptide there.

Preferred recombinant nucleic acid molecules of this invention comprise DNA encoding starch-encapsulating regions selected from the starch synthesizing gene sequences set forth in the tables hereof.

10

5

Preferred plasmids of this invention are adapted for use with specific hosts.

Plasmids comprising a promoter, a plastid-targeting sequence, a nucleic acid sequence encoding a starch-encapsulating region, and a terminator sequence, are provided herein.

Such plasmids are suitable for insertion of DNA sequences encoding payload polypeptides and starch-encapsulating regions for expression in selected hosts.

15

Plasmids of this invention can optionally include a spacer or a linker unit proximate the fusion site between nucleic acids encoding the SER and the nucleic acids encoding the payload polypeptide. This invention includes plasmids comprising promoters adapted for a prokaryotic or eukaryotic hosts. Such promoters may also be specifically adapted for expression in monocots or in dicots.

20

A method of forming peptide-modified starch of this invention includes the steps of: supplying a plasmid having a promoter associated with a nucleic acid sequence encoding a starch-encapsulating region, the nucleic acid sequence encoding the starch-encapsulating region being connected to a nucleic acid region encoding a payload polypeptide, and transforming a host with the plasmid whereby the host expresses peptide-modified starch.

25

This invention furthermore comprises starch-bearing grains comprising: an embryo, nutritive tissues; and, modified starch granules having encapsulated therein a protein that is

not endogenous to starch granules of said grain which are not modified. Such starchbearing grains may be grains wherein the embryo is a maize embryo, a rice embryo, or a wheat embryo.

11

PCT/US97/17555

All publications referred to herein are incorporated by reference to the extent not 5 inconsistent herewith.

## BRIEF DESCRIPTION OF THE DRAWINGS

- FIG. 1a shows the plasmid pEXS114 which contains the synthetic GFP (Green Fluorescent Protein) subcloned into pBSK from Stratagene.
  - FIG. 1b shows the plasmid pEXS115.
- 10 FIG. 2a. shows the waxy gene with restriction sites subcloned into a commercially available plasmid.
  - FIG. 2b shows the p ET-21A plasmid commercially available from Novagen having the GFP fragment from pEXS115 subcloned therein.
    - FIG. 3a shows pEXS114 subcloned into pEXSWX, and the GFP-FLWX map.
- 15 FIG. 3b shows the GFP-Bam HIWX plasmid.
  - FIG. 4 shows the SGFP fragment of pEXS115 subcloned into pEXSWX, and the GFP-NcoWX map.
    - FIG. 5 shows a linear depiction of a plasmid that is adapted for use in monocots.
    - FIG. 6 shows the plasmid pEXS52.

FIG. 7 shows the six introductory plasmids used to form pEXS51 and pEX560.

FIG. 7a shows pEXS adh1. FIG. 7b shows pEXS adh1-nos3'. FIG. 7c shows pEXS33.

FIG. 7d shows pEXS10zp. FIG. 7e shows pEXS10zp-adh1. FIG. 7f shows pEXS10zp-adh1-nos3'.

FIGS. 8a and 8b show the plasmids pEXS50 and pEXS51, respectively, containing the MS-SIII gene which is a starch-soluble synthase gene.

5

10

15

20

25

FIG. 9a shows the plasmid pEXS60 which excludes the intron shown in pEXS50, and FIG. 9b shows the plasmid pEXS61 which excludes the intron shown in pEXS60.

## **DETAILED DESCRIPTION**

The present invention provides, broadly, a hybrid polypeptide, a method for making a hybrid polypeptide, and nucleic acids encoding the hybrid polypeptide. A hybrid polypeptide consists of two or more subparts fused together into a single peptide chain. The subparts can be amino acids or peptides or polypeptides. One of the subparts is a starch-encapsulating region. Hybrid polypeptides may thus be targeted into starch granules produced by organisms expressing the hybrid polypeptides.

A method of making the hybrid polypeptides within cells involves the preparation of a DNA construct comprising at least a fragment of DNA encoding a sequence which functions to bind the expression product of attached DNA into a granule of starch, ligated to a DNA sequence encoding the polypeptide of interest (the payload polypeptide). This construct is expressed within a eukaryotic or prokaryotic cell. The hybrid polypeptide can be used to produce purified protein or to immobilize a protein of interest within the protection of a starch granule, or to produce grain that contains foreign amino acids or peptides.

The hybrid polypeptide according to the present invention has three regions.

Payload Peptide	Central Site	Starch-encapsulating
(X)	(CS)*	region (SER)

X is any amino acid or peptide of interest.

\* optional component.

WO 98/14601

The gene for X can be placed in the 5' or 3' position within the DNA construct described below.

13

PCT/US97/17555

5

10

CS is a central site which may be a leaving site, a cleavage site, or a spacer, as is known to the art. A cleavage site is recognized by a cleaving enzyme. A cleaving enzyme is an enzyme that cleaves peptides at a particular site. Examples of chemicals and enzymes that have been employed to cleave polypeptides include thrombin, trypsin, cyanobromide, formic acid, hydroxyl amine, collagenase, and alasubtilisin. A spacer is a peptide that joins the peptides comprising the hybrid polypeptide. Usually it does not have any specific activity other than to join the peptides or to preserve some minimum distance or to influence the folding, charge or water acceptance of the protein. Spacers may be any peptide sequences not interfering with the biological activity of the hybrid polypeptide.

15

20

25

The starch-encapsulating region (SER) is the region of the subject polypeptide that has a binding affinity for starch. Usually the SER is selected from the group consisting of peptides comprising starch-binding regions of starch synthases and branching enzymes of plants, but can include starch binding domains from other sources such as glucoamylase and the like. In the preferred embodiments of the invention, the SER includes peptide products of genes that naturally occur in the starch synthesis pathway. This subset of preferred SERs is defined as starch-forming encapsulating regions (SFER). A further subset of SERs preferred herein is the specific starch-encapsulating regions (SSER) from the specific enzymes starch synthase (STS), granule-bound starch synthase (GBSTS) and branching enzymes (BE) of starch-bearing plants. The most preferred gene product from this set is the GBSTS. Additionally, starch synthase I and branching enzyme II are useful gene products. Preferably, the SER (and all the subsets discussed above) are truncated versions of the full length starch synthesizing enzyme gene such that the truncated portion includes the starch-encapsulating region.

5

10

15

20

The DNA construct for expressing the hybrid polypeptide within the host, broadly is as follows:

Promoter Intron* Transit Peptide Coding Region*	x	SER	Terminator
---	---	-----	------------

<sup>\*</sup> optional component. Other optional components can also be used.

As is known to the art, a promoter is a region of DNA controlling transcription. Different types of promoters are selected for different hosts. Lac and T7 promoters work well in prokaryotes, the 35S CaMV promoter works well in dicots, and the polyubiquitin promoter works well in many monocots. Any number of different promoters are known to the art and can be used within the scope of this invention.

Also as is known to the art, an intron is a nucleotide sequence in a gene that does not code for the gene product. One example of an intron that often increases expression in monocots is the Adhl intron. This component of the construct is optional.

The transit peptide coding region is a nucleotide sequence that encodes for the translocation of the protein into organelles such as plastids. It is preferred to choose a transit peptide that is recognized and compatible with the host in which the transit peptide is employed. In this invention the plastid of choice is the amyloplast.

It is preferred that the hybrid polypeptide be located within the amyloplast in cells such as plant cells which synthesize and store starch in amyloplasts. If the host is a bacterial or other cell that does not contain an amyloplast, there need not be a transit peptide coding region.

A terminator is a DNA sequence that terminates the transcription.

X is the coding region for the payload polypeptide, which may be any polypeptide of interest, or chains of amino acids. It may have up to an entire sequence of a known polypeptide or comprise a useful fragment thereof. The payload polypeptide may be a

polypeptide, a fragment thereof, or biologically active protein which is an enzyme, hormone, growth factor, immunoglobulin, dye, etc. Examples of some of the payload polypeptides that can be employed in this invention include, but are not limited to, prolactin (PRL), serum albumin, growth factors and growth hormones, i.e., somatotropin. Serum albumins include bovine, ovine, equine, avian and human serum albumin. Growth factors include epidermal growth factor (EGF), insulin-like growth factor I (IGF-I), insulinlike growth factor II (IGF-II), fibroblast growth factor (FGF), transforming growth factor alpha (TGF-alpha), transforming growth factor beta (TGF-beta), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and recombinant human insulin-like growth factors I (rHuIGF-I) and II (rHuIGF-II). Somatotropins which can be employed to practice this invention include, but are not limited to, bovine, porcine, ovine, equine, avian and human somatotropin. Porcine somatotropin includes delta-7 recombinant porcine somatotropin, as described and claimed in European Patent Application Publication No. 104,920 (Biogen). Preferred payload polypeptides are somatotropin, insulin A and B chains, calcitonin, beta endorphin, urogastrone, beta globin, myoglobin, human growth hormone, angiotensin, proline, proteases, beta-galactosidase, and cellulases.

The hybrid polypeptide, the SER region and the payload polypeptides may also include post-translational modifications known to the art such as glycosylation, acylation, and other modifications not interfering with the desired activity of the polypeptide.

## Developing a Hybrid polypeptide

5

10

15

20

25

30

The SER region is present in genes involved in starch synthesis. Methods for isolating such genes include screening from genomic DNA libraries and from cDNA libraries. Genes can be cut and changed by ligation, mutation agents, digestion, restriction and other such procedures, e.g., as outlined in Maniatis et al., Molecular Cloning, Cold Spring Harbor Labs, Cold Spring Harbor, N.Y. Examples of excellent starting materials for accessing the SER region include, but are not limited to, the following: starch synthases I, II, III, IV, Branching Enzymes I, IIA and B and granule-bound starch synthase (GBSTS). These genes are present in starch-bearing plants such as rice, maize, peas, potatoes, wheat, and the like. Use of a probe of SER made from genomic DNA or cDNA or mRNA or antibodies raised against the SER allows for the isolation and identification

5

10

15

20

25

of useful genes for cloning. The starch enzyme-encoding sequences may be modified as long as the modifications do not interfere with the ability of the SER region to encapsulate associated polypeptides.

16

When genes encoding proteins that are encapsulated into the starch granule are located, then several approaches to isolation of the SER can be employed, as is known to the art. One method is to cut the gene with restriction enzymes at various sites, deleting sections from the N-terminal end and allowing the resultant protein to express. The expressed truncated protein is then run on a starch gel to evaluate the association and dissociation constant of the remaining protein. Marker genes known to the art, e.g., green fluorescent protein gene, may be attached to the truncated protein and used to determine the presence of the marker gene in the starch granule.

Once the SER gene sequence region is isolated it can be used in making the gene fragment sequence that will express the payload polypeptide encapsulated in starch. The SER gene sequence and the gene sequence encoding the payload polypeptide can be ligated together. The resulting fused DNA can then be placed in a number of vector constructs for expression in a number of hosts. The preferred hosts form starch granules in plastids, but the testing of the SER can be readily performed in bacterial hosts such as *E.coli*.

The nucleic acid sequence coding for the payload polypeptide may be derived from DNA, RNA, genomic DNA, cDNA, mRNA or may be synthesized in whole or in part. The sequence of the payload polypeptide can be manipulated to contain mutations such that the protein produced is a novel, mutant protein, so long as biological function is maintained.

When the payload polypeptide-encoding nucleic acid sequence is ligated onto the SER-encoding sequence, the gene sequence for the payload polypeptide is preferably attached at the end of the SER sequence coding for the N-terminus. Although the N-terminus end is preferred, it does not appear critical to the invention whether the payload polypeptide is ligated onto the N-terminus end or the C-terminus end of the SER. Clearly,

the method of forming the recombinant nucleic acid molecules of this invention, whether synthetically, or by cloning and ligation, is not critical to the present invention.

17

The central region of the hybrid polypeptide is optional. For some applications of the present invention it can be very useful to introduce DNA coding for a convenient protease cleavage site in this region into the recombinant nucleic acid molecule used to express the hybrid polypeptide. Alternatively, it can be useful to introduce DNA coding for an amino acid sequence that is pH-sensitive to form the central region. If the use of the present invention is to develop a pure protein that can be extracted and released from the starch granule by a protease or the like, then a protease cleavage site is useful. Additionally, if the protein is to be digested in an animal then a protease cleavage site may be useful to assist the enzymes in the digestive tract of the animal to release the protein from the starch. In other applications and in many digestive uses the cleavage site would be superfluous.

The central region site may comprise a spacer. A spacer refers to a peptide that joins the proteins comprising a hybrid polypeptide. Usually it does not have any specific activity other than to join the proteins, to preserve some minimum distance, to influence the folding, charge or hydrophobic or hydrophilic nature of the hybrid polypeptide.

#### **Construct Development**

5

10

15

20

25

Once the ligated DNA which encodes the hybrid polypeptide is formed, then cloning vectors or plasmids are prepared which are capable of transferring the DNA to a host for expressing the hybrid polypeptides. The recombinant nucleic acid sequence of this invention is inserted into a convenient cloning vector or plasmid. For the present invention the preferred host is a starch granule-producing host. However, bacterial hosts can also be employed. Especially useful are bacterial hosts that have been transformed to contain some or all of the starch-synthesizing genes of a plant. The ordinarily skilled person in the art understands that the plasmid is tailored to the host. For example, in a bacterial host transcriptional regulatory promoters include lac, TAC, trp and the like. Additionally, DNA coding for a transit peptide most likely would not be used and a secretory leader that is upstream from the structural gene may be used to get the

WO 98/14601

PCT/US97/17555

polypeptide into the medium. Alternatively, the product is retained in the host and the host is lysed and the product isolated and purified by starch extraction methods or by binding the material to a starch matrix (or a starch-like matrix such as amylose or amylopectin, glycogen or the like) to extract the product.

5

10

The preferred host is a plant and thus the preferred plasmid is adapted to be useful in a plant. The plasmid should contain a promoter, preferably a promoter adapted to target the expression of the protein in the starch-containing tissue of the plant. The promoter may be specific for various tissues such as seeds, roots, tubers and the like; or, it can be a constitutive promoter for gene expression throughout the tissues of the plant. Well-known promoters include the 10 kD zein (maize) promoter, the CAB promoter, patastin, 35S and 19S cauliflower mosaic virus promoters (very useful in dicots), the polyubiquitin promoter (useful in monocots) and enhancements and modifications thereof known to the art.

15

The cloning vector may contain coding sequences for a transit peptide to direct the plasmid into the correct location. Examples of transit peptide-coding sequences are shown in the sequence tables. Coding sequences for other transit peptides can be used. Transit peptides naturally occurring in the host to be used are preferred. Preferred transit peptide coding regions for maize are shown in the tables and figures hereof. The purpose of the transit peptide is to target the vector to the correct intracellular area.

20

25

Attached to the transit peptide-encoding sequence is the DNA sequence encoding the N-terminal end of the payload polypeptide. The direction of the sequence encoding the payload polypeptide is varied depending on whether sense or antisense transcription is desired. DNA constructs of this invention specifically described herein have the sequence encoding the payload polypeptide at the N- terminus end but the SER coding region can also be at the N-terminus end and the payload polypeptide sequence following. At the end of the DNA construct is the terminator sequence. Such sequences are well known in the art.

The cloning vector is transformed into a host. Introduction of the cloning vector, preferably a plasmid, into the host can be done by a number of transformation techniques known to the art. These techniques may vary by host but they include microparticle bombardment, micro injection, *Agrobacterium* transformation, "whiskers" technology (U.S. Patent Nos. 5,302,523 and 5,464,765), electroporation and the like. If the host is a plant, the cells can be regenerated to form plants. Methods of regenerating plants are known in the art. Once the host is transformed and the proteins expressed therein, the presence of the DNA encoding the payload polypeptide in the host is confirmable. The presence of expressed proteins may be confirmed by Western Blot or ELISA or as a result of a change in the plant or the cell.

19

## Uses of Encapsulated Protein

5

10

15

20

25

There are a number of applications of this invention. The hybrid polypeptide can be cleaved in a pure state from the starch (cleavage sites can be included) and pure protein can be recovered. Alternatively, the encapsulated payload polypeptide within the starch can be used in raw form to deliver protein to various parts of the digestive tract of the consuming animal ("animal" shall include mammals, birds and fish). For example if the starch in which the material is encapsulated is resistant to digestion then the protein will be released slowly into the intestine of the animal, therefore avoiding degradation of the valuable protein in the stomach. Amino acids such as methionine and lysine may be encapsulated to be incorporated directly into the grain that the animal is fed thus eliminating the need for supplementing the diet with these amino acids in other forms.

The present invention allows hormones, enzymes, proteins, proteinaceous nutrients and proteinaceous medicines to be targeted to specific digestive areas in the digestive tracts of animals. Proteins that normally are digested in the upper digestive tract encapsulated in starch are able to pass through the stomach in a nondigested manner and be absorbed intact or in part by the intestine. If capable of passing through the intestinal wall, the payload polypeptides can be used for medicating an animal, or providing hormones such as growth factors, e.g., somatotropin, for vaccination of an animal or for enhancing the nutrients available to an animal.

20

If the starch used is not resistant to digestion in the stomach (for example the sugary 2 starch is highly digestible), then the added protein can be targeted to be absorbed in the upper digestive tract of the animal. This would require that the host used to produce the modified starch be mutated or transformed to make sugary 2 type starch. The present invention encompasses the use of mutant organisms that form modified starch as hosts. Some examples of these mutant hosts include rice and maize and the like having sugary 1, sugary 2, brittle, shrunken, waxy, amylose extender, dull, opaque, and floury mutations, and the like. These mutant starches and starches from different plant sources have different levels of digestibility. Thus by selection of the host for expression of the DNA and of the animal to which the modified starch is fed, the hybrid polypeptide can be digested where it is targeted. Different proteins are absorbed most efficiently by different parts of the body. By encapsulating the protein in starch that has the selected digestibility, the protein can be supplied anywhere throughout the digestive tract and at specific times during the digestive process.

15

20

5

10

Another of the advantages of the present invention is the ability to inhibit or express differing levels of glycosylation of the desired polypeptide. The encapsulating procedure may allow the protein to be expressed within the granule in a different glycosylation state than if expressed by other DNA molecules. The glycosylation will depend on the amount of encapsulation, the host employed and the sequence of the polypeptide.

25

Improved crops having the above-described characteristics may be produced by genetic manipulation of plants known to possess other favorable characteristics. By manipulating the nucleotide sequence of a starch-synthesizing enzyme gene, it is possible to alter the amount of key amino acids, proteins or peptides produced in a plant. One or more genetically engineered gene constructs, which may be of plant, fungal, bacterial or animal origin, may be incorporated into the plant genome by sexual crossing or by transformation. Engineered genes may comprise additional copies of wildtype genes or may encode modified or allelic or alternative enzymes with new properties. Incorporation of such gene construct(s) may have varying effects depending on the amount and type of

gene(s) introduced (in a sense or antisense orientation). It may increase the plant's capacity to produce a specific protein, peptide or provide an improved amino acid balance.

## Cloning Enzymes Involved in Starch Biosynthesis

5

10

15

20

25

Known cloning techniques may be used to provide the DNA constructs of this invention. The source of the special forms of the SSTS, GBSTS, BE, glycogen synthase (GS), amylopectin, or other genes used herein may be any organism that can make starch or glycogen. Potential donor organisms are screened and identified. Thereafter there can be two approaches: (a) using enzyme purification and antibody/sequence generation following the protocols described herein; (b) using SSTS, GBSTS, BE, GS, amylopectin or other cDNAs as heterologous probes to identify the genomic DNAs for SSTS, GBSTS, BE, GS, amylopectin or other starch-encapsulating enzymes in libraries from the organism concerned. Gene transformation, plant regeneration and testing protocols are known to the art. In this instance it is necessary to make gene constructs for transformation which contain regulatory sequences that ensure expression during starch formation. These regulatory sequences are present in many small grains and in tubers and roots. For example these regulatory sequences are readily available in the maize endosperm in DNA encoding Granule Bound Starch Synthesis (GBSTS), Soluble Starch Synthases (SSTS) or Branching Enzymes (BE) or other maize endosperm starch synthesis pathway enzymes. These regulatory sequences from the endosperm ensure protein expression at the correct developmental time (e.g., ADPG pyrophosphorylase).

In this method we measure starch-binding constants of starch-binding proteins using native protein electrophoresis in the presence of suitable concentrations of carbohydrates such as glycogen or amylopectin. Starch-encapsulating regions can be elucidated using site-directed mutagenesis and other genetic engineering methods known to those skilled in the art. Novel genetically-engineered proteins carrying novel peptides or amino acid combinations can be evaluated using the methods described herein.

22

#### **EXAMPLES**

## Example One:

5

10

15

## Method for Identification of Starch-encapsulating Proteins

#### Starch-Granule Protein Isolation:

Homogenize 12.5 g grain in 25 ml Extraction buffer (50 mM Tris acetate, pH 7.5, 1 mM EDTA, 1 mM DTT for 3 x 20 seconds in Waring blender with 1 min intervals between blending). Keep samples on ice. Filter through mira cloth and centrifuge at 6,000 rpm for 30 min. Discard supernatant and scrape off discolored solids which overlay white starch pellet. Resuspend pellet in 25 ml buffer and recentrifuge. Repeat washes twice more. Resuspend washed pellet in -20°C acetone, allow pellet to settle at -20°C. Repeat. Dry starch under stream of air. Store at -20°C.

## Protein Extraction:

Mix 50 mg starch with 1 ml 2% SDS in eppendorf. Vortex, spin at 18,000 rpm, 5 min, 4°C. Pour off supernatant. Repeat twice. Add 1 ml sample buffer (4 ml distilled water, 1 ml 0.5 M Tris-HCl, pH 6.8, 0.8 ml glycerol, 1.6 ml 10% SDS, 0.4 ml B-mercaptoethanol, 0.2 ml 0.5% bromphenol blue). Boil eppendorf for 10 min with hole in lid. Cool, centrifuge 10,000 rpm for 10 min. Decant supernatant into new eppendorf. Boil for 4 minutes with standards. Cool.

## SDS-Page Gels: (non-denaturing)

20		10% Resolve	4% Stack
	Acryl/Bis 40% stock	2.5 ml	1.0 ml
	1.5 M Tris pH 8.8	2.5 ml	•
	0.5 M Tris pH 8.8	-	2.5 ml
	10% SDS	100 μ <b>l</b>	100 μ1
25	Water	4.845 ml	6.34 ml
	Degas 15 min add fresh		
	10% Ammonium Persulfate	50 μl	50 μl
	TEMED	5μi	10 μl

PCT/US97/17555 WO 98/14601

Mini-Protean II Dual Slab Cell; 3.5 ml of Resolve buffer per gel. 4% Stack is poured on top. The gel is run at 200V constant voltage. 10 x Running buffer (250 mM Tris, 1.92 M glycine, 1% SDS, pH 8.3).

23

## Method of Measurement of Starch-Encapsulating Regions:

#### 5 Solutions:

25

50 mM Tris-acetate pH 7.5, 10 mM EDTA, 10% Extraction Buffer:

sucrose, 2.5 mM DTT-fresh.

Stacking Buffer: 0.5 M Tris-HCl, pH 6.8

1.5 M Tris-HCl, pH 8.8 Resolve Buffer:

30.3 g Tris + 144 g Glycine qs to 1 L. (pH is ~8.3, no 10 10 X Lower Electrode Buffer:

adjustment). Dilute for use.

Upper Electrode Buffer: Same as Lower

Sucrose Solution: 18.66 g sucrose + 100 ml dH<sub>2</sub>O

146 g acrylamide + 4 g bis + 350 ml dH<sub>2</sub>O. Bring up 30% Acryl/Bis Stock (2.67%C):

to 500 ml. Filter and store at 4 C in the dark for up 15

to 1 month.

15% Acryl/Bis Stock (20% C): 6 g acrylamide + 1.5 g bis + 25 ml  $dH_2O$ . Bring up

to 50 ml. Filter and store at 4 C in the dark for up to

1 month.

20 Riboflavin Solution: 1.4 g riboflavin + 100 ml dH<sub>2</sub>O. Store in dark for up

to 1 month.

25 mM Sodium Citrate, 25 mM Bicine-NaOH (pH SS Assay mix:

8.0), 2 mM EDTA, 1 mM DTT-fresh, 1 mM

Adenosine 5' Diphosphoglucose-fresh, 10 mg/ml rabbit

liver glycogen Type III-fresh.

2 g iodine + 20 g KI, 0.1 N HCl up to 1 L. **Iodine Solution:** 

24

#### **Extract:**

- 4 ml extraction buffer + 12 g endosperm. Homogenize.
- filter through mira cloth or 4 layers cheesecloth, spin 20,000 g (14,500 rpm, SM-24 rotor), 20 min., 4°C.
- 5 remove supernatant using a glass pipette.
  - 0.85 ml extract + 0.1 ml glycerol + 0.05 ml 0.5% bromophenol blue.
  - vortex and spin 5 min. full speed microfuge. Use directly or freeze in liquid nitrogen and store at -80°C for up to 2 weeks.

## Cast Gels:

10

15

Attach Gel Bond PAG film (FMC Industries, Rockland, ME) to (inside of) outer glass plate using two-sided scotch tape, hydrophilic side up. The tape and the film is lined up as closely and evenly as possible with the bottom of the plate. The film is slightly smaller than the plate. Squirt water between the film and the plate to adhere the film. Use a tissue to push out excess water. Set up plates as usual, then seal the bottom of the plates with tacky adhesive. The cassette will fit into the casting stand if the gray rubber is removed from the casting stand. The gel polymerizes with the film, and stays attached during all subsequent manipulations.

Cast 4.5% T resolve mini-gel (0.75 mm):

2.25 ml dH<sub>2</sub>O

20 + 3.75 ml sucrose solution

+ 2.5 ml resolve buffer

+ 1.5 ml 30% Acryl/Bis stock

+ various amounts of glycogen for each gel (i.e., 0 - 1.0%)

DEGAS 15 MIN.

25 + 50 µl 10% APS

+ 5 µl TEMED

POLYMERIZE FOR 30 MIN. OR OVERNIGHT

Cast 3.125 % T stack:

1.59 ml dH<sub>2</sub>O

PCT/US97/17555 WO 98/14601

25

- + 3.75 ml sucrose solution
- + 2.5 ml stack buffer
- + 2.083 ml 15% Acryl/Bis stock

#### DO NOT DEGAS

5 15 µl 10% APS

- + 35 µl riboflavin solution
- + 30 µl TEMED

## POLYMERIZE FOR 2.5 HOURS CLOSE TO A LIGHT BULB

cool in 4°C before pulling out combs. Can also not use combs, and just cast a centimeter of stacker.

10

20

30

## The foregoing procedure:

- Can run at different temperatures; preincubate gels and solutions.
- Pre-run for 15 min. at 200 V
- Load gel: 7 µl per well, or 115 µl if no comb.
- Run at 140 V until dye front is close to bottom. Various running temperatures are 15 achieved by placing the whole gel rig into a water bath. Can occasionally stop the run to insert a temperature probe into the gel.
  - Enzyme assay: Cut gels off at dye front. Incubate in SS. Assay mix overnight at room temperature with gentle shaking. Rinse gels with water. Flood with I2/KI solution.
  - Take pictures of the gels on a light box, and measure the pictures. Rm = mm from top of gel to the active band/mm from top of gel to the bottom of the gel where it was cut (where the dye front was). Plot % glycogen vs. 1/Rm. The point where the line intersects the x axis is -K (where y=0).

#### 25 Testing and evaluation protocol for SER region length:

Following the procedure above for selection of the SER region requires four basic steps. First DNA encoding a protein having a starch-encapsulation region must be selected. This can be selected from known starch-synthesizing genes or starch-binding genes such as genes for amylases, for example. The protein must be extracted. A number of protein extraction techniques are well known in the art. The protein may be treated

with proteases to form protein fragments of different lengths. The preferred fragments have deletions primarily from the N-terminus region of the protein. The SER region is located nearer to the C-terminus end than the N-terminus end. The protein is run on the gels described above and affinity for the gel matrix is evaluated. Higher affinity shows more preference of that region of the protein for the matrix. This method enables comparison of different proteins to identify the starch-encapsulating regions in natural or synthetic proteins.

## Example Two:

#### **SER Fusion Vector:**

10

5

The following fusion vectors are adapted for use in E.coli. The fusion gene that was attached to the probable SER in these vectors encoded for the green fluorescent protein (GFP). Any number of different genes encoding for proteins and polypeptides could be ligated into the vectors. A fusion vector was constructed having the SER of waxy maize fused to a second gene or gene fragment, in this case GFP.

15

20

25

pEXS114 (see FIG. 1a): Synthetic GFP (SGFP) was PCR-amplified from the plasmid HBT-SGFP (from Jen Sheen; Dept. of Molecular Biology; Wellman 11, MGH; Boston, MA 02114) using the primers EXS73 (5'-GACTAGTCATATG GTG AGC AAG GGC GAG GAG-3') [SEQ ID NO:1] and EXS74 (5'-CTAGATCTTCATATG CTT GTA CAG CTC GTC CAT GCC-3') [SEQ ID NO:2]. The ends of the PCR product were polished off with T DNA polymerase to generate blunt ends; then the PCR product was digested with Spe I. This SGFP fragment was subcloned into the EcoRV-Spe I sites of pBSK (Stratagene at 11011 North Torrey Pines Rd. La Jolla, Ca.) to generate pEXS114.

plasmid HBT-SGFP (from Jen Sheen) using the primers EXS73 (see above) and EXS75 (5'-CTAGATCTTGGCCATGGC CTT GTA CAG CTC GTC CAT GCC-3') [SEO ID NO:3]. The ends of the PCR product were polished off with T DNA polymerase to generate blunt ends; then the PCR product was digested with Spe I. This SGFP fragment

was subcloned into the EcoRV-Spe I sites of pBSK (Stratagene) generating pEXS115.

pEXS115 [see FIG. 1b]: Synthetic GFP (SGFP) was PCR-amplified from the

27

pEXSWX (see FIG. 2a): Maize WX subcloned NdeI-Not I into pET-21a (see FIG. 2b). The genomic DNA sequence and associated amino acids from which the mRNA sequence can be generated is shown in TABLES 1a and 1b below and alternatively the DNA listed in the following tables could be employed.

#### 5 TABLE la DNA Sequence and Deduced Amino Acid Sequence of the waxy Gene in Maize

[SEQ ID NO:4 and SEQ ID NO:5]

10	LOCUS DEFINITION	ZMWAXY Zea mays	4800 bp DNA waxy (wx+) locus for	PLN UDP-glucose starch	glycosyl
	ACCESSION KEYWORDS		4258 transferase; transit		•
15	SOURCE ORGANISM	maize. Zea mays	se starch glycosyl t	ransferase; waxy loc	us.
		Commelin	; Plantae; Embryobio dae; Cyperales; Poac	nta; Magnoliophyta; eae.	Liliopsida;
20	REFERENCE AUTHORS TITLE JOURNAL	Kloesgen Molecular Mol. Gen	1 to 4800) R.B., Gierl, A., Schwanalysis of the wax Genet. 203, 237-244	y locus of Zea mays	edler,H.
	STANDARD	full auto			
25	COMMENT	NCBI gi:			
25	FEATURES		Location/Qualifiers		
	source		14800		
	repeat_	_region	organism="Zea mays" 283287		
			/note="direct repeat	1"	
30	repeat_	_region	288292		
		_	/note="direct repeat	1"	
	repeat	region	293297		
		_	/note="direct repeat	1"	
	repeat	region	298302		
35	-	-	/note="direct repeat	1"	
	misc fe	eature	372385		
	-		/note="GC stretch (pe	ot, regulatory facto	r binding
	site)"		, , , ,		
	misc fe	eature	442468		
40			/note="GC stretch (pe	ot, regulatory facto	r hinding
	site)"		, co	or regardedly rucce	1 Dinaing
	misc fe	eature	768782		
	200_1	Juduze	/note="GC stretch (po	ot regulatory facts	r hinding
	site)"		,	oc. regulatory races	i binding
45	misc fe	ature	810822		
	2.0_2.	Judulo	/note="GC stretch (pe	ot regulatory facto	r hinding
	site)"		, note = de bereten (p	oc. regardeory raced	t binding
	misc fe	eature	821828		
			/note="target duplication	ation site (Ac7)"	
50	CAAT si	ional	821828	acton sice (Act)	
	TATA si		867873		
	misc fe		887900		
		Jacure	note="GC stretch (po	ot regulatory facto	r hinding
	site)"		noce- de acrecen (po	oc. regulatory racto	r binding
55	misc fe	aturo	901		
J	""TSC_I6	-acure	/note="transcription:	al start sits"	
	exon		9011080	ar scarc sice	
	exon				
			/number=1		

28

```
1081..1219
            intron
                             /number=1
                             1220..1553
            exon
                              /number=2
 5
            transit_peptide 1233..1448
            CDS
                             join(1449..1553,1685..1765,1860..1958,2055..2144,
       2226..2289,2413..2513,2651..2760,2858..3101,3212..3394,
                             3490..3681,3793..3879,3977..4105,4227..4343)
/note="NCBI gi: 22510"
10
                             /codon start=1
                             /product="glucosyl transferase"
       /translation="ASAGMNVVFVGAEMAPWSKTGGLGDVLGGLPPAMAANGHRVMVV
15
       SPRYDQYKDAWDTSVVSEIKMGDGYETVRFFHCYKRGVDRVFVDHPLFLERVWGKTEE
       KIYGPVAGTDYRDNQLRFSLLCQAALEAPRILSLNNNPYFSGPYGEDVVFVCNDWHTG
20
       PLSCYLKSNYQSHGIYRDAKTAFCIHNISYQGRFAFSDYPELNLPERFKSSFDFIDGY
       EKPVEGRKINWMKAGILEADRVLTVSPYYAEELISGIARGCELDNIMRLTGITGIVNG
       MDVSEWDPSRDKYIAVKYDVSTAVEAKALNKEALQAEVGLPVDRNIPLVAFIGRLEEQ
25
       KGPDVMAAAIPOLMEMVEDVOIVLLGTGKKKFERMLMSAEEKFPGKVRAVVKFNAALA
       {\tt HHIMAGADVLAVTSRFEPCGLIQLQGMRYGTPCACASTGGLVDTIIEGKTGFHMGRLS}
30
       VDCNVVEPADVKKVATTLQRAIKVVGTPAYEEMVRNCMIQDLSWKGPAKNWENVLLSL
                             GVAGGEPGVEGEEIAPLAKENVAAP"
            intron
                             1554..1684
                              /number=2
                             1685..1765
            exon
35
                              /number=3
                              1766..1859
            intron
                              /number=3
                             1860..1958
            exon
                              /number=4
40
            intron
                              1959..2054
                              /number=4
            exon
                             2055..2144
                              /number=5
            intron
                             2145..2225
45
                              /number=5
            exon
                              2226..2289
                              /number=6
                             2290..2412
            intron
                              /number=6
50
            exon
                             2413..2513
                              /number=7
            intron
                              2514..2650
                              /number=7
                             2651..2760
            exon
55
                              /number=8
                             2761..2857
            intron
                              /number=8
            exon
                              2858..3101
                              /number=9
60
            intron
                             3102..3211
                              /number=9
            exon
                              .
3212..3394
                              /number=10
            misc_feature
                              3358..3365
65
                              /note="target duplication site (Ac9)"
                             3395..3489
            intron
                              /number=10
                             3490..3681
            exon
```

```
/number=11
                            .
3570..3572
           misc_feature
                            /note="target duplication site (Spm 18)"
                            3682..3792
           intron
5
                            /number=11
                           3793..3879
           exon
                            /number=12
                            3880..3976
           intron
                            /number=12
10
                           3977..4105
           exon
                           /number=13
           intron
                            4106..4226
                           /number=13
                           4227..4595
           exon
15
                           /number=14
           polyA_signal
                           4570..4575
           polyA_signal
polyA_site
polyA_signal
                           4593..4598
                           4595
                           4597..4602
20
                           4618
           polyA_site
      polyA_site
BASE COUNT
                           4625
                      935 A
                             1413 C
                                       1447 G
                                                1005 T
      ORIGIN
              1 CAGCGACCTA TTACACAGCC CGCTCGGGCC CGCGACGTCG GGACACATCT TCTTCCCCCT
25
             61 TTTGGTGAAG CTCTGCTCGC AGCTGTCCGG CTCCTTGGAC GTTCGTGTG CAGATTCATC
            121 TGTTGTCTCG TCTCCTGTGC TTCCTGGGTA GCTTGTGTAG TGGAGCTGAC ATGGTCTGAG
30
            181 CAGGCTTAAA ATTTGCTCGT AGACGAGGAG TACCAGCACA GCACGTTGCG GATTTCTCTG
            301 CGATGCGGTG GTGAGCAGAG CAGCAACAGC TGGGCGGCCC AACGTTGGCT TCCGTGTCTT
35
            361 CGTCGTACGT ACGCGCGCGC CGGGGACACG CAGCAGAGAG CGGAGAGCGA GCCGTGCACG
            421 GGGAGGTGGT GTGGAAGTGG AGCCGCGCGC CCGGCCGCCC GCGCCCGGTG GGCAACCCAA
40
            481 AAGTACCCAC GACAAGCGAA GGCGCCAAAG CGATCCAAGC TCCGGAACGC AACAGCATGC
            541 GTCGCGTCGG AGAGCCAGCC ACAAGCAGCC GAGAACCGAA CCGGTGGGCG ACGCGTCATG
            601 GGACGGACGC GGGCGACGCT TCCAAACGGG CCACGTACGC CGGCGTGTGC GTGCGTGCAG
45
            661 ACGACAAGCC AAGGCGAGGC AGCCCCCGAT CGGGAAAGCG TTTTGGGCGC GAGCGCTGGC
            721 GTGCGGGTCA GTCGCTGGTG CGCAGTGCCG GGGGGAACGG GTATCGTGGG GGGCGCGGGC
50
            781 GGAGGAGAC GTGGCGAGGG CCGAGAGCAG CGCGCGGCCG GGTCACGCAA CGCGCCCCAC
            841 GTACTGCCCT CCCCCTCCGC GCGCGCTAGA AATACCGAGG CCTGGACCGG GGGGGGCCC
            901 CGTCACATCC ATCCATCGAC CGATCGATCG CCACAGCCAA CACCACCCGC CGAGGCGACG
55
            961 CGACAGCCGC CAGGAGGAAG GAATAAACTC ACTGCCAGCC AGTGAAGGGG GAGAAGTGTA
            1021 CTGCTCCGTC GACCAGTGCG CGCACCGCCC GGCAGGGCTG CTCATCTCGT CGACGACCAG
60
            1081 GTTCTGTTCC GTTCCGATCC GATCCGATCC TGTCCTTGAG TTTCGTCCAG ATCCTGGCGC
           1141 GTATCTGCGT GTTTGATGAT CCAGGTTCTT CGAACCTAAA TCTGTCCGTG CACACGTCTT
           1201 TTCTCTCTC CCTACGCAGT GGATTAATCG GCATGGCGGC TCTGGCCACG TCGCAGCTCG
65
           1261 TCGCAACGCG CGCCGGCCTG GGCGTCCCGG ACGCGTCCAC GTTCCGCCGC GGCGCCGCGC
```

	1321	AGGGCCTGAG	GGGGGCCCGG	GCGICGGCGG	CGGCGGACAC	GCTCAGCATG	CGGACCAGCG
	1381	CGCGCGCGC	GCCCAGGCAC	CAGCAGCAGG	CGCGCCGCGG	GGGCAGGTTC	CCGTCGCTCG
5	1441	TCGTGTGCGC	CAGCGCCGGC	ATGAACGTCG	TCTTCGTCGG	CGCCGAGATG	GCGCCGTGGA
	1501	GCAAGACCGG	CGGCCTCGGC	GACGTCCTCG	GCGGCCTGCC	GCCGGCCATG	GCCGTAAGCG
10	1561	CGCGCACCGA	GACATGCATC	CGTTGGATCG	CGTCTTCTTC	GTGCTCTTGC	CGCGTGCATG
10	1621	ATGCATGTGT	TTCCTCCTGG	CTTGTGTTCG	TGTATGTGAC	GTGTTTGTTC	GGGCATGCAT
•	1681	GCAGGCGAAC	GGGCACCGTG	TCATGGTCGT	CTCTCCCCGC	TACGACCAGT	ACAAGGACGC
15	1741	CTGGGACACC	AGCGTCGTGT	CCGAGGTACG	GCCACCGAGA	CCAGATTCAG	ATCACAGTCA
	1801	CACACACCGT	CATATGAACC	TTTCTCTGCT	CTGATGCCTG	CAACTGCAAA	TGCATGCAGA
20	1861	TCAAGATGGG	AGACGGGTAC	GAGACGGTCA	GGTTCTTCCA	CTGCTACAAG	CGCGGAGTGG
20	1921	ACCGCGTGTT	CGTTGACCAC	CCACTGTTCC	TGGAGAGGGT	GAGACGAGAT	CTGATCACTC
	1981	GATACGCAAT	TACCACCCCA	TTGTAAGCAG	TTACAGTGAG	CTTTTTTCC	CCCCGCCTG
25	2041	GTCGCTGGTT	TCAGGTTTGG	GGAAAGACCG	AGGAGAAGAT	CTACGGGCCT	GTCGCTGGAA
	2101	CGGACTACAG	GGACAACCAG	CTGCGGTTCA	GCCTGCTATG	CCAGGTCAGG	ATGGCTTGGT
30	2161	ACTACAACTT	CATATCATCT	GTATGCAGCA	GTATACACTG	ATGAGAAATG	CATGCTGTTC
30	2221	TGCAGGCAGC	ACTTGAAGCT	CCAAGGATCC	TGAGCCTCAA	CAACAACCCA	TACTTCTCCG
	2281	GACCATACGG	TAAGAGTTGC	AGTCTTCGTA	TATATATCTG	TTGAGCTCGA	GAATCTTCAC
35	2341	AGGAAGCGGC	CCATCAGACG	GACTGTCATT	TTACACTGAC	TACTGCTGCT	GCTCTTCGTC
	2401	CATCCATACA	AGGGGAGGAC	GTCGTGTTCG	TCTGCAACGA	CTGGCACACC	GGCCCTCTCT
40	2461	CGTGCTACCT	CAAGAGCAAC	TACCAGTCCC	ACGGCATCTA	CAGGGACGCA	AAGGTTGCCT
	2521	TCTCTGAACT	GAACAACGCC	GTTTTCGTTC	TCCATGCTCG	TATATACCTC	GTCTGGTAGT
	2581	GGTGGTGCTT	CTCTGAGAAA	CTAACTGAAA	CTGACTGCAT	GTCTGTCTGA	CCATCTTCAC
45	2641	GTACTACCAG	ACCGCTTTCT	GCATCCACAA	CATCTCCTAC	CAGGGCCGGT	TCGCCTTCTC
	2701	CGACTACCCG	GAGCTGAACC	TCCCGGAGAG	ATTCAAGTCG	TCCTTCGATT	TCATCGACGG
50	2761	GTCTGTTTTC	CTGCGTGCAT	GTGAACATTC	ATGAATGGTA	ACCCACAACT	GTTCGCGTCC
	2821	TGCTGGTTCA	TTATCTGACC	TGATTGCATT	ATTGCAGCTA	CGAGAAGCCC	GTGGAAGGCC
	2881	GGAAGATCAA	CTGGATGAAG	GCCGGGATCC	TCGAGGCCGA	CAGGGTCCTC	ACCGTCAGCC
55	2941	CCTACTACGC	CGAGGAGCTC	ATCTCCGGCA	TCGCCAGGGG	CTGCGAGCTC	GACAACATCA
	3001	TGCGCCTCAC	CGGCATCACC	GGCATCGTCA	ACGGCATGGA	CGTCAGCGAG	TGGGACCCCA
60	3061	GCAGGGACAA	GTACATCGCC	GTGAAGTACG	ACGTGTCGAC	GGTGAGCTGG	CTAGCTCTGA
	3121	TTCTGCTGCC	TGGTCCTCCT	GCTCATCATG	CTGGTTCGGT	ACTGACGCGG	CAAGTGTACG
	3181	TACGTGCGTG	CGACGGTGGT	GTCCGGTTCA	GGCCGTGGAG	GCCAAGGCGC	TGAACAAGGA
65	3241	GGCGCTGCAG	GCGGAGGTCG	GGCTCCCGGT	GGACCGGAAC	ATCCCGCTGG	TGGCGTTCAT
	3301	CGGCAGGCTG	GAAGAGCAGA	AGGGCCCCGA	CGTCATGGCG	GCCGCCATCC	CGCAGCTCAT

31

3361 GGAGATGGTG GAGGACGTGC AGATCGTTCT GCTGGTACGT GTGCGCCGGC CGCCACCCGG 3421 CTACTACATG CGTGTATCGT TCGTTCTACT GGAACATGCG TGTGAGCAAC GCGATGGATA 5 3481 ATGCTGCAGG GCACGGGCAA GAAGAAGTTC GAGCGCATGC TCATGAGCGC CGAGGAGAAG 3541 TTCCCAGGCA AGGTGCGCGC CGTGGTCAAG TTCAACGCGG CGCTGGCGCA CCACATCATG 3601 GCCGGCGCCG ACGTGCTCGC CGTCACCAGC CGCTTCGAGC CCTGCGGCCT CATCCAGCTG 10 3661 CAGGGGATGC GATACGGAAC GGTACGAGAG AAAAAAAAA TCCTGAATCC TGACGAGAGG 3721 GACAGAGACA GATTATGAAT GCTTCATCGA TTTGAATTGA TTGATCGATG TCTCCCGCTG 15 3781 CGACTCTTGC AGCCCTGCGC CTGCGCGTCC ACCGGTGGAC TCGTCGACAC CATCATCGAA 3841 GGCAAGACCG GGTTCCACAT GGGCCGCCTC AGCGTCGACG TAAGCCTAGC TCTGCCATGT 3901 TCTTTCTTCT TTCTTTCTGT ATGTATGTAT GAATCAGCAC CGCCGTTCTT GTTTCGTCGT 20 3961 CGTCCTCTT TCCCAGTGTA ACGTCGTGGA GCCGGCGGAC GTCAAGAAGG TGGCCACCAC 4021 ATTGCAGCGC GCCATCAAGG TGGTCGGCAC GCCGGCGTAC GAGGAGATGG TGAGGAACTG 25 4081 CATGATCCAG GATCTCTCCT GGAAGGTACG TACGCCCGCC CCGCCCGCC CCGCCAGAGC 4141 AGAGCGCCAA GATCGACCGA TCGACCGACC ACACGTACGC GCCTCGCTCC TGTCGCTGAC 4201 CGTGGTTTAA TTTGCGAAAT GCGCAGGGCC CTGCCAAGAA CTGGGAGAAC GTGCTGCTCA 30 4261 GCCTCGGGGT CGCCGGCGGC GAGCCAGGGG TCGAAGGCGA GGAGATCGCG CCGCTCGCCA 4321 AGGAGAACGT GGCCGCGCC TGAAGAGTTC GGCCTGCAGG GCCCCTGATC TCGCGCGTGG 35 4381 TGCAAAGATG TTGGGACATC TTCTTATATA TGCTGTTTCG TTTATGTGAT ATGGACAAGT 4501 TAATAAGCGC ATGAACTAAT TGCTTGCGTG TGTAGTTAAG TACCGATCGG TAATTTTATA 40 4561 TTGCGAGTAA ATAAATGGAC CTGTAGTGGT GGAGTAAATA ATCCCTGCTG TTCGGTGTTC

4621 TTATCGCTCC TCGTATAGAT ATTATATAGA GTACATTTTT CTCTCTGA ATCCTACGTT

4681 TGTGAAATTT CTATATCATT ACTGTAAAAT TTCTGCGTTC CAAAAGAGAC CATAGCCTAT
4741 CTTTGGCCCT GTTTGTTTCG GCTTCTGGCA GCTTCTGGCC ACCAAAAGCT GCTGCGGACT

11

45

32

# TABLE 1b DNA Sequence and Deduced Amino Acid Sequence in waxy Gene in Rice [SEQ ID NO:6 and SEQ ID NO:7]

5	LOCUS DEFINITION ACCESSION KEYWORDS	X62134 S		•	Pi Losynthesis;	LN waxy gene.	
10	SOURCE ORGANISM	Eukaryota	a; Plantae;		nta; Magnolio	ophyta; Lil	iopsida;
15	REFERENCE AUTHORS TITLE JOURNAL R.J.	1 (bases Okayaki, Direct Su	noission		eae. e EMBL/GenBa	nk/DDBJ dat	abases.
		Okayaki,	University	of Florida	, Dep of Ve	getable Cro	ps, 1255
20	STANDARD REFERENCE AUTHORS	full auto	omatic s 1 to 2542		sville, Flor	ida 32611-0	514, USA
25	TITLE JOURNAL STANDARD	Nucleotic Plant Mod full auto	de sequence 1. Biol. 19 omatic		cDNA from the (1992)	ne rice wax	y gene
	COMMENT FEATURES source	NCBI gi:	20402 Location/Qu 12542 /organism=		wa "		
30	CDS		/dev_stage: /tissue_typ 4532282	="immature			
35			/gene="Wx" /standard_n /EC_number= /note="NCB: /codon_stan	="2.4.1.21' [ gi: 2040; rt=1	3"		
40				starch (bad	cterial glyco		ase"
	/translation	n="MSALTT	SQLATSATGFG:	IADRSAPSSLI	RHGFQGLKPRS	PAGGD	
	ATSLSVTTSAR	ATPKQQRSV(	QRGSRRFPSVV	YATGAGMNV	/FVGAEMAPWSK	rgglg	
45	DVLGGLPPAMA	ANGHRVMVI	SPRYDQYKDAWI	TSVVAEIKV!	DRYERVRFFHC	YKRGV	
	DRVFIDHPSFL	EKVWGKTGEI	KIYGPDTGVDYI	<b>CDNQMRFSLL</b> C	QAALEAPRILNI	LNNNP	
50	YFKGTYGEDVV	FVCNDWHTGI	PLASYLKNNYQI	PNGIYRNAKVA	AFCIHNISYQGR	FAFED	
50	YPELNLSERFR	SSFDFIDGY	TPVEGRKINW!	KAGILEADR	LTVSPYYAEEL:	ISGIA	
	RGCELDNIMRL	rgitgivng)	MDVSEWDPSKDI	(YITAKYDAT)	CAIEAKALNKEA	LQAEA	
55	GLPVDRKIPLI	AFIGRLEEQI	(GPDVMAAAIPI	ELMQEDVQIVI	LGTGKKKFEKLI	LKSME	
	EKYPGKVRAVVI	KFNAPLAHL:	MAGADVLAVP	SRFEPCGLIQI	.QGMRYGTPCAC	ASTGG	
60		FHMGRLSVDO	DLSWKGPAKN		VGTPAYEEMVRI AGSAPGIEGDEI	~	11
	3'UTR polyA_s		22832535 2535				
	BASE COUNT ORIGIN	610 1		693 G	574 T		
65	1 G	AATTCAGTG	TGAAGGAATA	GATTCTCTTC	AAAACAATTT	AATCATTCAT	CTGATCTGCT

	61	CAAAGCTCTG	TGCATCTCCG	GGTGCAACGG	CCAGGATATT	IMITGIGCAG	IMMMMMAIG
	121	TCATATCCCC	TAGCCACCCA	AGAAACTGCT	CCTTAAGTCC	TTATAAGCAC	ATATGGCATT
5	181	GTAATATATA	TGTTTGAGTT	TTAGCGACAA	TTTTTTTAAA	AACTTTTGGT	CCTTTTTATG
	241	AACGTTTTAA	GTTTCACTGT	CTTTTTTTT	CGAATTTTAA	ATGTAGCTTC	AAATTCTAAT
10	301	CCCCAATCCA	AATTGTAATA	AACTTCAATT	CTCCTAATTA	ACATCTTAAT	TCATTTATTT
10	361	GAAAACCAGT	TCAAATTCTT	TTTAGGCTCA	CCAAACCTTA	AACAATTCAA	TTCAGTGCAG
	421	AGATCTTCCA	CAGCAACAGC	TAGACAACCA	CCATGTCGGC	TCTCACCACG	TCCCAGCTCG
15	481	CCACCTCGGC	CACCGGCTTC	GGCATCGCCG	ACAGGTCGGC	GCCGTCGTCG	CTGCTCCGCC
	541	ACGGGTTCCA	GGGCCTCAAG	CCCCGCAGCC	CCGCCGGCGG	CGACGCGACG	TCGCTCAGCG
20	601	TGACGACCAG	CGCGCGCGCG	ACGCCCAAGC	AGCAGCGGTC	GGTGCAGCGT	GGCAGCCGGA
20	661	GGTTCCCCTC	CGTCGTCGTG	TACGCCACCG	GCGCCGGCAT	GAACGTCGTG	TTCGTCGGCG
	721	CCGAGATGGC	CCCCTGGAGC	AAGACCGGCG	GCCTCGGTGA	CGTCCTCGGT	GGCCTCCCC
25	781	CTGCCATGGC	TGCGAATGGC	CACAGGGTCA	TGGTGATCTC	TCCTCGGTAC	GACCAGTACA
	841	AGGACGCTTG	GGATACCAGC	GTTGTGGCTG	AGATCAAGGT	TGCAGACAGG	TACGAGAGGG
30	901	TGAGGTTTTT	CCATTGCTAC	AAGCGTGGAG	TCGACCGTGT	GTTCATCGAC	CATCCGTCAT
30	961	TCCTGGAGAA	GGTTTGGGGA	AAGACCGGTG	AGAAGATCTA	CGGACCTGAC	ACTGGAGTTG
	1021	ATTACAAAGA	CAACCAGATG	CGTTTCAGCC	TTCTTTGCCA	GGCAGCACTC	GAGGCTCCTA
35	1081	GGATCCTAAA	CCTCAACAAC	AACCCATACT	TCAAAGGAAC	TTATGGTGAG	GATGTTGTGT
	1141	TCGTCTGCAA	CGACTGGCAC	ACTGGCCCAC	TGGCGAGCTA	CCTGAAGAAC	AACTACCAGO
40	1201	CCAATGGCAT	CTACAGGAAT	GCAAAGGTTG	CTTTCTGCAT	CCACAACATC	TCCTACCAGG
-10	1261	GCCGTTTCGC	TTTCGAGGAT	TACCCTGAGC	TGAACCTCTC	CGAGAGGTTC	AGGTCATCCT
	1321	TCGATTTCAT	CGACGGGTAT	GACACGCCGG	TGGAGGGCAG	GAAGATCAAC	TGGATGAAGG
45	1381	CCGGAATCCT	GGAAGCCGAC	AGGGTGCTCA	CCGTGAGCCC	GTACTACGCC	GAGGAGCTCA
	1441	TCTCCGGCAT	CGCCAGGGGA	TGCGAGCTCG	ACAACATCAT	GCGGCTCACC	GGCATCACCG
50	1501	GCATCGTCAA	CGGCATGGAC	GTCAGCGAGT	GGGATCCTAG	CAAGGACAAG	TACATCACCG
	1561	CCAAGTACGA	CGCAACCACG	GCAATCGAGG	CGAAGGCGCT	GAACAAGGAG	GCGTTGCAGG
	1621	CGGAGGCGGG	TCTTCCGGTC	GACAGGAAAA	TCCCACTGAT	CGCGTTCATC	GGCAGGCTGG
55	1681	AGGAACAGAA	GGGCCCTGAC	GTCATGGCCG	CCGCCATCCC	GGAGCTCATG	CAGGAGGACG
	1741	TCCAGATCGT	TCTTCTGGGT	ACTGGAAAGA	AGAAGTTCGA	GAAGCTGCTC	AAGAGCATGG
60	1801	AGGAGAAGTA	TCCGGGCAAG	GTGAGGGCGG	TGGTGAAGTT	CAACGCGCCG	CTTGCTCATC
	1861	TCATCATGGC	CGGAGCCGAC	GTGCTCGCCG	TCCCCAGCCG	CTTCGAGCCC	TGTGGACTCA
	1921	TCCAGCTGCA	GGGGATGAGA	TACGGAACGC	CCTGTGCTTG	CGCGTCCACC	GGTGGGCTCG
65	1981	TGGACACGGT	CATCGAAGGC	AAGACTGGTT	TCCACATGGG	CCGTCTCAGC	GTCGACTGC
	2041	AGGTGGTGGA	GCCAAGCGAC	GTGAAGAAGG	TGGCGGCCAC	CCTGAAGCGC	GCCATCAAGG

PCT/US97/17555 WO 98/14601

34

2101 TCGTCGGCAC GCCGGCGTAC GAGGAGATGG TCAGGAACTG CATGAACCAG GACCTCTCCT 2161 GGAAGGGCC TGCGAAGAAC TGGGAGAATG TGCTCCTGGG CCTGGGCGTC GCCGGCAGCG 5 2221 CGCCGGGGAT CGAAGGCGAC GAGATCGCGC CGCTCGCCAA GGAGAACGTG GCTGCTCCTT 2281 GAAGAGCCTG AGATCTACAT ATGGAGTGAT TAATTAATAT AGCAGTATAT GGATGAGAGA 2341 CGAATGAACC AGTGGTTTGT TTGTTGTAGT GAATTTGTAG CTATAGCCAA TTATATAGGC 10 2401 TAATAAGTTT GATGTTGTAC TCTTCTGGGT GTGCTTAAGT ATCTTATCGG ACCCTGAATT 2461 TATGTGTGTG GCTTATTGCC AATAATATTA AGTAATAAAG GGTTTATTAT ATTATTATAT 15 2521 ATGTTATATT ATACTAAAAA AA

//

20

## TABLE 2 DNA Sequence and Deduced Amino Acid Sequence of the Soluble Starch Synthase IIa Gene in Maize [SEO ID NO:8 and SEO ID NO:9]

SEQUENCE : NORMAL FILE NAME : MSS2C.SEQ 2007 BP

CODON TABLE : UNIV.TCN

SEQUENCE REGION: 1 -2007

25 1 - 2007 TRANSLATION REGION :

#### \*\*\* DNA TRANSLATION \*\*\*

48 A E A E A G G K D A P P E R S G 16 49 GAC GCC GCC AGG TTG CCC CGC GCT CGG CGC AAT GCG GTC TCC AAA CGG 96 30 R Р R Α N R L R Α 32 AGG GAT CCT CTT CAG CCG GTC GGC CGG TAC GGC TCC GCG ACG GGA AAC 144 P L O P V G R Y G S A 48 145 ACG GCC AGG ACC GGC GCC GCG TCC TGC CAG AAC GCC GCA TTG GCG GAC 192 RTGAA s c o N A 64 35 193 GTT GAG ATC GTT GAG ATC AAG TCC ATC GTC GCC GCG CCG ACG AGC 240 I V E K P 80 I S I A A 241 ATA GTG AAG TTC CCA GGG CGC GGG CTA CAG GAT GAT CCT TCC CTC TGG 288 F P G R Q D D96 G L GAC ATA GCA CCG GAG ACT GTC CTC CCA GCC CCG AAG CCA CTG CAT GAA 336 40 E L A 112 TCG CCT GCG GTT GAC GGA GAT TCA AAT GGA ATT GCA CCT CCT ACA GTT 384 113 D T A 128 GAG CCA TTA GTA CAG GAG GCC ACT TGG GAT TTC AAG AAA TAC ATC GGT 385 432 LVQEATW 129 D F K K 144 45 433 TTT GAC GAG CCT GAC GAA GCG AAG GAT GAT TCC AGG GTT GGT GCA GAT 480

	145	F	D	E	P	D	E	A	K.	D	D	s	R	V	G	A	D	160
	481	GAT	GCT	GGT	TCT	TTT	GAA	CAT	TAT	GGG	ACA	ATG	ATT	CTG	GGC	CTT	TGT	528
	161	D	A	G	S	F	E	H	Y	G	T	M	I	L	G	L	C	176
5	529	GGG	GAG	AAT	GTT	ATG	AAC	GTG	ATC	GTG	gtg	GCT	GCT	GAA	TGT	TCT	CCA	576
	177	G	E	N	V	M	N	V	I	V	V	A	A	E	C	S	P	192
	577	TGG	TGC	AAA	ACA	GGT	GGT	CTT	GGA	GAT	GTT	gtg	GGA	GCT	TTA	CCC	AAG	624
	193	W	C	K	T	G	G	L	G	D	V	V	G	A	L	P	K	208
	625	GCT	TTA	GCG	AGA	AGA	GGA	CAT	CGT	GTT	ATG	GTT	GTG	GTA	CCA	AGG	TAT	672
	209	A	L	A	R	R	G	H	R	V	M	V	V	V	P	R	Y	224
10	673	GGG	GAC	TAT	GTG	GAA	GCC	TTT	GAT	ATG	GGA	ATC	CGG	AAA	TAC	TAC	AAA	720
	225	G	D	Y	V	E	A	F	D	M	G	I	R	K	Y	Y	K	240
	721	GCT	GCA	GGA	CAG	GAC	CTA	GAA	GTG	AAC	TAT	TTC	CAT	GCA	TTT	ATT	GAT	768
	241	A	A	G	Q	D	L	E	V	N	Y	F	H	A	F	I	D	256
15	769	GGA	GTC	GAC	TTT	GTG	TTC	ATT	GAT	GCC	TCT	TTC	CGG	CAC	CGT	CAA	GAT	816
	257	G	V	D	F	V	F	I	D	A	S	F	R	H	R	Q	D	272
	817	GAC	ATA	TAT	GGG	GGA	AGT	AGG	CAG	GAA	ATC	ATG	AAG	CGC	ATG	TTA	TTG	864
	273	D	I	Y	G	G	S	R	Q	E	I	M	K	R	M	I	L	288
	865	TTT	TGC	AAG	GTT	GCT	GTT	GAG	GTT	CCT	TGG	CAC	GTT	CCA	TGC	GGT	GGT	912
	289	F	C	K	V	A	V	E	V	P	W	H	V	P	C	G	G	304
20	913 305	GTG V	TGC C	TAC Y	GGA G	GAT D	GGA G	AAT N	TTG L	GTG V	TTC F	ATT	GCC A	ATG M	AAT N	TGG W	CAC H	960 320
	961	ACT	GCA	CTC	CTG	CCT	GTT	TAT	CTG	AAG	GCA	TAT	TAC	AGA	GAC	CAT	GGG	1008
	321	T	A	L	L	P	V	Y	L	K	A	Y	Y	R	D	H	G	336
25	1009	TTA	ATG	CAG	TAC	ACT	CGC	TCC	GTC	CTC	GTC	ATA	CAT	AAC	ATC	GGC	CAC	1056
	337	L	M	Q	Y	T	R	S	V	L	V	I	H	N	I	G	H	352
	1057 353	CAG Q	G G G	CGT R	G G G	CCT P	GTA V	A CAT	GAA E	TTC F	C CCC	TAC Y	ATG M	GAC D	TTG L	CTC L	AAC N	1104 368
	1105 369	ACT T	' AAC N	CTT L	CAA Q	CAT H	TTC	GAG E	CTC L	TAC Y	GAT D	CCC P	GTC V	GGI G	G GGC	GAG E	CAC H	1152 384
30	1153 385	GCC A	AAC N	ATC	TTT F	GCC A	GCC A	TGI C	GTI V	CTC L	AAG K	ATG M	GCA A	GAC D	CGG R	GTC V	GTG V	1200 400
	1201	ACT	GTC	AGC	CGC	GGC	TAC	CTC	TGC	GAC	CTC	AAG	ACA	GTG	GAA	GGC	GGC	1248
	401	T	V	S	R	G	Y	L	W	E	L	K	T	V	E	G	G	416
35	1249 417	TGG W	G G G	CTC L	CAC H	GAC D	ATC I	ATC I	CGT R	TC1	AA 1 N	GAC D	TGG W	AAG K	ATC I	RAA I	GGC G	1296 432
	1297	ATT	CGT	GAA	CGC	ATC	GAC	CAC	CAG	GAC	TGC	AAC	CCC	AAG	GTG	GAC	GTG	1344
	433	I	R	E	R	I	D	H	Q	E	W	N	P	K	V	D	V	448
	1345 449	CAC H	CTG L	CGG R	TCG S	GAC D	G G	TAC Y	ACC T	AAC N	TAC Y	TCC S	CTC L	GAG E	ACA T	CTC L	GAC D	1392 464
40	1393 465	GCT A	GGA G	AAG K	CGG R	CAG Q	TGC C	AAG K	GCG A	GC(	CTC L	CAG Q	CGG R	GAC D	GTG V	GG C	CTG L	1440 480
	1441 481	GAA E	GTG V	CGC R	GAC D	GAC D	GTC V	CCG P	CTC L	CTC L	G GG	TTC F	ATC	GGG G	CGT R	CTC	GAT D	1488 496
45	1489 497	GGA G	CAG Q	AAG K	GGC G	GTG V	GAC D	TA S	ATC	G GG	GAC D	GCG A	ATG M	CCG	TGG W	ATC	GCG A	1536 512

WO 98/14601 PCT/US97/17555

	1537	GGG	CAG	GAC	GTG	CAG	CTG	GTG	ATG	CTG	GGC	ACC	GGC	CCA	CCT	GAC	CTG	1584
	513	G	Q	D	V	Q	L	V	M	L	G	T	G	P	P	D	L	528
	1585	GAA	CGA	ATG	CTG	CAG	CAC	TTG	GAG	CGG	GAG	CAT	CCC	AAC	AAG	GTG	CGC	1632
	529	E	R	M	L	Q	H	L	E	R	E	H	P	N	K	V	R	544
5	1633	GGG	TGG	GTC	GGG	TTC	TCG	GTC	CTA	ATG	GTG	CAT	CGC	ATC	ACG	CCG	GGC	1680
	545	G	W	V	G	F	S	V	L	M	V	H	R	I	T	P	G	560
	1681 561	GCC A	AGC S	GTG V	CTG L	GTG V	ATG M	CCC	TCC S	CGC R	TTC F	GCC A	GGC G	GGG G	CTG L	AAC N	CAG Q	1728 576
10	1729	CTC	TAC	GCG	ATG	GCA	TAC	GGC	ACC	GTC	CCT	gtg	GTG	CAC	GCC	GTG	GGC	1776
	577	L	Y	A	M	A	Y	G	T	V	P	V	V	H	A	V	G	592
	1777	GGG	CTC	AGG	GAC	ACC	GTG	GCG	CCG	TTC	GAC	CCG	TTC	GGC	GAC	GCC	GGG	1824
	593	G	L	R	D	T	V	A	P	F	D	P	F	G	D	A	G	608
	1825	CTC	GGG	TGG	ACT	TTT	GAC	CGC	GCC	GAG	GCC	AAC	AAG	CTG	ATC	GAG	GTG	1872
	609	L	G	W	T	F	D	R	A	E	A	N	K	L	I	E	V	624
15	1873	CTC	AGC	CAC	TGC	CTC	GAC	ACG	TAC	CGA	AAC	TAC	GAG	GAG	AGC	TGG	AAG	1920
	625	L	S	H	C	L	D	T	Y	R	N	Y	E	E	S	W	K	640
	1921 641	AGT S	CTC L	CAG Q	GCG	CGC R	GGC G	ATG M	TCG S	CAG Q	AAC N	CTC L	AGC S	TGG W	GAC D	CAC H	GCG A	1968 656
20	1969 657	GCT A	GAG E	CTC L	TAC Y	GAG E	GAC D	GTC V	CTT L	GTC V	AAG K	TAC Y	CAG Q	TGG W				2007 669

# TABLE 3 DNA Sequence and Deduced Amino Acid Sequence of The Soluble Starch Synthase Ilb Gene in Maize [SEQ ID NO:10 and SEQ ID NO: 11]

25 FILE NAME : MSS3FULL.DNA SEQUENCE : NORMAL 2097 BP

CODON TABLE : UNIV.TCN

SEQUENCE REGION: 1 - 2097
TRANSLATION REGION: 1 - 2097

#### \*\*\* DNA TRANSLATION \*\*\*

30	1	ATG M	CCG P	GGG G	GCA A	ATC I	TCT S	TCC S	TCG S	TCG S	TCG S	GCT A	TTT F	CTC L	CTC L	CCC P	GTC V	48 16
	49 17	GCG A	TCC	TCC S	TCG S	CCG P	CGG R	CGC R	AGG R	CGG R	GGC G	AGT S	GTG V	GGT G	GCT A	GCT A	CTG L	96 32
35	97	CGC	TCG	TAC	GGC	TAC	AGC	GGC	GCG	GAG	CTG	CGG	TTG	CAT	TGG	GCG	CGG	144
	33	R	S	Y	G	Y	S	G	A	E	L	R	L	H	W	A	R	48
	145	CGG	GGC	CCG	CCT	CAG	GAT	GGA	GCG	GCG	TCG	GTA	CGC	GCC	GCA	GCG	GCA	192
	49	R	G	P	P	Q	D	G	A	A	S	V	R	A	A	A	A	64
	193	CCG	GCC	GGG	GGC	GAA	AGC	GAG	GAG	GCA	GCG	AAG	AGC	TCC	TCC	TCG	TCC	240
	65	P	A	G	G	E	S	E	E	A	A	K	S	S	S	S	S	80
40	241	CAG	GCG	GGC	GCT	GTT	CAG	GGC	AGC	ACG	GCC	AAG	GCT	GTG	GAT	TCT	GCT	288

	81	Q	A	G	A	V	Q	G	s	T	A	ĸ	A	V	D	s	A	96
	289 97	TCA S	CCT P	CCC	AAT N	CCT P	TTG L	ACA T	TCT S	GCT A	CCG P	AAG K	CAA Q	AGT S	CAG Q	AGC S	GCT A	336 112
5	337	GCA	ATG	CAA	AAC	GGA	ACG	AGT	GGG	GGC	AGC	AGC	GCG	AGC	ACC	GCC	GCG	384
	113	A	M	Q	N	G	T	S	G	G	S	S	A	S	T	A	A	128
	385	CCG	GTG	TCC	GGA	CCC	AAA	GCT	GAT	CAT	CCA	TCA	GCT	CCT	GTC	ACC	AAG	432
	129	P	V	S	G	P	K	A	D	H	P	S	A	P	V	T	K	144
	433	AGA	GAA	ATC	GAT	GCC	AGT	GCG	GTG	AAG	CCA	GAG	CCC	GCA	GGT	GAT	GAT	480
	145	R	E	I	D	A	S	A	V	K	P	E	P	A	G	D	D	160
10	481	GCT	AGA	CCG	GTG	GAA	AGC	ATA	GGC	ATC	GCT	GAA	CCG	GTG	GAT	GCT	AAG	528
	161	A	R	P	V	E	S	I	G	I	A	E	P	V	D	A	K	176
	529	GCT	GAT	GCA	GCT	CCG	GCT	ACA	GAT	GCG	GCG	GCG	AGT	GCT	CCT	TAT	GAC	576
	177	A	D	A	A	P	A	T	D	A	A	A	S	A	P	Y	D	192
15	577	AGG	GAG	GAT	AAT	GAA	CCT	GGC	CCT	TTG	GCT	GGG	CCT	AAT	GTG	ATG	AAC	624
	193	R	E	D	N	E	P	G	P	L	A	G	P	N	V	M	N	208
	625	GTC	GTC	GTG	GTG	GCT	TCT	GAA	TGT	GCT	CCT	TTC	TGC	AAG	ACA	GGT	GGC	672
	209	V	V	V	V	A	S	E	C	A	P	F	C	K	T	G	G	224
	673	CTT	GGA	GAT	GTC	GTG	GGT	GCT	TTG	CCT	AAG	GCT	CTG	GCG	AGG	AGA	GGA	720
	225	L	G	D	V	V	G	A	L	P	K	A	L	A	R	R	G	240
20	721	CAC	CGT	GTT	ATG	GTC	GTG	ATA	CCA	AGA	TAT	GGA	GAG	TAT	GCC	GAA	GCC	768
	241	H	R	V	M	V	V	I	P	R	Y	G	E	Y	A	E	A	256
	769	CGG	GAT	TTA	GGT	GTA	AGG	AGA	CGT	TAC	AAG	GTA	GCT	GGA	CAG	GAT	TCA	816
	257	R	D	L	G	V	R	R	R	Y	K	V	A	G	Q	D	S	272
25	817 273	GAA E	GTT V	ACT T	TAT Y	TTT F	CAC H	TCT S	TAC Y	ATT	GAT D	GGA G	GTT V	GAT D	TTT F	GTA V	TTC F	864 288
	865	GTA	GAA	GCC	CCT	CCC	TTC	CGG	CAC	CGG	CAC	AAT	AAT	TTA	TAT	GGG	GGA	912
	289	V	E	A	P	P	F	R	H	R	H	N	N	I	Y	G	G	304
	913	GAA	AGA	TTG	GAT	ATT	TTG	AAG	CGC	ATG	ATT	TTG	TTC	TGC	AAG	GCC	GCT	960
	305	E	R	L	D	I	L	K	R	M	I	L	F	C	K	A	A	320
30	961	GTT	GAG	GTT	CCA	TGG	TAT	GCT	CCA	TGT	GGC	GGT	ACT	GTC	TAT	GGT	GAT	1008
	321	V	E	V	P	W	Y	A	P	C	G	G	T	V	Y	G	D	336
	1009 337	GG(	C AAG N	C TTA	A GTI V	TTC F	TA S	r gct A	CAA 1 N	r GA' D	T TG	G CAT	T ACC	G GCI	A CT	r cte	G CCT	1056 352
35	1057 353				A AAG	GCC A		TAC Y		G GA			r TTC L	ATC M	G CAC	G TA' Y	T GCT A	1104 368
	1105 369		-	_	CTI L	GTG V	ATA S	A CAC				r ca:	r cac Q	G GG	r cg: R		C CCT	1152 384
	1153 385			C GAC	TTC F	GTC V	AA: N	r TT	GAC D	C TT	G CC'	r gaz	A CAC	TAC Y	ATC I	C GA	C CAC H	1200 400
40	1201 401		C AA		TAT Y	GAC D	AA S N	AT:	r GG? G	r GG G		r cae	C AGC	C AAC N	GT'	r TT	T GCT A	1248 416
	1249 417				AAG K	ACC T	GC A	A GAO	C CGC	G GT			C GT	AGC S	C AA' N	r GG	C TAC	1296 432
45	1297 433			G GAG										C CTC	C CA	C GA	C ATC	1344 448

38

	1345	ATA	AAC	CAG	AAC	GAC	TGG	AAG	CTG	CAG	GGC	ATC	GTG	AAC	GGC	ATC	GAC	1392
	449	I	N	Q	N	D	W	K	L	Q	G	I	V	N	G	I	D	464
	1393	ATG	AGC	GAG	TGG	AAC	CCC	GCT	GTG	GAC	GTG	CAC	CTC	CAC	TCC	GAC	GAC	1440
	465	M	S	E	W	N	P	A	V	D	V	H	L	H	S	D	D	480
5	1441	TAC	ACC	AAC	TAC	ACG	TTC	GAG	ACG	CTG	GAC	ACC	GGC	AAG	CGG	CAG	TGC	1488
	481	Y	T	N	Y	T	F	E	T	L	D	T	G	K	R	Q	C	496
	1489	AAG	GCC	GCC	CTG	CAG	CGG	CAG	CTG	GGC	CTG	CAG	GTC	CGC	GAC	GAC	GTG	1536
	497	K	A	A	L	Q	R	Q	L	G	L	Q	V	R	D	D	V	512
10	1537	CCA	CTG	ATC	GGG	TTC	ATC	GGG	CGG	CTG	GAC	CAC	CAG	AAG	GGC	GTG	GAC	1584
	513	P	L	I	G	F	I	G	R	L	D	H	Q	K	G	V	D	528
	1585	ATC	ATC	GCC	GAC	GCG	ATC	CAC	TGG	ATC	GCG	GGG	CAG	GAC	GTG	CAG	CTC	632
	529	I	I	A	D	A	I	H	W	I	A	G	Q	D	V	Q	L	544
	1633	gtg	ATG	CTG	GGC	ACC	GGG	CGG	GCC	GAC	CTG	GAG	GAC	ATG	CTG	CGG	CGG	1680
	545	V	M	L	G	T	G	R	A	D	L	E	D	M	L	R	R	560
15	1681	TTC	GAG	TCG	GAG	CAC	AGC	GAC	AAG	GTG	CGC	GCG	TGG	GTG	GGG	TTC	TCG	1728
	561	F	E	S	E	H	S	D	K	V	R	A	W	V	G	F	S	576
	1729	GTG	CCC	CTG	GCG	CAC	CGC	ATC	ACG	GCG	GGC	GCG	GAC	ATC	CTG	CTG	ATG	1776
	577	V	P	L	A	H	R	I	T	A	G	A	D	I	L	L	M	592
20	1777	CCG	TCG	CGG	TTC	GAG	CCG	TGC	GGG	CTG	AAC	CAG	CTC	TAC	GCC	ATG	GCG	1824
	593	P	S	R	F	E	P	C	G	L	N	Q	L	Y	A	M	A	608
	1825	TAC	GGG	ACC	GTG	CCC	GTG	GTG	CAC	GCC	GTG	GGG	GGG	CTC	CGG	GAC	ACG	1872
	609	Y	G	T	V	P	V	V	H	A	V	G	G	L	R	D	T	624
	1873	GTG	GCG	CCG	TTC	GAC	CCG	TTC	AAC	GAC	ACC	GGG	CTC	GGG	TGG	ACG	TTC	1920
	625	V	A	P	F	D	P	F	N	D	T	G	L	G	W	T	F	640
25	1921	GAC	CGC	GCG	GAG	GCG	AAC	CGG	ATG	ATC	GAC	GCG	CTC	TCG	CAC	TGC	CTC	1968
	641	D	R	A	E	A	N	R	M	I	D	A	L	S	H	C	L	656
	1969	ACC	ACG	TAC	CGG	AAC	TAC	AAG	GAG	AGC	TGG	CGC	GCC	TGC	AGG	GCG	CGC	2016
	657	T	T	Y	R	N	Y	K	E	S	W	R	A	C	R	A	R	672
30	2017	GGC	ATG	GCC	GAG	GAC	CTC	AGC	TGG	GAC	CAC	GCC	GCC	GTG	CTG	TAT	GAG	2064
	673	G	M	A	E	D	L	S	W	D	H	A	A	V	L	Y	E	688
	2065 689	GAC D	GTG V	CTC L	GTC V	AAG K	GCG A	AAG K	TAC Y	CAG Q	TGG W	TGA *						2097 699

### TABLE 4

DNA and Deduced Amino Acid Sequence of
The Soluble Starch Synthase I Gene in Maize
[SEQ ID NO:12; SEQ ID NO: 13]

FILE NAME : MSS1FULL.DNA SEQUENCE : NORMAL 1752 BP

CODON TABLE : UNIV.TCN

35

SEQUENCE REGION: 1 - 1752

40 TRANSLATION REGION: 1 - 1752

									GGG Gly								48
5									GTG Val								96
	GCC Ala	GAG Glu	CCC Pro	ACG Thr 735	GGT Gly	GAG Glu	CCG Pro	GCA Ala	TCG Ser 740	ACG Thr	CCG Pro	CCG Pro	CCC Pro	GTG Val 745	CCC Pro	GAC Asp	144
10									GAA Glu								192
15									GCA Ala								240
									GCT Ala								288
20									TAT Tyr								336
									GCT Ala 820								384
25									TTA Leu								432
30									AAA Lys								480
									TTC Phe								528
35									TCA Ser								576
									GGT Gly 900	Asp		_					624
40				Tyr					GCT Ala								672
45									ATG Met								720
									GCT Ala								768
50	GTT Val	TAT Tyr	AAA Lys	GAC Asp	TCC Ser 960	CGC Arg	AGC Ser	ATT Ile	CTT Leu	GTA Val 965	ATA Ile	CAT His	AAT Asn	TTA Leu	GCA Ala 970	CAT	816

			CA TAT CCT GAC CTT G hr Tyr Pro Asp Leu G 980	
5		Ala Leu Glu Ti	GG GTA TTC CCT GAA T rp Val Phe Pro Glu T 95	
	CAT GCC CTT GAC His Ala Leu Asp 1005	AAG GGT GAG GG Lys Gly Glu Al 1010	CA GTT AAT TTT TTG A la Val Asn Phe Leu L 1015	AA GGT GCA GTT 960 ys Gly Ala Val
10			CT GTC AGT AAG GGT T hr Val Ser Lys Gly T 1030	
15	_		AG GGC CTC AAT GAG C ln Gly Leu Asn Glu L 1045	<del>-</del>
		Leu Asn Gly I	TT GTA AAT GGA ATT G le Val Asn Gly Ile A 1060	
20		Thr Asp Lys Cy	GT ATC CCC TGT CAT T ys Ile Pro Cys His T 075	
			GT AAA GGT GCA TTG C ys Lys Gly Ala Leu G 1095	
25			TT CCT CTG ATT GGC T al Pro Leu Ile Gly P 1110	
30			AT CTC ATT CAA CTT A sp Leu Ile Gln Leu I 1125	
		Asp Val Gln Pl	TT GTC ATG CTT GGA T he Val Met Leu Gly S 1140	
35		Trp Met Arg Se	CT ACA GAG TCG ATC T er Thr Glu Ser Ile P 155 1	
			GT GTT CCA GTT TCC C er Val Pro Val Ser H 1175	
40			TG CCA TCC AGA TTC G et Pro Ser Arg Phe G 1190	
45			AG TAT GGC ACA GTT C ln Tyr Gly Thr Val P 1205	
		Leu Arg Asp Ti	CC GTG GAG AAC TTC A hr Val Glu Asn Phe A 1220	
50		Gln Gly Thr G	GG TGG GCA TTC GCA C ly Trp Ala Phe Ala P 235 1	

			Ala Asn Cys	AAT ATC TAC ATA Asn Ile Tyr Ile 1255	
5				GCG AGG CAT GTC Ala Arg His Val 1270	
	CTT CAC GTG GGA Leu His Val Gly				1752
10	(2) INFORMATION	FOR SEQ ID	NO:13:		
	(A	ENCE CHARACT LENGTH: 58 TYPE: amin TOPOLOGY:	4 amino acida o acid	3	
15	(ii) MOLE	CULE TYPE: p	rotein		
	(xi) SEQU	ENCE DESCRIP	TION: SEQ ID	NO:13:	
	Cys Val Ala Glu 1	Leu Ser Arg 5	Glu Gly Pro 10	Ala Pro Arg Pro	Leu Pro 15
20	Pro Ala Leu Leu 20		Leu Val Pro 25	Gly Phe Leu Ala 30	Pro Pro
	Ala Glu Pro Thr	Gly Glu Pro	Ala Ser Thr 40	Pro Pro Pro Val 45	Pro Asp
	Ala Gly Leu Gly 50	Asp Leu Gly 55	Leu Glu Pro	Glu Gly Ile Ala	Glu Gly
25	Ser Ile Asp Asn 65	Thr Val Val	Val Ala Ser	Glu Gln Asp Ser 75	Glu Ile 80
	Val Val Gly Lys	Glu Gln Ala 85	Arg Ala Lys 90	Val Thr Gln Ser	Ile Val 95
30	Phe Val Thr Gly		Pro Tyr Ala 105	Lys Ser Gly Gly 110	Leu Gly
	Asp Val Cys Gly 115	Ser Leu Pro	Val Ala Leu 120	Ala Ala Arg Gly 125	His Arg
	Val Met Val Val 130	Met Pro Arg 135	Tyr Leu Asn	Gly Thr Ser Asp	Lys Asn
35	Tyr Ala Asn Ala 145	Phe Tyr Thr 150	Glu Lys His	Ile Arg Ile Pro 155	Cys Phe 160
	Gly Gly Glu His	Glu Val Thr 165	Phe Phe His 170	Glu Tyr Arg Asp	Ser Val 175
40	Asp Trp Val Phe		Pro Ser Tyr 185	His Arg Pro Gly 190	Asn Leu
	Tyr Gly Asp Lys	Phe Gly Ala	Phe Gly Asp	Asn Gln Phe Arg 205	Tyr Thr
	Leu Leu Cys Tyr 210	Ala Ala Cys 215	Glu Ala Pro	Leu Ile Leu Glu 220	Leu Gly
45	Gly Tyr Ile Tyr 225	Gly Gln Asn 230	Cys Met Phe	Val Val Asn Asp 235	Trp His 240

Ala Ser Leu Val Pro Val Leu Leu Ala Ala Lys Tyr Arg Pro Tyr Gly 245 250 255 Val Tyr Lys Asp Ser Arg Ser Ile Leu Val Ile His Asn Leu Ala His Gln Gly Val Glu Pro Ala Ser Thr Tyr Pro Asp Leu Gly Leu Pro Pro 275 280 285 5 Glu Trp Tyr Gly Ala Leu Glu Trp Val Phe Pro Glu Trp Ala Arg Arg 290 295 300 His Ala Leu Asp Lys Gly Glu Ala Val Asn Phe Leu Lys Gly Ala Val 305 310 315 32010 Val Thr Thr Ala Glu Gly Gly Gln Gly Leu Asn Glu Leu Leu Ser Ser 340 345 35015 Trp Asn Pro Ala Thr Asp Lys Cys Ile Pro Cys His Tyr Ser Val Asp 370 380 Asp Leu Ser Gly Lys Ala Lys Cys Lys Gly Ala Leu Gln Lys Glu Leu 385 390 395 400 20 Gly Leu Pro Ile Arg Pro Asp Val Pro Leu Ile Gly Phe Ile Gly Arg
405 410 415 Leu Asp Tyr Gln Lys Gly Ile Asp Leu Ile Gln Leu Ile Ile Pro Asp 420 425 430 Leu Met Arg Glu Asp Val Gln Phe Val Met Leu Gly Ser Gly Asp Pro 435 445 25 Glu Leu Glu Asp Trp Met Arg Ser Thr Glu Ser Ile Phe Lys Asp Lys 450 460 Phe Arg Gly Trp Val Gly Phe Ser Val Pro Val Ser His Arg Ile Thr 465 470 475 48030 Ala Gly Cys Asp Ile Leu Leu Met Pro Ser Arg Phe Glu Pro Cys Gly Leu Asn Gln Leu Tyr Ala Met Gln Tyr Gly Thr Val Pro Val Val His 500 510 Ala Thr Gly Gly Leu Arg Asp Thr Val Glu Asn Phe Asn Pro Phe Gly 515 520 52535 Glu Asn Gly Glu Gln Gly Thr Gly Trp Ala Phe Ala Pro Leu Thr Thr 530 540 Glu Asn Met Phe Val Asp Ile Ala Asn Cys Asn Ile Tyr Ile Gln Gly 545 550 555 560 40 Thr Gln Val Leu Gly Arg Ala Asn Glu Ala Arg His Val Lys Arg 565 570 575 Leu His Val Gly Pro Cys Arg \* 580

#### TABLE 5

## mRNA Sequence and Deduced Amino Acid Sequence of The Maize Branching Enzyme II Gene and the Transit Peptide [SEO ID NO:14 and SEO ID NO:15]

```
5
                                 2725 bp ss-mRNA
      LOCUS
                   MZEGLUCTRN
                   Corn starch branching enzyme II mRNA, complete cds.
       DEFINITION
      ACCESSION
                   L08065
       KEYWORDS
                   1,4-alpha-glucan branching enzyme; amylo-transglycosylase;
                   glucanotransferase; starch branching enzyme II.
10
                   Zea mays cDNA to mRNA.
       SOURCE
         ORGANISM Zea mays
                   Eukaryota; Plantae; Embryobionta; Magnoliophyta; Liliopsida;
                   Commelinidae; Cyperales; Poaceae.

1 (bases 1 to 2725)
Fisher, D. K., Boyer, C.D. and Hannah, L.C.
       REFERENCE
15
         AUTHORS
         TITLE
                   Starch branching enzyme II from maize endosperm
                   Plant Physiol. 102, 1045-1046 (1993)
         JOURNAL
                   full automatic
         STANDARD
       COMMENT
                   NCBI gi: 168482
20
       FEATURES
                             Location/Qualifiers
                             1..2725
                             /cultivar="W64Ax182E"
                             /dev stage="29 days post pollenation"
                             /tissue_type="endosperm"
25
                             /organism="Zea mays"
            sig_peptide
                             91..264
                             /codon_start=1
91..2490
            CDS
                             /EC number="2.4.1.18"
30
                             /note="NCBI gi: 168483"
                             /codon start=1
                             /product="starch branching enzyme II"
       /translation="MAFRVSGAVLGGAVRAPRLTGGGEGSLVFRHTGLFLTRGARVGC
35
       SGTHGAMRAAAARKAVMVPEGENDGLASRADSAQFQSDELEVPDISEETTCGAGVAD
       AQALNRVRVVPPPSDGQKIFQIDPMLQGYKYHLEYRYSLYRRIRSDIDEHEGGLEAFS
40
       RSYEKFGFNASAEGITYREWAPGAFSAALVGDVNNWDPNADRMSKNEFGVWEIFLPNN
       ADGTSPIPHGSRVKVRMDTPSGIKDSIPAWIKYSVOAPGEIPYDGIYYDPPEEVKYVF
       RHAQPKRPKSLRIYETHVGMSSPEPKINTYVNFRDEVLPRIKKLGYNAVQIMAIQEHS
45
       YYGSFGYHVTNFFAPSSRFGTPEDLKSLIDRAHELGLLVLMDVVHSHASSNTLDGLNG
       FDGTDTHYFHSGPRGHHWMWDSRLFNYGNWEVLRFLLSNARWWLEEYKFDGFRFDGVT
50
       SMMYTHHGLQVTFTGNFNEYFGFATDVDAVVYLMLVNDLIHGLYPEAVTIGEDVSGMP
       TFALPVHDGGVGFDYRMHMAVADKWIDLLKQSDETWKMGDIVHTLTNRRWLEKCVTYA
       ESHDOALVGDKTIAFWLMDKDMYDFMALDRPSTPTIDRGIALHKMIRLITMGLGGEGY
55
       LNFMGNEFGHPEWIDFPRGPORLPSGKFIPGNNNSYDKCRRRFDLGDADYLRYHGMQE
       FDOAMOHLEOKYEFMTSDHOYISRKHEEDKVIVFEKGDLVFVFNFHCNNSYFDYRIGC
60
       RKPGVYKVVLDSDAGLFGGFSRIHHAAEHFTADCSHDNRPYSFSVYTPSRTCVVYAPV
            mat peptide
                             265..2487
                             /codon start=1
                             /product="starch branching enzyme II"
65
       BASE COUNT
                                534 C
                                          715 G
                        727 A
                                                  749 T
```

	ORIGIN	COCCODODA CO ACACCOCAM MINOCOMENCO COCOMOCOMOS COMMUNICAS MINOCOMOS MA
		GGCCCAGAGC AGACCCGGAT TTCGCTCTTG CGGTCGCTGG GGTTTTAGCA TTGGCTGATC AGTTCGATCC GATCCGGCTG CGAAGGCGAG ATGGCGTTCC GGGTTTCTGG GGCGGTGCTC
		GGTGGGGCCG TAAGGGCTCC CCGACTCACC GGCGGCGGGG AGGGTAGTCT AGTCTTCCGG
5		CACACCGGCC TCTTCTTAAC TCGGGGTGCT CGAGTTGGAT GTTCGGGGAC GCACGGGGCC
	241	ATGCGCGCGG CGGCCGCGC CAGGAAGGCG GTCATGGTTC CTGAGGGCGA GAATGATGGC
		CTCGCATCAA GGGCTGACTC GGCTCAATTC CAGTCGGATG AACTGGAGGT ACCAGACATT
		TCTGAAGAGA CAACGTGCGG TGCTGGTGTG GCTGATGCTC AAGCCTTGAA CAGAGTTCGA
10		GTGGTCCCCC CACCAAGCGA TGGACAAAAA ATATTCCAGA TTGACCCCAT GTTGCAAGGC
10		TATAAGTACC ATCTTGAGTA TCGGTACAGC CTCTATAGAA GAATCCGTTC AGACATTGAT GAACATGAAG GAGGCTTGGA AGCCTTCTCC CGTAGTTATG AGAAGTTTGG ATTTAATGCC
		AGCGCGGAAG GTATCACATA TCGAGAATGG GCTCCTGGAG CATTTTCTGC AGCATTGGTG
		GGTGACGTCA ACAACTGGGA TCCAAATGCA GATCGTATGA GCAAAAATGA GTTTGGTGTT
		TGGGAAATTT TTCTGCCTAA CAATGCAGAT GGTACATCAC CTATTCCTCA TGGATCTCGT
15	781	GTAAAGGTGA GAATGGATAC TCCATCAGGG ATAAAGGATT CAATTCCAGC CTGGATCAAG
		TACTCAGTGC AGGCCCCAGG AGAAATACCA TATGATGGGA TTTATTATGA TCCTCCTGAA
	901	GAGGTAAAGT ATGTGTTCAG GCATGCGCAA CCTAAACGAC CAAAATCATT GCGGATATAT
	961	GAAACACATG TCGGAATGAG TAGCCCGGAA CCGAAGATAA ACACATATGT AAACTTTAGG
20		GATGAAGTCC TCCCAAGAAT AAAAAAACTT GGATACAATG CAGTGCAAAT AATGGCAATC CAAGAGCACT CATATTATGG AAGCTTTGGA TACCATGTAA CTAATTTTTT TGCGCCAAGT
20	1141	AGTCGTTTTG GTACCCCAGA AGATTTGAAG TCTTTGATTG ATAGAGCACA TGAGCTTGGT
		TTGCTAGTTC TCATGGATGT GGTTCATAGT CATGCGTCAA GTAATACTCT GGATGGGTTG
		AATGGTTTTG ATGGTACAGA TACACATTAC TTTCACAGTG GTCCACGTGG CCATCACTGG
,		ATGTGGGATT CTCGCCTATT TAACTATGGG AACTGGGAAG TTTTAAGATT TCTTCTCCC
25	1381	AATGCTAGAT GGTGGCTCGA GGAATATAAG TTTGATGGTT TCCGTTTTGA TGGTGTGACC
		TCCATGATGT ACACTCACCA CGGATTACAA GTAACATTTA CGGGGAACTT CAATGAGTAT
	1501	TTTGGCTTTG CCACCGATGT AGATGCAGTG GTTTACTTGA TGCTGGTAAA TGATCTAATT
		CATGGACTTT ATCCTGAGGC TGTAACCATT GGTGAAGATG TTAGTGGAAT GCCTACATTT GCCCTTCCTG TTCACGATGG TGGGGTAGGT TTTGACTATC GGATGCATAT GGCTGTGGCT
30		GACAAATGGA TTGACCTTCT CAAGCAAAGT GATGAAACTT GGAAGATGGG TGATATTGTG
		CACACACTGA CAAATAGGAG GTGGTTAGAG AAGTGTGTAA CTTATGCTGA AAGTCATGAT
		CAAGCATTAG TCGGCGACAA GACTATTGCG TTTTGGTTGA TGGACAAGGA TATGTATGAT
	1861	TTCATGGCCC TCGATAGACC TTCAACTCCT ACCATTGATC GTGGGATAGC ATTACATAAG
2.5		ATGATTAGAC TTATCACAAT GGGTTTAGGA GGAGAGGGCT ATCTTAATTT CATGGGAAAT
35		GAGTTTGGAC ATCCTGAATG GATAGATTTT CCAAGAGGTC CGCAAAGACT TCCAAGTGGT
		AAGTTTATTC CAGGGAATAA CAACAGTTAT GACAAATGTC GTCGAAGATT TGACCTGGGT
		GATGCAGACT ATCTTAGGTA TCATGGTATG CAAGAGTTTG ATCAGGCAAT GCAACATCTT GAGCAAAAAT ATGAATTCAT GACATCTGAT CACCAGTATA TTTCCCGGAA ACATGAGGAG
		GATAAGGTGA TTGTGTTCGA AAAGGGAGAT TTGGTATTTG TGTTCAACTT CCACTGCAAC
40		AACAGCTATT TTGACTACCG TATTGGTTGT CGAAAGCCTG GGGTGTATAA GGTGGTCTTG
		GACTCCGACG CTGGACTATT TGGTGGATTT AGCAGGATCC ATCACGCAGC CGAGCACTTC
		ACCGCCGACT GTTCGCATGA TAATAGGCCA TATTCATTCT CGGTTTATAC ACCAAGCAGA
		ACATGTGTCG TCTATGCTCC AGTGGAGTGA TAGCGGGGTA CTCGTTGCTG CGCGGCATGT
45		GTGGGGCTGT CGATGTGAGG AAAAACCTTC TTCCAAAACC GGCAGATGCA TGCATGCATG
40		CTACAATAAG GTTCTGATAC TTTAATCGAT GCTGGAAAGC CCATGCATCT CGCTGCGTTG TCCTCTCTAT ATATATAAGA CCTTCAAGGT GTCAATTAAA CATAGAGTTT TCGTTTTTCG
		CTTTCCTAAA AAAAAAAAA AAAAA
	//	OTTIOOTING, INGUINING INGUI.
	• •	
		TABLE 6
50		mRNA Sequence and Deduced Amino Acid Sequence of the
		Maize Branching Enzyme I and the Transit Peptide
		[SEQ ID NO:16 and SEQ ID NO:17]
	Locus	MZEBEI 2763 bp ss-mRNA PLN
	DEFINITION	
55	ACCESSION	
	KEYWORDS	branching enzyme-I.
	SOURCE	Zea mays L. (inbred Oh43), cDNA to mRNA.
	ORGANIS	
60		Eukaryota; Plantae; Embryobionta; Magnoliophyta; Liliopsida; Commelinidae; Liliopsida.
00	REFERENCE	
	AUTHORS	
		Arai,Y.
		•

```
Sequence conservation of the catalytic regions of Amylolytic
         TITLE
                   enzymes in maize branching enzyme-I
                   Biochem. Biophys. Res. Commun. 181, 87-94 (1991)
         JOURNAL
         STANDARD
                   full automatic
                   Submitted (30-APR-1992) to DDBJ by: Tadashi Baba
 5
       COMMENT
                   Institute of Applied Biochemistry
                   University of Tsukuba
                   Tsukuba, Ibaraki 305
                   Japan
10
                            0298-53-6632
                   Phone:
                   Fax:
                            0298-53-6632.
                   NCBI gi: 217959
                             Location/Qualifiers
       FEATURES
                             1..2763
            source
                             /organism="Zea mays"
15
                             <1..2470
            CDS
                             /note="NCBI gi: 217960"
                             /codon start=2
                             /product="branching enzyme-I precursor"
20
       /translation="LCLVSPSSSPTPLPPPRRSRSHADRAAPPGIAGGGNVRLSVLSV
       QCKARRSGVRKVKSKFATAATVQEDKTMATAKGDVDHLPIYDLDPKLEIFKDHFRYRM
25
       KRFLEQKGSIEENEGSLESFSKGYLKFGINTNEDGTVYREWAPAAQEAELIGDFNDWN
       GANHKMEKDKFGVWSIKIDHVKGKPAIPHNSKVKFRFLHGGVWVDRIPALIRYATVDA
       SKFGAPYDGVHWDPPASERYTFKHPRPSKPAAPRIYEAHVGMSGEKPAVSTYREFADN
30
       VLPRIRANNYNTVOLMAVMEHSYYASFGYHVTNFFAVSSRSGTPEDLKYLVDKAHSLG
       LRVLMDVVHSHASNNVTDGLNGYDVGQSTQESYFHAGDRGYHKLWDSRLFNYANWEVL
35
       RFLLSNLRYWLDEFMFDGFRFDGVTSMLYHHHGINVGFTGNYQEYFSLDTAVDAVVYM
       MLANHLMHKLLPEATVVAEDVSGMPVLCRPVDEGGVGFDYRLAMAIPDRWIDYLKNKD
       DSEWSMGEIAHTLTNRRYTEKCIAYAESHDQSIVGDKTIAFLLMDKEMYTGMSDLQPA
40
       SPTIDRGIALOKMIHFITMALGGDGYLNFMGNEFGHPEWIDFPREGNNWSYDKCRRQW
       SLVDTDHLRYKYMNAFDQAMNALDERFSFLSSSKQIVSDMNDEEKVIVFERGDLVFVF
45
       NFHPKKTYEGYKVGCDLPGKYRVALDSDALVFGGHGRVGHDVDHFTSPEGVPGVPETN
       FNNRPNSFKVLSPPRTCVAYYRVDEAGAGRRLHAKAETGKTSPAESIDVKASRASSKE
                             DKEATAGGKKGWKFARQPSDQDTK"
            transit peptide 2..190
50
            mat_peptide
                             191..2467
                             /EC number="2.4.1.18"
                             /codon start=1
                             /product="branching enzyme-I precursor"
                             2734..2739
            polyA_signal
55
       BASE COUNT
                       719 A
                                 585 C
                                           737 G
                                                    722 T
       ORIGIN
               1 GCTGTGCCTC GTGTCGCCCT CTTCCTCGCC GACTCCGCTT CCGCCGCCGC GGCGCTCTCG
              61 CTCGCATGCT GATCGGGCGG CACCGCCGGG GATCGCGGGT GGCGGCAATG TGCGCCTGAG
             121 TGTGTTGTCT GTCCAGTGCA AGGCTCGCCG GTCAGGGGTG CGGAAGGTCA AGAGCAAATT
             181 CGCCACTGCA GCTACTGTGC AAGAAGATAA AACTATGGCA ACTGCCAAAG GCGATGTCGA
60
             241 CCATCTCCC ATATACGACC TGGACCCCAA GCTGGAGATA TTCAAGGACC ATTTCAGGTA
              301 CCGGATGAAA AGATTCCTAG AGCAGAAAGG ATCAATTGAA GAAAATGAGG GAAGTCTTGA
             361 ATCTTTTCT AAAGGCTATT TGAAATTTGG GATTAATACA AATGAGGATG GAACTGTATA
421 TCGTGAATGG GCACCTGCTG CGCAGGAGGC AGAGCTTATT GGTGACTTCA ATGACTGGAA
65
             481 TGGTGCAAAC CATAAGATGG AGAAGGATAA ATTTGGTGTT TGGTCGATCA AAATTGACCA
             541 TGTCAAAGGG AAACCTGCCA TCCCTCACAA TTCCAAGGTT AAATTTCGCT TTCTACATGG
             601 TGGAGTATGG GTTGATCGTA TTCCAGCATT GATTCGTTAT GCGACTGTTG ATGCCTCTAA
```

PCT/US97/17555 WO 98/14601

		721	TAA	GCAT	CCT	CGGC	CCTTC	AA .	AGCCI	GCTG	C T	CCAC	GTATO	TA	rgaa(	GCCC	ATGT	CACATT AGGTAT GCCACG
_		841	CAT	ACG	AGCA	AAT	AACTA	CA.	ACAC	GTTC	CA G	TTGA:	rggc#	GT	<b>TATG</b>	GAGC	ATTC	GTACTA
5																		CACACC GATGGA
		1021	TGT	TGT	CCAT	AGC	CATGO	AA	GTAA1	PAATO	T C	ACAG	ATGGI	TT	TAAA	GGCT	ATGA	TGTTGG
																		TTGGGA
10																		CCTGAG AATGCT
		1261	GT?	ATCAT	CAC	CATO	GTAI	CA .	ATGT	GGGT	T T	ACTG	GAAAC	TA	CCAG	GAAT	ATTT	CAGTTT
																		CAAACT
																		TAGATG
15		1501	GAT	TGAC	CTAC	CTG	AAGAA	TA.	AAGA'	[GAC]	C TO	GAGT	GTCG	AT	GGGT	GAAA	TAGC	GCATAC
																		TCAGTC TGGCAT
		1681	GTO	CAGAC	CTTG	CAG	CCTGC	TT	CACC	CACA	AT TO	GATC	GAGGG	AT'	TGCA	CTCC	AAAA	GATGAT
20																		TGAGTT
20																		TAAATG TGCGTT
		1921	TG	ACCAZ	AGCG	ATG	AATGC	CGC	TCGAT	rgag <i>i</i>	AG A	rttt(	CCTTC	CT'	TTCG'	TCGT	CAAA	GCAGAT
																		AGTTTT
25																		TTTGCC AAGAGT
		2161	TGC	CCAC	CGAC	GTG	GATCA	CT	TCAC	STCGC	CC T	GAAG	GGGT	CC	AGGG	GTGC	CCGA	AACGAA
																		GGCTTA AGGAAA
																		AGGAAA AGACAA
30		2401	GG?	AGGC	AACG	GCT	GTGG	CA	AGAAC	GGAT	rg G	AAGT:	rtgco	CG	GCAG	CCAT	CCGA	TCAAGA
																		GTTAGT GTAGCT
		2581	TG	CAGG	CGAC	TGG:	rgtci	CA	TCAC	CGAGO	CA G	GCAG	GCACI	C GC	TTGT:	ATAG	CTTT	TCTAGA
35																		TGTGCC
33		2761			STAT	GTA	CAGGA	1GC	AGTTO	CCG	re e	AGAA'	LAAAA	A AA	AAAC'	TTGT	TGGG	GGGTTT
	//																	
										ABL								
				<u>C</u>	oding	g Sec	-		d Dec					<u>Sequ</u>	ence	<u>for</u>		
40									t Pept									
					<u>S</u> c	oluble	e Star	rch S	Synth:	ase I	Mai	ze Ge	ene (	153 t	<u>(qq</u>			
							SEQ_	<u>1 (D</u>	<u> 1:07</u>	3 and	SEC	DI (	NO:	19]				
					_	• •		~										
		FII	E !	IAME	: }	4SS1:	TRPT.	DNA	SI	EQUEN	NCE	: NOI	RMAL		153	BP		
					E : T													
45		SEÇ	UEN	CE	REC	SION	:		1 -	15	53							
		TRA	NSL!	ATION	N REC	GION	:		1 -	15	53							
	**	* DNA	TRI	ANSLA	OITA	4 * *	*											
	1	ATG	GCG	ACG	ccc	TCG	GCC	GTG	GGC	GCC	GCG	TGC	стс	CTC	СТС	GCG	CGG	48
	ī	M			P				G							A		16
50	40	000	~~~	maa	000	000	000	CTIC	000	CNC	000	000	000	000	000	300	om o	0.6
30	49 17	GCC A	GCC A	TGG W	P	GCC A	A	V	GGC	D	R	GCG A	R	P	R	AGG R	L	96 32
						-										-		
	97 33								TGC C					AGC S			GGG G	144
	33	¥	М	٧	.,	N.	A	~	C	٧	Ω	c	ב	3	Α.	2	G	48
55	145																	153
33	49	P	H	М														51

#### **GFP** constructs:

5

10

15

20

1. GFP only in pET-21a:

pEXS115 is digested with *Nde* I and *Xho* I and the 740 bp fragment containing the SGFP coding sequence is subcloned into the *Nde* I and *Xho* I sites of pET-21a (Novagen 601 Science Dr. Madison WI). (See FIG. 2b GFP-21a map.)

2. GFP subcloned in-frame at the 5' end of full-length mature WX:

The 740 bp *Nde* I fragment containing SGFP from pEXS114 is subcloned into the *Nde* I site of pEXSWX. (See FIG.3a GFP-FLWX map.)

3. GFP subcloned in-frame at the 5' end of N-terminally truncated WX:

WX truncated by 700 bp at N-terminus.

The 1 kb BamH I fragment encoding the C-terminus of WX from pEXSWX is subcloned into the Bgl II site of pEXS115. Then the entire SGFP-truncated WX fragment is subcloned into pET21a as a Nde I-HindIII fragment. (See FIG. 3b GFP-BamHIWX map.)

4. GFP subcloned in-frame at the 5' end of truncated WX: WX truncated by 100 bp at N-terminus.

The 740 bp *Nde* I-*Nco* I fragment containing SGFP from pEXS115 is subcloned into pEXSWX at the *Nde* I and *Nco* I sites. (See Fig. 4 GFP-NcoWX map.)

#### Example Three:

#### Plasmid Transformation into Bacteria:

Escherichia coli competent cell preparation:

- 1. Inoculate 2.5 ml LB media with a single colony of desired *E. coli* strain: selected strain was XLIBLUE DL2IDE3 from (Stratagene); included appropriate antibiotics. Grow at 37°C, 250 rpm overnight.
- Inoculate 100 ml of LB media with a 1:50 dilution of the overnight culture,
   including appropriate antibiotics. Grow at 37°C, 250 rpm until OD<sub>600</sub>=0.3-0.5.
  - 3. Transfer culture to sterile centrifuge bottle and chill on ice for 15 minutes.

PCT/US97/17555

- 4. Centrifuge 5 minutes at 3,000x g (4°C).
- 5. Resuspend pellet in 8 ml ice-cold Transformation buffer. Incubate on ice for 15 minutes.
  - 6. Centrifuge 5 minutes at 3,000x g (4°C).
- 5 7. Resuspend pellet in 8 ml ice-cold Transformation buffer 2. Aliquot, flash-freeze in liquid nitrogen, and stored at -70°C.

	Transformation Buffer	Transformation B	uffer 2
	RbCl 1.2 g	MOPS (10 mM)	0.209 g
	MnCl <sub>2</sub> 4H <sub>2</sub> O 0.99g	RbCl	0.12 g
10	K-Acetate 0.294 g	CaCl <sub>2</sub> 2H <sub>2</sub> O	1.1 g
	CaCl <sub>2</sub> 2H <sub>2</sub> O 0.15 g	Glycerol	15 g
	Glycerol 15 g	dH <sub>2</sub> O	100 ml
	$dH_2O$ 100 ml	pH to 6.8 with N	aOH
	pH to 5.8 with 0.2 M a	cetic acid Filter sterilize	
15	Filter sterilize		

Escherichia coli transformation by rubidium chloride heat shock method: Hanahan, D. (1985) in DNA cloning: a practical approach (Glover, D.M. ed.), pp. 109-135, IRL Press.

- 1. Incubate 1-5  $\mu$ l of DNA on ice with 150  $\mu$ l *E. coli* competent cells for 30 minutes.
- 20 2. Heat shock at 42°C for 45 seconds.
  - 3. Immediately place on ice for 2 minutes.
  - 4. Add 600  $\mu$ l LB media and incubate at 37°C for 1 hour.

5. Plate on LB agar including the appropriate antibiotics.

This plasmid will express the hybrid polypeptide containing the green fluorescent protein within the bacteria.

#### **Example Four:**

#### 5 Expression of Construct in E. coli:

- 1. Inoculate 3 ml LB with *E. coli* containing plasmid of interest. Include appropriate antibiotics. 37°C, 250 rpm, overnight.
- 2. Inoculate 100 ml LB with 2 ml of overnight culture. Include appropriate antibiotics. Grow at 37°C, 250 rpm.
- 10 3. At  $OD_{600}$  about 0.4-0.5, place at room temperature, 200 rpm.
  - 4. At OD<sub>600</sub> about 0.6-0.8, induce with 100  $\mu$ l 1M 1PTG. Final 1PTG concentration is 1 mM.
  - 5. Grow at room temperature, 200 rpm, 4-5 hours.
  - 6. Collect cells by centrifugation.

20

7. Flash freeze in liquid nitrogen and store at -70°C until use.

Cells can be resuspended in  $dH_2O$  and viewed under UV light ( $\lambda_{max} = 395$  nm) for intrinsic fluorescence. Alternatively, the cells can be sonicated and an aliquot of the cell extract can be separated by SDS-PAGE and viewed under UV light to detect GFP fluorescence. When the protein employed is a green fluorescent protein, the presence of the protein in the lysed material can be evaluated under UV at 395 nm in a light box and the signature green glow can be identified.

#### **Example Five:**

#### Plasmid Extraction from Bacteria:

The following is one of many common alkaline lysis plasmid purification protocols useful in practicing this invention.

- 5 1. Inoculate 100-200 ml LB media with a single colony of E. coli transformed with the one of the plasmids described above. Include appropriate antibiotics. Grow at 37°C. 250 rpm overnight.
  - 2. Centrifuge 10 minutes at 5,000x g (4°C).
- 3. Resuspend cells in 10 ml water, transfer to a 15 ml centrifuge tube, and repeat 10 centrifugation.
  - 4. Resuspend pellet in 5 ml 0.1 M NaOH, 0.5% SDS. Incubate on ice for 10 minutes.
  - 5. Add 2.5 ml of 3 M sodium acetate (pH 5.2), invert gently, and incubate 10 minutes on ice.
  - 6. Centrifuge 5 minutes at 15,000-20,000x g (4°C).
- 15 7. Extract supernatant with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1).
  - 8. Centrifuge 10 minutes at 6,000-10,000x g (4°C).
  - 9. Transfer aqueous phase to clean tube and precipitate with 1 volume of isopropanol.
  - 10. Centrifuge 15 minutes at 12,000x g (4°C).
- 20 11. Dissolve pellet in 0.5 ml TE, add 20 µl of 10 mg/ml Rnase, and incubate 1 hour at 37°C.

51

- 12. Extract twice with phenol:chloroform:isoamyl alcohol (25:24:1).
- 13. Extract once with chloroform.
- 14. Precipitate aqueous phase with 1 volume of isopropanol and 0.1 volume of 3 M sodium acetate.
- 5 15. Wash pellet once with 70% ethanol.
  - 16. Dry pellet in SpeedVac and resuspend pellet in TE.

This plasmid can then be inserted into other hosts.

### TABLE 8 DNA Sequence and Deduced Amino Acid Sequence of Coding Region from PEYS52 ISEO ID NO.20: SEO ID NO.21:

Starch Synthase Coding Region from pEXS52 [SEQ ID NO:20; SEQ ID NO:21]

FILE NAME : MSS1DELN.DNA SEQUENCE : NORMAL 1626 BP CODON TABLE : UNIV.TCN

SEQUENCE REGION: 1 - 1626 TRANSLATION REGION: 1 - 1626

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

				AGG										48	
3 mm	 ~~~	 mcc	3.00	CAM	220	707	Cm2	CMM	CTC	CCN	N.C.M	CNC	CDB	06	

ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA

20 Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln
70 75 80

GAT	TCT	GAG	ATT	GTG	GTT	GGA	AAG	GAG	CAA	GCT	CGA	GCT	AAA	GTA	ACA	144
Asp	Ser 85	Glu	Ile	Val	Val	Gly 90	Lys	Glu	Gln	Ala	Arg 95	Ala	Lys	Val	Thr	

25 CAA AGC ATT GTC TTT GTA ACC GGC GAA GCT TCT CCT TAT GCA AAG TCT
Gln Ser Ile Val Phe Val Thr Gly Glu Ala Ser Pro Tyr Ala Lys Ser
100 115

GGG GGT CTA GGA GAT GTT TGT GGT TCA TTG CCA GTT GCT CTT GCT GCT GCT GLy Gly Gly Leu Gly Asp Val Cys Gly Ser Leu Pro Val Ala Leu Ala Ala 120 125 130

CGT GGT CAC CGT GTG ATG GTT GTA ATG CCC AGA TAT TTA AAT GGT ACC
Arg Gly His Arg Val Met Val Val Met Pro Arg Tyr Leu Asn Gly Thr

			135				140					145		
				TAT Tyr										336
5				GGC Gly										384
10				GAC Asp										432
				TAT Tyr 200										480
15				CTC Leu										528
				GGA Gly										576
20				GCC Ala										624
25				GTT Val										672
				CAG Gln 280										720
30				GAA Glu										768
				CAT His										816
35	Lys	Ala		GTG Val	Thr	Ala	Arg	Ile	Val	Thr	Val			864
40				GTC Val										912
				AGA Arg 360										960
45				TGG Trp										1008
				yab GyC										1056

PCT/US97/17555

53

										<i>J</i> .	,						
	CAG Gln	AAG Lys 405	GAG Glu	CTG Leu	GGT Gly	TTA Leu	CCT Pro 410	ATA Ile	AGG Arg	CCT Pro	GAT Asp	GTT Val 415	CCT Pro	CTG Leu	ATT Ile	GGC Gly	1104
5													CTC Leu				1152
	ATC Ile	ATA Ile	CCA Pro	GAT Asp	CTC Leu 440	ATG Met	CGG Arg	GAA Glu	GAT Asp	GTT Val 445	CAA Gln	TTT Phe	GTC Val	ATG Met	CTT Leu 450	GGA Gly	1200
10													ACA Thr				1248
15													GTT Val 480				1296
													CCA Pro				1344
20													TAT Tyr				1392
													GTG Val				1440
25													TGG Trp				1488
30													AAC Asn 560				1536
	TAC Tyr	ATA Ile 565	CAG Gln	GGA Gly	ACA Thr	CAA Gln	GTC Val 570	CTC Leu	CTG Leu	GGA Gly	AGG Arg	GCT Ala 575	AAT Asn	GAA Glu	GCG Ala	AGG Arg	1584
35		Val			CTT Leu												1620
	(2)	INF	ORMA'	TION	FOR	SEQ	ID	NO:2	1:								
			(i) :	SEOU	ENCE	CHA	RACT	ERIS	TICS	:		•					

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 540 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

#### (ii) MOLECULE TYPE: protein

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 1 5 10 15 45

Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 20

Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr 35 40 45

	GIN	50	He	vaı	Pne	vai	55	GIY	Giu	Ala	ser	60	Tyr	ATG	гàв	261
	Gly 65	Gly	Leu	Gly	Asp	Val 70	Сув	Gly	Ser	Leu	Pro 75	Val	Ala	Leu	Ala	Ala 80
5	Arg	Gly	His	Arg	Val 85	Met	Val	Val	Met	Pro 90	Arg	Tyr	Leu	Asn	Gly 95	Thi
	Ser	Asp	Lys	Asn 100	Tyr	Ala	Asn	Ala	Phe 105	Tyr	Thr	Glu	Lys	His 110	Ile	Arg
10	Ile	Pro	Сув 115	Phe	Gly	Gly	Glu	His 120	Glu	Val	Thr	Phe	Phe 125	His	Glu	Ту
	Arg	Asp 130	Ser	Val	Asp	Trp	Val 135	Phe	Val	Asp	His	Pro 140	Ser	Tyr	His	Arg
	Pro 145	Gly	Asn	Leu	Tyr	Gly 150	Asp	Lys	Phe	Gly	Ala 155	Phe	Gly	Asp	Asn	Gl: 160
15	Phe	Arg	Tyr	Thr	Leu 165	Leu	Сув	Tyr	Ala	Ala 170	Cys	Glu	Ala	Pro	Leu 175	Ile
	Leu	Glu	Leu	Gly 180	Gly	Tyr	Ile	Tyr	Gly 185	Gln	Asn	Сув	Met	Phe 190	Val	Va:
20	Asn	Asp	Trp 195	His	Ala	Ser	Leu	Val 200	Pro	Val	Leu	Leu	Ala 205	Ala	Lys	Ту
	Arg	Pro 210	Tyr	Gly	Val	Tyr	Lys 215	Asp	Ser	Arg	Ser	Ile 220	Leu	Val	Ile	His
	Asn 225	Leu	Ala	His	Gln	Gly 230	Val	Glu	Pro	Ala	Ser 235	Thr	Tyr	Pro	Asp	Le: 240
25	Gly	Leu	Pro	Pro	Glu 245	Trp	Tyr	Gly	Ala	Leu 250	Glu	Trp	Val	Phe	Pro 255	Gl
	Trp	Ala	Arg	Arg 260	His	Ala	Leu	Asp	Lys 265	Gly	Glu	Ala	Val	Asn 270	Phe	Le
30	Lys	Gly	Ala 275	Val	Val	Thr	Ala	Asp 280	Arg	Ile	Val	Thr	Val 285	Ser	Lys	Gl
	Tyr	Ser 290	Trp	Glu	Val	Thr	Thr 295	Ala	Glu	Gly	Gly	Gln 300	Gly	Leu	Asn	Gl
	Leu 305	Leu	Ser	Ser	Arg	Lys 310	Ser	Val	Leu	Asn	Gly 315	Ile	Val	Asn	Gly	11d 32d
35	Asp	Ile	Asn	Asp	Trp 325	Asn	Pro	Ala	Thr	Asp 330	Lys	Сув	Ile	Pro	Cys 335	Hi
	Tyr	Ser	Val	Asp 340	Asp	Leu	Ser	Gly	Lys 345	Ala	Lys	Cys	Lys	Gly 350	Ala	Le
40	Gln	Lys	Glu 355	Leu	Gly	Leu	Pro	Ile 360	Arg	Pro	Asp	Val	Pro 365	Leu	Ile	Gl
	Phe	Ile 370	Gly	Arg	Leu	Asp	Tyr 375	Gln	Lys	Gly	Ile	Asp 380	Leu	Ile	Gln	Le
	Ile 385	Ile	Pro	Asp	Leu	Met 390	Arg	Glu	Asp	Val	Gln 395	Phe	Val	Met	Leu	G1; 40
45	Ser	Gly	Asp	Pro	Glu	Leu	Glu	Asp	Trp	Met		Ser	Thr	Glu	Ser	

PCT/US97/17555 WO 98/14601

55

Phe Lys Asp Lys Phe Arg Gly Trp Val Gly Phe Ser Val Pro Val S r His Arg Ile Thr Ala Gly Cys Asp Ile Leu Leu Met Pro Ser Arg Phe 5 Glu Pro Cys Gly Leu Asn Gln Leu Tyr Ala Met Gln Tyr Gly Thr Val Pro Val Val His Ala Thr Gly Gly Leu Arg Asp Thr Val Glu Asn Phe Asn Pro Phe Gly Glu Asn Gly Glu Gln Gly Thr Gly Trp Ala Phe Ala 485 490 495 10 Pro Leu Thr Thr Glu Asn Met Phe Val Asp Ile Ala Asn Cys Asn Ile Tyr Ile Gln Gly Thr Gln Val Leu Leu Gly Arg Ala Asn Glu Ala Arg 15 His Val Lys Arg Leu His Val Gly Pro Cys Arg

#### **Example Six:**

20

30

This experiment employs a plasmid having a maize promoter, a maize transit peptide, a starch-encapsulating region from the starch synthase I gene, and a ligated gene fragment attached thereto. The plasmid shown in FIG. 6 contains the DNA sequence listed in Table 8.

Plasmid pEXS52 was constructed according to the following protocol:

Materials used to construct transgenic plasmids are as follows:

Plasmid pBluescript SK-

Plasmid pMF6 (contain nos3' terminator)

25 Plasmid pHKH1 (contain maize adh1 intron)

> Plasmid MstsI(6-4) (contain maize stsI transit peptide, use as a template for PCT stsI transit peptide out)

Plasmid MstsIII in pBluescript SK-

Primers EXS29 (GTGGATCCATGGCGACGCCCTCGGCCGTGG) [SEQ ID NO:22]

EXS35 (CTGAATTCCATATGGGGCCCCTCCCTGCTCAGCTC) [SEQ ID NO:23] both used for PCT stsI transit peptide

Primers EXS31 (CTCTGAGCTCAAGCTTGCTACTTTCTTTCCTTAATG) [SEQ ID NO:24]

15

EXS32 (GTCTCCGCGGTGGTGTCCTTGCTTCCTAG) [SEQ ID NO:25] both used for PCR maize 10KD zein promoter (Journal: Gene 71:359-370 [1988]) Maize A632 genomic DNA (used as a template for PCR maize 10KD zein promoter).

Step 1: Clone maize 10KD zein promoter in pBluescriptSK-(named as pEXS10zp).

1. PCR 1.1Kb maize 10KD zein promoter

primers: EXS31, EXS32

template: maize A632 genomic DNA

2. Clone 1.1Kb maize, 10KD zein promoter PCR product into pBluescript SK-plasmid at SacI and SacII site (See FIG. 7).

10 Step 2: Delete NdeI site in pEXS10zp (named as pEXS10zp-NdeI).

NdeI is removed by fill in and blunt end ligation from maize 10KD zein promoter in pBluescriptSK.

Step 3: Clone maize adh1 intron in pBluescriptSK- (named as pEXSadh1).

Maize adh1 intron is released from plasmid pHKH1 at XbaI and BamHI sites. Maize adh1 intron (XbaI/BamHI fragment) is cloned into pBluescriptSK- at XbaI and BamHI sites (see FIG. 7).

Step 4: Clone maize 10KD zein promoter and maize adh1 intron into pBluescriptSK-(named as pEXS10zp-adh1).

Maize 10KD zein promoter is released from plasmid pEXS 10zp-NdeI at SacI and SacII sites. Maize 10KD zein promoter (SacI/SacII fragment) is cloned into plasmid pEXSadh1 (contain maize adh1 intron) at SacI and SacII sites (see FIG. 7).

PCT/US97/17555

5

10

15

57

Step 5: Clone maize nos3' terminator into plasmid pEXSadh1 (named as pEXSadh1-nos3').

Maize nos3' terminator is released from plasmid pMF6 at EcoRI and HindIII sites.

Maize nos3' terminator (EcoRI/HindIII fragment) is cloned into plasmid pEXSadh1 at
EcoRI and HindIII (see FIG. 7).

Step 6: Clone maize nos3' terminator into plasmid pEXS10zp-adh1 (named as pEXS10zp-adh1-nos3').

Maize nos3' terminator is released from plasmid pEXSadh1-nos3' at EcoRI and ApaI sites. Maize nos3' terminator (EcoRI/ApaI fragment) is cloned into plasmid pEXS10zp-adh1 at EcoRI and ApaI sites (see FIG. 7).

- Step 7: Clone maize STSI transit peptide into plasmid pEXS10zp-adh1-nos3' (named as pEXS33).
  - PCR 150bp maize STSI transit peptide primer: EXS29, EXS35 template: MSTSI(6-4) plasmid
  - 2. Clone 150bp maize STSI transit peptide PCR product into plasmid pEXS10zp-adh1-nos3' at EcoRI and BamHI sites (see FIG. 7).
- Step 8: Site-directed mutagenesis on maize STSI transit peptide in pEXS33 (named as pEXS33(m)).
- There is a mutation (stop codon) on maize STSI transit peptide in plasmid pEXS33.

  Site-directed mutagenesis is carried out to change stop codon to non-stop codon. New plasmid (containing maize 10KD zein promoter, maize STSI transit peptide, maize adh1 intron, maize nos3' terminator) is named as pEXS33(m).

58

Step 9: NotI site in pEXS33(m) deleted (named as pEXS50).

NotI site is removed from pEXS33 by NotI fillin, blunt end ligation to form pEXS50 (see FIG. 8).

Step 10: Maize adh1 intron deleted in pEXS33(m) (named as pEXS60).

Maize adh1 intron is removed by NotI/BamHI digestion, filled in with Klenow fragment, blunt end ligation to form pEXS60 (see FIG. 9).

Step 11: Clone maize STSIII into pEXS50, pEXS60.

5

10

15

20

Maize STSIII is released from plasmid maize STSIII in pBluescript SK- at NdeI and EcoRI sites. Maize STSIII (NdeI-EcoRI fragment) is cloned into pEXS50, pEXS60 separately, named as pEXS51, pEXS61 (see FIGS. 8 and 9, respectively).

Step 12: Clone the gene in Table 8 into pEXS51 at NdeI/NotI site to form pEXS52.

Other similar plasmids can be made by cloning other genes (STSI, II, WX, glgA, glgB, glgC, BEI, BEII, etc.) into pEXS51, pEXS61 at NdeI/NotI site.

Plasmid EXS52 was transformed into rice. The regenerated rice plants transformed with pEXS52 were marked and placed in a magenta box.

Two siblings of each line were chosen from the magenta box and transferred into 2.5 inch pots filled with soil mix (topsoil mixed with peat-vermiculite 50/50). The pots were placed in an aquarium (fish tank) with half an inch of water. The top was covered to maintain high humidity (some holes were made to help heat escape). A thermometer monitored the temperature. The fish tank was placed under fluorescent lights. No fertilizer was used on the plants in the first week. Light period was 6 a.m.-8 p.m., minimum 14 hours light. Temperature was minimum 68°F at night, 80°-90°F during the day. A heating mat was used under the fish tank to help root growth when necessary. The plants stayed in the

above condition for a week. (Note: the seedlings began to grow tall because of low light intensity.)

After the first week, the top of the aquarium was opened and rice transformants were transferred to growth chambers for three weeks with high humidity and high light intensity.

5

10

Alternatively, water mix in the greenhouse can be used to maintain high humidity. The plants grew for three weeks. Then the plants were transferred to 6-inch pots (minimum 5-inch pots) with soil mix (topsoil and peat-Vet, 50/50). The pots were in a tray filled with half an inch of water. 15-16-17 (N-K-P) was used to fertilize the plants (250 ppm) once a week or according to the plants' needs by their appearances. The plants remained in 14 hours light (minimum) 6 a.m.-8 p.m. high light intensity, temperature 85°-90°/70°F day/night.

The plants formed rice grains and the rice grains were harvested. These harvested seeds can have the starch extracted and analyzed for the presence of the ligated amino acids C, V, A, E, L, S, R, E [SEQ ID NO:27] in the starch within the seed.

#### **Example Seven:**

#### 15 SER Vector for Plants:

The plasmid shown in Figure 6 is adapted for use in monocots, i.e., maize. Plasmid pEXS52 (FIG. 6) has a promoter, a transit peptide (from maize), and a ligated gene fragment (TGC GTC GCG GAG CTG AGC AGG GAG) [SEQ ID NO:26] which encodes the amino acid sequence C V A E L S R E [SEQ ID NO:27].

20

25

This gene fragment naturally occurs close to the N-terminal end of the maize soluble starch synthase (MSTSI) gene. As is shown in TABLE 8, at about amino acid 292 the SER from the starch synthase begins. This vector is preferably transformed into a maize host. The transit peptide is adapted for maize so this is the preferred host. Clearly the transit peptide and the promoter, if necessary, can be altered to be appropriate for the host plant desired. After transformation by "whiskers" technology (U.S. Patent Nos. 5,302,523 and 5,464,765), the transformed host cells are regenerated by methods known in the art, the

transformant is pollinated, and the resultant kernels can be collected and analyzed for the presence of the peptide in the starch and the starch granule.

5

10

15

20

25

This plasmid may be transformed into other cereals such as rice, wheat, barley, oats, sorghum, or millet with little to no modification of the plasmid. The promoter may be the waxy gene promoter whose sequence has been published, or other zein promoters known to the art.

Additionally these plasmids, without undue experimentation, may be transformed into dicots such as potatoes, sweet potato, taro, yam, lotus cassava, peanuts, peas, soybean, beans, or chickpeas. The promoter may be selected to target the starch-storage area of particular dicots or tubers, for example the patatin promoter may be used for potato tubers.

Various methods of transforming monocots and dicots are known in the industry and the method of transforming the genes is not critical to the present invention. The plasmid can be introduced into Agrobacterium tumefaciens by the freeze-thaw method of An et al. (1988) Binary Vectors, in Plant Molecular Biology Manual A3, S.B. Gelvin and R.A. Schilperoot, eds. (Dordrecht, The Netherlands: Kluwer Academic Publishers), pp. 1-19. Preparation of Agrobacterium inoculum carrying the construct and inoculation of plant material, regeneration of shoots, and rooting of shoots are described in Edwards et al., "Biochemical and molecular characterization of a novel starch synthase from potatoes," Plant J. 8, 283-294 (1995).

10

15

20

25

A number of encapsulating regions are present in a number of different genes.

Although it is preferred that the protein be encapsulated within the starch granule (granule encapsulation), encapsulation within non-granule starch is also encompassed within the scope of the present invention in the term "encapsulation." The following types of genes are useful for this purpose.

#### Use of Starch-Encapsulating Regions of Glycogen Synthase:

E. coli glycogen synthase is not a large protein: the structural gene is 1431 base pairs in length, specifying a protein of 477 amino acids with an estimated molecular weight of 49,000. It is known that problems of codon usage can occur with bacterial genes inserted into plant genomes but this is generally not so great with E. coli genes as with those from other bacteria such as those from Bacillus. Glycogen synthase from E. coli has a codon usage profile much in common with maize genes but it is preferred to alter, by known procedures, the sequence at the translation start point to be more compatible with a plant consensus sequence:

glgA G A T A A T G C A G [SEQ ID NO:31] cons A A C A A T G G C T [SEQ ID NO:32]

#### Use of Starch-Encapsulating Regions of Soluble Starch Synthase:

cDNA clones of plant-soluble starch synthases are described in the background section above and can be used in the present invention. The genes for any such SSTS protein may be used in constructs according to this invention.

#### Use of Starch-Encapsulating Regions of Branching Enzyme:

cDNA clones of plant, bacterial and animal branching enzymes are described in the background section above can be used in the present invention. Branching enzyme [1,4Dglucan: 1,4Dglucan 6D(1,4Dglucano) transferase (E.C. 2.4.1.18)] converts amylose to amylopectin, (a segment of a 1,4Dglucan chain is transferred to a primary hydroxyl group in a similar glucan chain) sometimes called Q-enzyme.

The sequence of maize branching enzyme I was investigated by Baba et al. (1991) BBRC, 181:87-94. Starch branching enzyme II from maize endosperm was investigated by

Fisher et al. (1993) Plant Physiol, 102:1045-1046. The BE gene construct may require the presence of an amyloplast transit peptide to ensure its correct localization in the amyloplast. The genes for any such branching enzyme of GBSTS protein may be used in constructs according to this invention.

#### 5 Use of Starch-Binding Domains of Granule-Bound Starch Synthase:

The use of cDNA clones of plant granule-bound starch synthases are described in Shure et al. (1983) Cell 35:225-233, and Visser et al. (1989) Plant Sci. 64(2):185-192. Visser et al. have also described the inhibition of the expression of the gene for granule-bound starch synthase in potato by antisense constructs (1991) Mol. Gen. Genetic 225(2):289-296; (1994) The Plant Cell 6:43-52.) Shimada et al. show antisense in rice (1993) Theor. Appl. Genet. 86:665-672. Van der Leij et al. show restoration of amylose synthesis in low-amylose potato following transformation with the wild-type waxy potato gene (1991) Theor. Appl. Genet. 82:289-295.

The amino acid sequences and nucleotide sequences of granule starch synthases from, for example, maize, rice, wheat, potato, cassava, peas or barley are well known. The genes for any such GBSTS protein may be used in constructs according to this invention.

#### **Construction of Plant Transformation Vectors:**

Plant transformation vectors for use in the method of the invention may be constructed using standard techniques

20 -

25

15

10

#### **Use of Transit Peptide Sequences:**

Some gene constructs require the presence of an amyloplast transit peptide to ensure correct localization in the amyloplast. It is believed that chloroplast transit peptides have similar sequences (Heijne et al. describe a database of chloroplast transit peptides in (1991) Plant Mol. Biol. Reporter, 9(2):104-126). Other transit peptides useful in this invention are those of ADPG pyrophosphorylase (1991) Plant Mol. Biol. Reporter, 9:104-126), small subunit RUBISCO, acetolactate synthase, glyceraldehyde3Pdehydrogenase and nitrite reductase.

The consensus sequence of the transit peptide of small subunit RUBISCO from many genotypes has the sequence:

MASSMLSSAAVATRTNPAQASM VAPFTGLKSAAFPVSRKQNLDI TSIASNGGRVQC [SEQ ID NO:33]

5 The corn small subunit RUBISCO has the sequence:

MAPTVMMASSATATRTNPAQAS AVAPFQGLKSTASLPVARRSSR SLGNVASNGGRIRC [SEQ ID NO:34]

The transit peptide of leaf glyceraldehyde3Pdehydrogenase from corn has the sequence:

10 MAQILAPSTQWQMRITKTSPCA TPITSKMWSSLVMKQTKKVAHS AKFRVMAVNSENGT [SEQ ID NO:35]

The transit peptide sequence of corn endosperm-bound starch synthase has the sequence:

MAALATSQLVATRAGHGVPDASTFRRGAAQGLRGARASAAADTLSMRTSARAAPRHQ
QQARRGGRFPFPSLVVC [SEQ ID NO:36]

The transit peptide sequence of corn endosperm soluble starch synthase has the sequence:

MATPSAVGAACLLLARXAWPAAVGDRARPRRLQRVLRRR [SEQ ID NO:37]

Engineering New Amino Acids or Peptides into Starch-Encapsulating Proteins:

The starch-binding proteins used in this invention may be modified by methods known to those skilled in the art to incorporate new amino acid combinations. For example,

10

15

20

25

sequences of starch-binding proteins may be modified to express higher-than-normal levels of lysine, methionine or tryptophan. Such levels can be usefully elevated above natural levels and such proteins provide nutritional enhancement in crops such as cereals.

In addition to altering amino acid balance, it is possible to engineer the starch-binding proteins so that valuable peptides can be incorporated into the starch-binding protein.

Attaching the payload polypeptide to the starch-binding protein at the N-terminal end of the protein provides a known means of adding peptide fragments and still maintaining starch-binding capacity. Further improvements can be made by incorporating specific protease cleavage sites into the site of attachment of the payload polypeptide to the starch-encapsulating region. It is well known to those skilled in the art that proteases have preferred specificities for different amino-acid linkages. Such specificities can be used to provide a vehicle for delivery of valuable peptides to different regions of the digestive tract of animals and man.

In yet another embodiment of this invention, the payload polypeptide can be released following purification and processing of the starch granules. Using amylolysis and/or gelatinization procedures it is known that the proteins bound to the starch granule can be released or become available for proteolysis. Thus recovery of commercial quantities of proteins and peptides from the starch granule matrix becomes possible.

In yet another embodiment of the invention it is possible to process the starch granules in a variety of different ways in order to provide a means of altering the digestibility of the starch. Using this methodology it is possible to change the bioavailablility of the proteins, peptides or amino acids entrapped within the starch granules.

Although the foregoing invention has been described in detail by way of illustration and example for purposes of clarity and understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

65

#### SEQUENCE LISTING

- (1) GENERAL INFORMATION:
  - (i) APPLICANT: Keeling, Peter Guan, Hanping
  - (ii) TITLE OF INVENTION: Starch Encapsulation
  - (iii) NUMBER OF SEQUENCES: 37
  - (iv) CORRESPONDENCE ADDRESS:
    - (A) ADDRESSEE: Greenlee, Winner and Sullivan, P.C.
    - (B) STREET: 5370 Manhattan Circle
    - (C) CITY: Boulder
    - (D) STATE: CO
    - (E) COUNTRY: US
    - (F) ZIP: 80303
  - (v) COMPUTER READABLE FORM:
    - (A) MEDIUM TYPE: Floppy disk
    - (B) COMPUTER: IBM PC compatible
    - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
    - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER: US
    - (B) FILING DATE: 30-SEP-1997
    - (C) CLASSIFICATION:
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: US 60/026,855
    - (B) FILING DATE: 30-SEP-1996
  - (viii) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: Winner, Ellen P
    - (B) REGISTRATION NUMBER: 28,547
    - (C) REFERENCE/DOCKET NUMBER: 89-97
    - (ix) TELECOMMUNICATION INFORMATION:
      - (A) TELEPHONE: (303) 499-8080
      - (B) TELEFAX: (303) 499-8089
- (2) INFORMATION FOR SEQ ID NO:1:

	66
(i) SEQUENCE CHARACTERISTICS:	•
(A) LENGTH: 31 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: other nucle	eic acid
(A) DESCRIPTION: /desc =	"Oligonucleotide"
(iii) HYPOTHETICAL: NO	
(xi) SEQUENCE DESCRIPTION: SEQ	TD NO.1.
(XI) DEGOENCE DESCRIPTION. DEG	15 110.11.
GACTAGTCAT ATGGTGAGCA AGGGCGAGGA G	31
(2) INFORMATION FOR SEQ ID NO:2:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 36 base pairs	3
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: other nucle	
(A) DESCRIPTION: /desc =	"Oligonucleotide"
//···	
(iii) HYPOTHETICAL: NO	
(xi) SEQUENCE DESCRIPTION: SEQ	ID NO:2:
-	
CTAGATCTTC ATATGCTTGT ACAGCTCGTC CA	ATGCC 36
(2) INFORMATION FOR SEQ ID NO:3:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 39 base pairs	3
(B) TYPE: nucleic acid	

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

<pre>(ii) MOLECULE TYPE: other nucleic acid   (A) DESCRIPTION: /desc = "Oligonucleotide"</pre>	
(iii) HYPOTHETICAL: NO	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:	
CTAGATCTTG GCCATGGCCT TGTACAGCTC GTCCATGCC	39
(2) INFORMATION FOR SEQ ID NO:4:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 4800 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: not relevant	
(ii) MOLECULE TYPE: DNA (genomic)	
(iii) HYPOTHETICAL: NO	
(vi) ORIGINAL SOURCE:	
(A) ORGANISM: Zea mays	
(ix) FEATURE:	
(A) NAME/KEY: CDS	
(B) LOCATION: join(14491553, 16851765, 18601958, 2055 2144, 22262289, 24132513, 26512760, 2858 3101, 32123394, 34903681, 37933879, 3977 4105, 42274343)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:	
CAGCGACCTA TTACACAGCC CGCTCGGGCC CGCGACGTCG GGACACATCT TCTTCCCCCT	60
TTTGGTGAAG CTCTGCTCGC AGCTGTCCGG CTCCTTGGAC GTTCGTGTGG CAGATTCATC	120
TGTTGTCTCG TCTCCTGTGC TTCCTGGGTA GCTTGTGTAG TGGAGCTGAC ATGGTCTGAG	180
CACCOTTANA ATTROCTOCT ACACCACCAC TACCACACA CCACCTTGCC CATTROCTO	240

CCTGTGAAGT GCAACGTCTA GGATTGTCAC ACGCCTTGGT CGCGTCGCGT	300
CGATGCGGTG GTGAGCAGAG CAGCAACAGC TGGGCGGCCC AACGTTGGCT TCCGTGTCTT	360
CGTCGTACGT ACGCGCGCGC CGGGGACACG CAGCAGAGAG CGGAGAGCGA GCCGTGCACG	420
GGGAGGTGGT GTGGAAGTGG AGCCGCGCCC CCGGCCGCCC GCGCCCGGTG GGCAACCCAA	480
AAGTACCCAC GACAAGCGAA GGCGCCAAAG CGATCCAAGC TCCGGAACGC AACAGCATGC	540
GTCGCGTCGG AGAGCCAGCC ACAAGCAGCC GAGAACCGAA CCGGTGGGCG ACGCGTCATG	600
GGACGGACGC GGGCGACGCT TCCAAACGGG CCACGTACGC CGGCGTGTGC GTGCGTGCAG	660
ACGACAAGCC AAGGCGAGGC AGCCCCCGAT CGGGAAAGCG TTTTGGGCGC GAGCGCTGGC	720
GTGCGGGTCA GTCGCTGGTG CGCAGTGCCG GGGGGAACGG GTATCGTGGG GGGCGCGGGC	780
GGAGGAGAGC GTGGCGAGGG CCGAGAGCAG CGCGCCCCG GGTCACGCAA CGCGCCCCAC	840
GTACTGCCCT CCCCCTCCGC GCGCGCTAGA AATACCGAGG CCTGGACCGG GGGGGGGCCC	900
CGTCACATCC ATCCATCGAC CGATCGATCG CCACAGCCAA CACCACCCGC CGAGGCGACG	960
CGACAGCCGC CAGGAGGAAG GAATAAACTC ACTGCCAGCC AGTGAAGGGG GAGAAGTGTA	1020
CTGCTCCGTC GACCAGTGCG CGCACCGCCC GGCAGGGCTG CTCATCTCGT CGACGACCAG	1080
GTTCTGTTCC GTTCCGATCC GATCCGATCC TGTCCTTGAG TTTCGTCCAG ATCCTGGCGC	1140
GTATCTGCGT GTTTGATGAT CCAGGTTCTT CGAACCTAAA TCTGTCCGTG CACACGTCTT	1200
TTCTCTCTCT CCTACGCAGT GGATTAATCG GCATGGCGGC TCTGGCCACG TCGCAGCTCG	1260
TCGCAACGCG CGCCGGCCTG GGCGTCCCGG ACGCGTCCAC GTTCCGCCGC GGCGCCGCGC	1320
AGGGCCTGAG GGGGGCCCGG GCGTCGGCGG CGGCGGACAC GCTCAGCATG CGGACCAGCG	1380
CGCGCGCGC GCCCAGGCAC CAGCAGCAGG CGCGCCGCG GGGCAGGTTC CCGTCGCTCG	1440
TCGTGTGC GCC AGC GCC GGC ATG AAC GTC GTC TTC GTC GGC GCC GAG ATG Ala Ser Ala Gly Met Asn Val Val Phe Val Gly Ala Glu Met 1 5 10	1490
GCG CCG TGG AGC AAG ACC GGC GGC CTC GGC GAC GTC CTC GGC GGC CTG	1538

WO 98/14601 PCT/US97/17555

Ala 15	Pro	Trp	Ser	Lys	Thr 20	Gly	Gly	Leu	Gly	Asp 25	Val	Leu	Gly	Gly	Leu 30	
	-	GCC Ala			GTAP	AGCGC	ege e	CACC	CGAGA	C AT	rgcat	rccgi	TG(	GATCO	GCGT	1593
CTT	CTTC	GTG C	CTCTT	rgcco	C GI	rgcat	GAT	CAT	rgtgi	TTC	CTC	CTGGC	CTT (	STGTT	CGTGT	1653
ATGTGACGTG TTTGTTCGGG CATGCATGCA G GCG AAC GGG CAC CGT GTC ATG Ala Asn Gly His Arg Val Met 40													1705			
														ACC Thr		1753
		TCC Ser		GTAC	CGGCC	CAC C	CGAG	ACCAC	GA TI	CAG	ATCAC	C AG1	rcaci	ACAC		1805
ACC	GTCA!	TAT (	GAAC	CTTT	et ci	rgcto	CTGAT	GC(	CTGC	ACT	GCA/	AATGO	CAT (	GCAG	ATC Ile	1862
														TAC Tyr		1910
														GAG Glu		1958
GTG	AGAC	GAG A	ATCT	GATC	AC TO	CGAT	ACGC	A ATT	racca	ACCC	CAT	rgta <i>i</i>	AGC I	AGTT/	ACAGTG	2018
AGC	PTTT:	rtt (	cccc	CCGG	CC TO	GTC	CTG	G TT	TCAG					ACC Thr 100		2072
														AAC Asn		2120
		TTC Phe						GTC	AGGAT	rgg (	CTTG	GTAC:	ra ci	AACT	rcata	2174

120 123	
TCATCTGTAT GCAGCAGTAT ACACTGATGA GAAATGCATG CTGTTCTGCA G GCA Ala Ala	2231
CTT GAA GCT CCA AGG ATC CTG AGC CTC AAC AAC AAC CCA TAC TTC TCC Leu Glu Ala Pro Arg Ile Leu Ser Leu Asn Asn Asn Pro Tyr Phe Ser 130 135 140	2279
GGA CCA TAC G GTAAGAGTTG CAGTCTTCGT ATATATATCT GTTGAGCTCG Gly Pro Tyr 145	2329
AGAATCTTCA CAGGAAGCGG CCCATCAGAC GGACTGTCAT TTTACACTGA CTACTGCTGC	2389
TGCTCTTCGT CCATCCATAC AAG GG GAG GAC GTC GTG TTC GTC TGC AAC Gly Glu Asp Val Val Phe Val Cys Asn 150 155	2438
GAC TGG CAC ACC GGC CCT CTC TCG TGC TAC CTC AAG AGC AAC TAC CAG Asp Trp His Thr Gly Pro Leu Ser Cys Tyr Leu Lys Ser Asn Tyr Gln 160 165 170	2486
TCC CAC GGC ATC TAC AGG GAC GCA AAG GTTGCCTTCT CTGAACTGAA	2533
CAACGCCGTT TTCGTTCTCC ATGCTCGTAT ATACCTCGTC TGGTAGTGGT GGTGCTTCTC	2593
TGAGAAACTA ACTGAAACTG ACTGCATGTC TGTCTGACCA TCTTCACGTA CTACCAG	2650
ACC GCT TTC TGC ATC CAC AAC ATC TCC TAC CAG GGC CGG TTC GCC TTC Thr Ala Phe Cys Ile His Asn Ile Ser Tyr Gln Gly Arg Phe Ala Phe 185 190 195	2698
TCC GAC TAC CCG GAG CTG AAC CTC CCG GAG AGA TTC AAG TCG TCC TTC Ser Asp Tyr Pro Glu Leu Asn Leu Pro Glu Arg Phe Lys Ser Ser Phe 200 205 210	2746
GAT TTC ATC GAC GG GTCTGTTTTC CTGCGTGCAT GTGAACATTC ATGAATGGTA Asp Phe Ile Asp Gly 215	2800
ACCCACAACT GTTCGCGTCC TGCTGGTTCA TTATCTGACC TGATTGCATT ATTGCAG C	2858

						GGC										2906
Tyr	GIU	-	Pro	Val	GIU	Gly	225	rys	116	Asn	rrp	230	гåа	Ala	GIY	
		220					225					230				
ATC	СТС	GAG	GCC	GAC	AGG	GTC	СТС	ACC	GTC	AGC	CCC	TAC	TAC	GCC	GAG	2954
						Val										_,_,
	235					240					245		- 4			
GAG	CTC	ATC	TCC	GGC	ATC	GCC	AGG	GGC	TGC	GAG	CTC	GAC	AAC	ATC	ATG	3002
Glu	Leu	Ile	Ser	Gly	Ile	Ala	Arg	Gly	Сув	Glu	Leu	Asp	Asn	Ile	Met	
250					255					260					265	
CGC	CTC	ACC	GGC	ATC	ACC	GGC	ATC	GTC	AAC	GGC	ATG	GAC	GTC	AGC	GAG	3050
Arg	Leu	Thr	Gly	Ile	Thr	Gly	Ile	Val	Asn	Gly	Met	Asp	Val	Ser	Glu	
				270					275					280		
						AAG										3098
Trp	Asp	Pro		Arg	yab	Lys	Tyr		Ala	Val	Lys	Tyr	-	Val	Ser	
			285					290					295			
200	CTC1	N C C C C C	200 1	71 A C C 1	יסיים	NOTE OFF	מווים פי	ייייייייייייייייייייייייייייייייייייייי	P CC	POOT!	orano.	CTC	ስ ጥ <i>ር</i> ግ እ	rcc		3151
Thr	GIG	AGCI	<b>3</b> 60 .	I'AGC	ICIG	T TA	J16C.	IGCC.	L GG.	CCIC	CIG	CIC	AICA.	IGC		3131
1111																
TGG'	rtcg(	GTA (	CTGA(	CGCG	GC A	AGTG:	racg:	r ac	GTGC	STGC	GAC	GGTG	etg :	rccg	GTTCAG	3211
TGG	rtcg	GTA (	CTGA	CGCG	GC A	AGTG:	racg:	r ac	GTGC	STGC	GAC	GGTGG	GTG '	rccg	GTTCAG	3211
						AGTG:										3211 3259
GCC	GTG	GAG	GCC	AAG	GCG		AAC	AAG	GAG	GCG	CTG	CAG	GCG	GAG	GTC	
GCC	GTG	GAG	GCC	AAG	GCG	CTG	AAC	AAG	GAG	GCG	CTG	CAG	GCG	GAG	GTC	
GCC	GTG Val	GAG	GCC	AAG	GCG	CTG Leu	AAC	AAG	GAG	GCG	CTG Leu	CAG	GCG	GAG	GTC	
GCC Ala	GTG Val 300	GAG Glu	GCC Ala	AAG Lys	GCG Ala	CTG Leu	AAC Asn	AAG Lys	GAG Glu	GCG Ala	CTG Leu 310	CAG Gln	GCG Ala	GAG Glu	GTC Val	
GCC Ala	GTG Val 300	GAG Glu CCG	GCC Ala	AAG Lys GAC	GCG Ala	CTG Leu 305	AAC Asn	AAG Lys CCG	GAG Glu CTG	GCG Ala	CTG Leu 310 GCG	CAG Gln TTC	GCG Ala	GAG Glu GGC	GTC Val	3259
GCC Ala	GTG Val 300	GAG Glu CCG	GCC Ala	AAG Lys GAC	GCG Ala	CTG Leu 305	AAC Asn	AAG Lys CCG	GAG Glu CTG	GCG Ala	CTG Leu 310 GCG	CAG Gln TTC	GCG Ala	GAG Glu GGC	GTC Val	3259
GCC Ala GGG Gly	GTG Val 300	GAG Glu CCG	GCC Ala	AAG Lys GAC	GCG Ala CGG Arg	CTG Leu 305	AAC Asn	AAG Lys CCG	GAG Glu CTG	GCG Ala GTG Val	CTG Leu 310 GCG	CAG Gln TTC	GCG Ala	GAG Glu GGC	GTC Val AGG Arg	3259
GCC Ala GGG Gly 315	GTG Val 300 CTC Leu	GAG Glu CCG Pro	GCC Ala GTG Val	AAG Lys GAC Asp	GCG Ala CGG Arg 320	CTG Leu 305 AAC Asn	AAC Asn ATC Ile	AAG Lys CCG Pro	GAG Glu CTG Leu	GCG Ala GTG Val 325 GCG	CTG Leu 310 GCG Ala	CAG Gln TTC Phe	GCG Ala ATC Ile	GAG Glu GGC Gly	GTC Val AGG Arg 330	3259
GCC Ala GGG Gly 315	GTG Val 300 CTC Leu	GAG Glu CCG Pro	GCC Ala GTG Val	AAG Lys GAC Asp AAG	GCG Ala CGG Arg 320	CTG Leu 305 AAC Asn	AAC Asn ATC Ile	AAG Lys CCG Pro	GAG Glu CTG Leu ATG Met	GCG Ala GTG Val 325 GCG	CTG Leu 310 GCG Ala	CAG Gln TTC Phe	GCG Ala ATC Ile	GAG Glu GGC Gly CCG Pro	GTC Val AGG Arg 330	3259 3307
GCC Ala GGG Gly 315	GTG Val 300 CTC Leu	GAG Glu CCG Pro	GCC Ala GTG Val	AAG Lys GAC Asp	GCG Ala CGG Arg 320	CTG Leu 305 AAC Asn	AAC Asn ATC Ile	AAG Lys CCG Pro	GAG Glu CTG Leu	GCG Ala GTG Val 325 GCG	CTG Leu 310 GCG Ala	CAG Gln TTC Phe	GCG Ala ATC Ile	GAG Glu GGC Gly	GTC Val AGG Arg 330	3259 3307
GCC Ala GGG Gly 315 CTG Leu	GTG Val 300 CTC Leu GAA Glu	GAG Glu CCG Pro GAG Glu	GCC Ala GTG Val CAG Gln	AAG Lys GAC Asp AAG Lys 335	GCG Ala CGG Arg 320 GGC Gly	CTG Leu 305 AAC Asn CCC Pro	AAC Asn ATC Ile GAC Asp	AAG Lys CCG Pro GTC Val	GAG Glu CTG Leu ATG Met 340	GCG Ala GTG Val 325 GCG Ala	CTG Leu 310 GCG Ala GCC	CAG Gln TTC Phe GCC Ala	GCG Ala ATC Ile ATC	GAG Glu GGC Gly CCG Pro 345	GTC Val AGG Arg 330 CAG Gln	3259 3307 3355
GCC Ala GGG Gly 315 CTG Leu	GTG Val 300 CTC Leu GAA Glu	GAG Glu CCG Pro GAG Glu	GCC Ala GTG Val CAG Gln	AAG Lys GAC Asp AAG Lys 335	GCG Ala CGG Arg 320 GGC Gly	CTG Leu 305 AAC Asn CCC Pro	AAC Asn ATC Ile GAC Asp	AAG Lys CCG Pro GTC Val	GAG Glu CTG Leu ATG Met 340	GCG Ala GTG Val 325 GCG Ala	CTG Leu 310 GCG Ala GCC Ala	CAG Gln TTC Phe GCC Ala	GCG Ala ATC Ile ATC	GAG Glu GGC Gly CCG Pro 345	GTC Val AGG Arg 330 CAG Gln	3259 3307
GCC Ala GGG Gly 315 CTG Leu	GTG Val 300 CTC Leu GAA Glu	GAG Glu CCG Pro GAG Glu	GCC Ala GTG Val CAG Gln	AAG Lys GAC Asp AAG Lys 335 GTG Val	GCG Ala CGG Arg 320 GGC Gly	CTG Leu 305 AAC Asn CCC Pro	AAC Asn ATC Ile GAC Asp	AAG Lys CCG Pro GTC Val	GAG Glu CTG Leu ATG Met 340	GCG Ala GTG Val 325 GCG Ala	CTG Leu 310 GCG Ala GCC Ala	CAG Gln TTC Phe GCC Ala	GCG Ala ATC Ile ATC	GAG Glu GGC Gly CCG Pro 345	GTC Val AGG Arg 330 CAG Gln	3259 3307 3355
GCC Ala GGG Gly 315 CTG Leu	GTG Val 300 CTC Leu GAA Glu	GAG Glu CCG Pro GAG Glu	GCC Ala GTG Val CAG Gln	AAG Lys GAC Asp AAG Lys 335 GTG Val	GCG Ala CGG Arg 320 GGC Gly	CTG Leu 305 AAC Asn CCC Pro	AAC Asn ATC Ile GAC Asp	AAG Lys CCG Pro GTC Val	GAG Glu CTG Leu ATG Met 340	GCG Ala GTG Val 325 GCG Ala	CTG Leu 310 GCG Ala GCC Ala	CAG Gln TTC Phe GCC Ala	GCG Ala ATC Ile ATC	GAG Glu GGC Gly CCG Pro 345	GTC Val AGG Arg 330 CAG Gln	3259 3307 3355
GCC Ala GGG Gly 315 CTG Leu CTC	GTG Val 300 CTC Leu GAA Glu ATG Met	GAG Glu CCG Pro GAG Glu	GCC Ala GTG Val CAG Gln ATG Met 350	AAG Lys GAC Asp AAG Lys 335 GTG Val	GCG Ala CGG Arg 320 GGC Gly	CTG Leu 305 AAC Asn CCC Pro	AAC Asn ATC Ile GAC Asp GTG Val	AAG Lys CCG Pro GTC Val CAG Gln 355	GAG Glu CTG Leu ATG Met 340 ATC	GCG Ala GTG Val 325 GCG Ala GTT Val	CTG Leu 310 GCG Ala GCC Ala	CAG Gln TTC Phe GCC Ala CTG Leu	GCG Ala ATC Ile	GAG Glu GGC Gly CCG Pro 345	GTC Val AGG Arg 330 CAG Gln	3259 3307 3355
GCC Ala GGG Gly 315 CTG Leu CTC	GTG Val 300 CTC Leu GAA Glu ATG Met	GAG Glu CCG Pro GAG Glu	GCC Ala GTG Val CAG Gln ATG Met 350	AAG Lys GAC Asp AAG Lys 335 GTG Val	GCG Ala CGG Arg 320 GGC Gly	CTG Leu 305 AAC Asn CCC Pro	AAC Asn ATC Ile GAC Asp GTG Val	AAG Lys CCG Pro GTC Val CAG Gln 355	GAG Glu CTG Leu ATG Met 340 ATC	GCG Ala GTG Val 325 GCG Ala GTT Val	CTG Leu 310 GCG Ala GCC Ala	CAG Gln TTC Phe GCC Ala CTG Leu	GCG Ala ATC Ile	GAG Glu GGC Gly CCG Pro 345	GTC Val AGG Arg 330 CAG Gln	3259 3307 3355
GCC Ala GGG Gly 315 CTG Leu CTC Leu	GTG Val 300 CTC Leu GAA Glu ATG Met	GAG Glu CCG Pro GAG Glu GAG Glu	GCC Ala GTG Val CAG Gln ATG Met 350	AAG Lys GAC Asp AAG Lys 335 GTG Val	GCG Ala CGG Arg 320 GGC Gly GAG Glu	CTG Leu 305 AAC Asn CCC Pro	AAC Asn ATC Ile GAC Asp GTG Val	AAG Lys CCG Pro GTC Val CAG Gln 355	GAG Glu CTG Leu ATG Met 340 ATC Ile	GCG Ala GTG Val 325 GCG Ala GTT Val	CTG Leu 310 GCG Ala GCC Ala CTG Leu	CAG Gln TTC Phe GCC Ala CTG	GCG Ala ATC Ile ATC Ile	GAG Glu GGC Gly CCG Pro 345	GTC Val AGG Arg 330 CAG Gln TGC	3259 3307 3355

PCT/US97/17555

Gly Thr Gly Lys Lys Phe Glu Arg 360 365	
ATG CTC ATG AGC GCC GAG GAG AAG TTC CCA GGC AAG GTG CGC GCC GTG	3564
Met Leu Met Ser Ala Glu Glu Lys Phe Pro Gly Lys Val Arg Ala Val	
370 375 380	
GTC AAG TTC AAC GCG GCG CTG GCG CAC CAC ATC ATG GCC GGC GCC GAC	3612
Val Lys Phe Asn Ala Ala Leu Ala His His Ile Met Ala Gly Ala Asp	
385 390 395 400	
GTG CTC GCC GTC ACC AGC CGC TTC GAG CCC TGC GGC CTC ATC CAG CTG	2660
Val Leu Ala Val Thr Ser Arg Phe Glu Pro Cys Gly Leu Ile Gln Leu	3660
405 410 415	
CAG GGG ATG CGA TAC GGA ACG GTACGAGAGA AAAAAAAAAT CCTGAATCCT	3711
Gln Gly Met Arg Tyr Gly Thr	
420	
GACGAGAGG ACAGAGACAG ATTATGAATG CTTCATCGAT TTGAATTGAT TGATCGATGT	3771
CTCCCGCTGC GACTCTTGCA G CCC TGC GCC TGC GCG TCC ACC GGT GGA CTC	3822
Pro Cys Ala Cys Ala Ser Thr Gly Gly Leu	
425 430	
GTC GAC ACC ATC ATC GAA GGC AAG ACC GGG TTC CAC ATG GGC CGC CTC	3870
Val Asp Thr Ile Ile Glu Gly Lys Thr Gly Phe His Met Gly Arg Leu	
435 440 445	
NGC CTC CAC CTAACCCTAC CTCTCCCCAATC TTCCTTCTTCTTTCT	3919
AGC GTC GAC GTAAGCCTAG CTCTGCCATG TTCTTTCTTC TTTCTTTCTG  Ser Val Asp	3313
450	
TATGTATGTA TGAATCAGCA CCGCCGTTCT TGTTTCGTCG TCGTCCTCTC TTCCCAG	3976
TGT AAC GTC GTG GAG CCG GCG GAC GTC AAG AAG GTG GCC ACC ACA TTG	4024
Cys Asn Val Val Glu Pro Ala Asp Val Lys Lys Val Ala Thr Thr Leu	
455 460 465	
CAG CGC GCC ATC AAG GTG GTC GGC ACG CCG GCG TAC GAG GAG ATG GTG	4072
Gln Arg Ala Ile Lys Val Val Gly Thr Pro Ala Tyr Glu Glu Met Val	
470 475 480	
AGG AAC TGC ATG ATC CAG GAT CTC TCC TGG AAG GTACGTACGC CCGCCCCGCC	4125
Arg Asn Cys Met Ile Gln Asp Leu Ser Trp Lys	

73

490 495 485 CCGCCCCGCC AGAGCAGAGC GCCAAGATCG ACCGATCGAC CGACCACACG TACGCGCCTC 4185 GCTCCTGTCG CTGACCGTGG TTTAATTTGC GAAATGCGCA G GGC CCT GCC AAG 4238 Gly Pro Ala Lys AAC TGG GAG AAC GTG CTG CTC AGC CTC GGG GTC GCC GGC GAG CCA 4286 Asn Trp Glu Asn Val Leu Leu Ser Leu Gly Val Ala Gly Glu Pro GGG GTC GAA GGC GAG GAG ATC GCG CCG CTC GCC AAG GAG AAC GTG GCC 4334 Gly Val Glu Glu Glu Ile Ala Pro Leu Ala Lys Glu Asn Val Ala 520 525 530 GCG CCC TGA AGAGTTCGGC CTGCAGGGCC CCTGATCTCG CGCGTGGTGC 4383 Ala Pro \* AAAGATGTTG GGACATCTTC TTATATATGC TGTTTCGTTT ATGTGATATG GACAAGTATG 4443 TGTAGCTGCT TGCTTGTGCT AGTGTAATGT AGTGTAGTGG TGGCCAGTGG CACAACCTAA 4503 TAAGCGCATG AACTAATTGC TTGCGTGTGT AGTTAAGTAC CGATCGGTAA TTTTATATTG 4563 CGAGTAAATA AATGGACCTG TAGTGGTGGA GTAAATAATC CCTGCTGTTC GGTGTTCTTA 4623 TCGCTCCTCG TATAGATATT ATATAGAGTA CATTTTTCTC TCTCTGAATC CTACGTTTGT 4683 GAAATTTCTA TATCATTACT GTAAAATTTC TGCGTTCCAA AAGAGACCAT AGCCTATCTT 4743 TGGCCCTGTT TGTTTCGGCT TCTGGCAGCT TCTGGCCACC AAAAGCTGCT GCGGACT 4800

#### (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 534 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ala 1	Ser	Ala	Gly	Met 5	Asn	Val	Val	Phe	Val 10	Gly	Ala	Glu	Met	Ala 15	Pro
Trp	Ser	Lys	Thr 20	Gly	Gly	Leu	Gly	<b>Asp</b> 25	Val	Leu	Gly	Gly	Leu 30	Pro	Pro
Ala	Met	Ala 35	Ala	Asn	Gly	His	Arg 40	Val	Met	Vál	Val	Ser 45	Pro	Arg	Tyr
Asp	Gln 50	Tyr	Lys	Asp	Ala	Trp 55	Asp	Thr	Ser	Val	Val 60	Ser	Glu	Ile	Lys
Met 65	Gly	Asp	Gly	Tyr	Glu 70	Thr	Val	Arg	Phe	Phe 75	His	Cys	Tyr	Lys	Arg 80
Gly	Val	Asp	Arg	Val 85	Phe	Val	Asp	His	Pro 90	Leu	Phe	Leu	Glu	Arg 95	Val
Trp	Gly	Lys	Thr 100	Glu	Glu	Lys	Ile	Tyr 105	Gly	Pro	Val	Ala	Gly 110	Thr	Asp
Tyr	Arg	Asp 115	Asn	Gln	Leu	Arg	Phe 120	Ser	Leu	Leu	Cys	Gln 125	Ala	Ala	Leu
Glu	Ala 130	Pro	Arg	Ile	Leu	Ser 135	Leu	Asn	Asn	Asn	Pro 140	Tyr	Phe	Ser	Gly
Pro 145	Tyr	Gly	Glu	Asp	Val 150	Val	Phe	Val	Сув	Asn 155	Asp	Trp	His	Thr	Gly 160
Pro	Leu	Ser	Cys	Tyr 165	Leu	Lys	Ser	Asn	Tyr 170	Gln	Ser	His	Gly	Ile 175	Tyr
Arg	Asp	Ala	Lys 180	Thr	Ala	Phe	Cys	Ile 185		Asn	Ile	Ser	Tyr 190	Gln	Gly
Arg	Phe	Ala 195	Phe	Ser	Asp	Tyr	Pro 200	Glu	Leu	Asn	Leu	Pro 205	Glu	Arg	Phe
Lys	Ser 210	Ser	Phe	Asp	Phe	Ile 215	Asp	Gly	Tyr	Glu	Lys 220	Pro	Val	Glu	Gly
Arg 225	Lys	Ile	Asn	Trp	Met 230	Lys	Ala	Gly	Ile	Leu 235	Glu	Ala	Asp	Arg	Val 240

Leu	Thr	Val	Ser	Pro 245	Tyr	Tyr	Ala	Glu	Glu 250	Leu	Ile	Ser	Gly	11e 255	Ala
Arg	Gly	Сув	Glu 260	Leu	Asp	Asn	Ile	Met 265	Arg	Leu	Thr	Gly	Ile 270	Thr	Gly
Ile	Val	Asn 275	Gly	Met	Asp	Val	<i>Ser</i> 280	Glu	Trp	Asp	Pro	Ser 285	Arg	Asp	Lys
Tyr	Ile 290	Ala	Val	Lys	Tyr	Asp 295	Val	Ser	Thr	Ala	Val 300	Glu	Ala	Lys	Ala
Leu 305	Asn	Lys	Glu	Ala	Leu 310	Gln	Ala	Glu	Val	Gly 315	Leu	Pro	Val	Asp	Arg 320
Asn	Ile	Pro	Leu	Val 325	Ala	Phe	Ile	Gly	Arg 330	Leu	Glu	Glu	Gln	Lys 335	Gly
Pro	Asp	Val	Met 340	Ala	Ala	Ala	Ile	Pro 345	Gln	Leu	Met	Glu	Met 350	Val	Glu
Asp	Val	Gln 355	Ile	Val	Leu	Leu	Gly 360	Thr	Gly	Lys	Lys	<b>Lys</b> 365	Phe	Glu	Arg
Met	Leu 370	Met	Ser	Ala	Glu	Glu 375	Lys	Phe	Pro	Gly	380	Val	Arg	Ala	Val
Val 385	Lys	Phe	Asn	Ala	Ala 390	Leu	Ala	His	His	Ile 395	Met	Ala	Gly	Ala	Авр 400
Val	Leu	Ala	Val	Thr 405	Ser	Arg	Phe	Glu	Pro 410	Сув	Gly	Leu	Ile	Gln 415	Leu
Gln	Gly	Met	Arg 420	Tyr	Gly	Thr	Pro	Сув 425	Ala	Сув	Ala	Ser	Thr 430	Gly	Gly
Leu	Val	Asp 435	Thr	Ile	Ile	Glu	Gly 440	Lys	Thr	Gly	Phe	His 445	Met	Gly	Arg
Leu	Ser 450	Val	Asp	Суз	Asn	Val 455	Val	Glu	Pro	Ala	Asp 460	Val	Lys	Lys	Val
Ala 465	Thr	Thr	Leu	Gln	Arg 470	Ala <sup>.</sup>	Ile	Lys	Val	Val 475	Gly	Thr	Pro	Ala	Tyr 480

PCT/US97/17555 WO 98/14601

-	-
•	n

										_						
Glu	Glu	Met	Val	Arg 485	Asn	Сув	Met	Ile	Gln 490	Asp	Leu	S	r	Trp	Lys 495	Gly
Pro	Ala	Lys	Asn 500	Trp	Glu	Asn	Val	Leu 505	Leu	Ser	Leu	Gl	Y	Val 510	Ala	Gly
Gly	Glu	Pro 515	Gly	Val	Glu	Gly	Glu 520	Glu	Ile	Ala	Pro	Le 52		Ala	ГЛа	Glu

Asn Val Ala Ala Pro \* 530

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2542 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Oryza sativa
- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 453..2282
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GAATTCAGTG	TGAAGGAATA	GATTCTCTTC	AAAACAATTT	AATCATTCAT	CTGATCTGCT	60
CAAAGCTCTG	TGCATCTCCG	GGTGCAACGG	CCAGGATATT	TATTGTGCAG	TAAAAAAATG	120
TCATATCCCC	TAGCCACCCA	AGAAACTGCT	CCTTAAGTCC	TTATAAGCAC	ATATGGCATT	180
GTAATATATA	TGTTTGAGTT	TTAGCGACAA	TTTTTTTAAA	AACTTTTGGT	CCTTTTTATG	240
AACGTTTTAA	GTTTCACTGT	CTTTTTTTT	CGAATTTTAA	ATGTAGCTTC	AAATTCTAAT	300
CCCCAATCCA	AATTGTAATA	AACTTCAATT	CTCCTAATTA	ACATCTTAAT	TCATTTATTT	360

GAAA	ACCA	GT I	CAAA	TTCI	т т	TAGO	CTCA	CC	AAACO	TTA	AACA	ATTO	CAA 1	TCAC	STGCAG	420
AGAT	CTTC	CA C	CAGCA	ACAC	C TA	GACA	ACCA	cc	ATG	TCG	GCT	CTC	ACC	ACG	TCC	473
									Met	Ser	Ala	Leu	Thr	Thr	Ser	
									535					540		
CAG	CTC	GCC	ACC	TCG	GCC	ACC	GGC	TTC	GGC	ATC	GCC	GAC	AGG	TCG	GCG	521
Gln	Leu	Ala		Ser	Ala	Thr	Gly		Gly	Ile	Ala	yab	_	Ser	Ala	
			545					550					555			
CCG	TCG	TCG	CTG	CTC	CGC	CAC	GGG	TTC	CAG	GGC	CTC	AAG	CCC	CGC	AGC	569
Pro	Ser	Ser	Leu	Leu	Arg	His	Gly	Phe	Gln	Gly	Leu	Lys	Pro	Arg	Ser	
		560					565					570				
CCC	GCC	GGC	GGC	GAC	GCG	ACG	TCG	СТС	AGC	GTG	ACG	ACC	AGC	GCG	CGC	617
														Ala		
	575					580					585					
														AGG		665
590	THE	PIO	гда	GIII	595	Arg	Ser	vai	GIII	600	GIY	ser	ALG	Arg	605	
CCC	TCC	GTC	GTC	GTG	TAC	GCC	ACC	GGC	GCC	GGC	ATG	AAC	GTC	GTG	TTC	713
Pro	Ser	Val	Val	Val	Tyr	Ala	Thr	Gly		Gly	Met	Asn	Val	Val	Phe	
				610					615					620		
GTC	GGC	GCC	GAG	ATG	GCC	ccc	TGG	AGC	AAG	ACC	GGC	GGC	CTC	GGT	GAC	761
Val	Gly	Ala	Glu	Met	Ala	Pro	Trp	Ser	Lys	Thr	Gly	Gly	Leu	Gly	Asp	
			625					630					635			
CTC	CTC	CCT	ccc	CTC	ccc	CCT	ccc	አጥር	COT	ccc	<b>ח</b> ממ	ccc	CAC	AGG	CTC	809
														Arg		809
		640	,				645					650		3	· = <del>-</del>	
														GAT		857
Met		Ile	Ser	Pro	Arg		Asp	Gln	Tyr	Lys	Asp 665	Ala	Trp	Asp	Thr	
	655					660					665					
AGC	GTT	GTG	GCT	GAG	ATC	AAG	GTT	GCA	GAC	AGG	TAC	GAG	AGG	GTG	AGG	905
Ser	Val	Val	Ala	Glu	Ile	Lys	Val	Ala	Asp	Arg	Tyr	Glu	Arg	Val	Arg	
670					675					680					685	
ው ሙ ተ	ጥጥር	CAT	ሞርር	ጥልጥ	ልልሮ	CGm	GG A	ርጥር	GAC	ሮርም	ርጥር	ጥጥር	ልጥሮ	GAC	CAT	953
														Asp		,,,
			4 -	690	4 -	,	4		695	- 3				700		

						GTT Val						_				1001
						GAT Asp										1049
						CTC Leu 740										1097
						GGA Gly										1145
						GGC Gly			_							1193
						TAC Tyr										1241
						GGC Gly										1289
						TTC Phe 820										1337
	Asp					GGC Gly										1385
						GTG Val										1433
				Gly		GCC Ala										1481
CGG	CTC	ACC	GGC	ATC	ACC	GGC	ATC	GTC	AAC	GGC	ATG	GAC	GTC	AGC	GAG	1529

Arg Leu Thr Gly Ile Thr Gly Ile Val Asn Gly Met Asp Val Ser Glu TGG GAT CCT AGC AAG GAC AAG TAC ATC ACC GCC AAG TAC GAC GCA ACC Trp Asp Pro Ser Lys Asp Lys Tyr Ile Thr Ala Lys Tyr Asp Ala Thr ACG GCA ATC GAG GCG AAG GCG CTG AAC AAG GAG GCG TTG CAG GCG GAG Thr Ala Ile Glu Ala Lys Ala Leu Asn Lys Glu Ala Leu Gln Ala Glu GCG GGT CTT CCG GTC GAC AGG AAA ATC CCA CTG ATC GCG TTC ATC GGC Ala Gly Leu Pro Val Asp Arg Lys Ile Pro Leu Ile Ala Phe Ile Gly AGG CTG GAG GAA CAG AAG GGC CCT GAC GTC ATG GCC GCC GCC ATC CCG Arg Leu Glu Glu Gln Lys Gly Pro Asp Val Met Ala Ala Ala Ile Pro GAG CTC ATG CAG GAG GAC GTC CAG ATC GTT CTT CTG GGT ACT GGA AAG Glu Leu Met Gln Glu Asp Val Gln Ile Val Leu Gly Thr Gly Lys AAG AAG TTC GAG AAG CTG CTC AAG AGC ATG GAG GAG AAG TAT CCG GGC Lys Lys Phe Glu Lys Leu Leu Lys Ser Met Glu Glu Lys Tyr Pro Gly AAG GTG AGG GCG GTG GTG AAG TTC AAC GCG CCG CTT GCT CAT CTC ATC Lys Val Arg Ala Val Val Lys Phe Asn Ala Pro Leu Ala His Leu Ile ATG GCC GGA GCC GAC GTG CTC GCC GTC CCC AGC CGC TTC GAG CCC TGT Met Ala Gly Ala Asp Val Leu Ala Val Pro Ser Arg Phe Glu Pro Cys GGA CTC ATC CAG CTG CAG GGG ATG AGA TAC GGA ACG CCC TGT GCT TGC Gly Leu Ile Gln Leu Gln Gly Met Arg Tyr Gly Thr Pro Cys Ala Cys GCG TCC ACC GGT GGG CTC GTG GAC ACG GTC ATC GAA GGC AAG ACT GGT Ala Ser Thr Gly Gly Leu Val Asp Thr Val Ile Glu Gly Lys Thr Gly TTC CAC ATG GGC CGT CTC AGC GTC GAC TGC AAG GTG GTG GAG CCA AGC Phe His Met Gly Arg Leu Ser Val Asp Cys Lys Val Val Glu Pro Ser

80

	1055	i				1060	)				106	5				
												ATC Ile				2105
1070	)				1075	5				1080	)				1085	
GGC	ACG	CCG	GCG	TAC	GAG	GAG	ATG	GTC	AGG	AAC	TGC	ATG	AAC	CAG	GAC	2153
Gly	Thr	Pro	Ala	Tyr	Glu	Glu	Met	Val	Arg	Asn	Cys	Met	Asn	Gln	Asp	
				1090	)				109	5				1100	)	
												GTG				2201
Leu	Ser	Trp	_	-	Pro	Ala	rya			GIU	Asn	Val			GIA	•
			110	•				1110	,				111	5		
CTG	GGC	GTC	GCC	GGC	AGC	GCG	CCG	GGG	ATC	GAA	GGC	GAC	GAG	ATC	GCG	2249
												Asp				
	_	112	0				112	5				1130	כ			
											AGA	GCCT	GAG .	ATCT	ACATAT	2302
Pro			Lys	Glu	Asn			Ala	Pro	*						
	113	5				1140	ט									
GGA	GTGA:	TTA I	ATTA	ATAT	AG C	AGTA:	ratge	G AT	GAGA	GACG	AAT	GAAC	CAG '	TGGT'	TTGTTT	2362
GTT	GTAG:	IGA I	ATTT	GTAG	CT A	TAGC	CAAT'	T AT	ATAG	GCTA	ATA.	AGTT'	rga -	TGTT	GTACTC	2422
TTC	TGGG'	rgt (	GCTT	AAGT	AT C	TTAT	CGGA	c cc	TGAA	TTTA	TGT	GTGT	GGC	TTAT'	TGCCAA	2482
TAA	TATT	AAG '	TAAT	AAAG	GG T	TTAT'	TATA'	T TA	TTAT.	TATA	GTT.	ATAT'	TAT	ACTA.	AAAAA	2542

# (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 610 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ser Ala Leu Thr Thr Ser Gln Leu Ala Thr Ser Ala Thr Gly Phe
1 5 10 15

Gly	Ile	Ala	Asp 20	Arg	Ser	Ala	Pro	Ser 25	Ser	Leu	Leu	Arg	His 30	Gly	Phe
Gln	Gly	Leu 35	Lys	Pro	Arg	Ser	Pro 40	Ala	Gly	Gly	Asp	Ala 45	Thr	Ser	Lev
Ser	Val 50	Thr	Thr	Ser	Ala	Arg 55	Ala	Thr	Pro	Lys	Gln 60	Gln	Arg	Ser	Va]
Gln 65	Arg	Gly	Ser	Arg	Arg 70	Phe	Pro	Ser	Val	Val 75	Val	Tyr	Ala	Thr	G13 80
Ala	Gly	Met	Asn	Val 85	Val	Phe	Val	Gly	Ala 90	Glu	Met	Ala	Pro	Trp 95	Sei
Lys	Thr	Gly	Gly 100	Leu	Gly	Asp	Val	Leu 105	Gly	Gly	Leu	Pro	Pro 110	Ala	Met
Ala	Ala	Asn 115	Gly	His	Arg	Val	Met 120	Val	Ile	Ser	Pro	Arg 125	Tyr	Asp	Glr
Tyr	Lys 130	Asp	Ala	Trp	Asp	Thr 135	Ser	Val	Val	Ala	Glu 140	Ile	Lys	Val	Ala
Asp 145	Arg	Tyr	Glu	Arg	Val 150	Arg	Phe	Phe	His	Сув 155	Tyr	Lys	Arg	Gly	Va1
Asp	Arg	Val	Phe	Ile 165	Asp	His	Pro	Ser	Phe 170	Leu	Glu	Lys	Val	Trp 175	Gly
Lys	Thr	Gly	Glu 180	Lys	Ile	Tyr	Gly	Pro 185	Asp	Thr	Gly	Val	Asp 190	Tyr	Lys
Asp	Asn	Gln 195	Met	Arg	Phe	Ser	Leu 200	Leu	Cys	Gln	Ala	Ala 205	Leu	Glu	Ala
Pro	Arg 210	Ile	Leu	Asn	Leu	Asn 215	Asn	Asn	Pro	Tyr	Phe 220	Lys	Gly	Thr	Туз
Gly 225	Glu	Asp	Val	Val	Phe 230	Val	Сув	Asn	Yab	Trp 235	His	Thr	Gly	Pro	Le:

Ala Ser Tyr Leu Lys Asn Asn Tyr Gln Pro Asn Gly Ile Tyr Arg Asn

Ala L	'Aa	Val	Ala	Phe	Cys	Ile	His	Asn	Ile	Ser	Tyr	Gln	Gly	Arg	Phe
			260					265					270		

- Ala Phe Glu Asp Tyr Pro Glu Leu Asn Leu Ser Glu Arg Phe Arg Ser 275 280 285
- Ser Phe Asp Phe Ile Asp Gly Tyr Asp Thr Pro Val Glu Gly Arg Lys 290 295 300
- Ile Asn Trp Met Lys Ala Gly Ile Leu Glu Ala Asp Arg Val Leu Thr 305 310 315 320
- Val Ser Pro Tyr Tyr Ala Glu Glu Leu Ile Ser Gly Ile Ala Arg Gly 325 330 335
- Cys Glu Leu Asp Asn Ile Met Arg Leu Thr Gly Ile Thr Gly Ile Val 340 345 350
- Asn Gly Met Asp Val Ser Glu Trp Asp Pro Ser Lys Asp Lys Tyr Ile 355 360 365
- Thr Ala Lys Tyr Asp Ala Thr Thr Ala Ile Glu Ala Lys Ala Leu Asn 370 375 380
- Lys Glu Ala Leu Gln Ala Glu Ala Gly Leu Pro Val Asp Arg Lys Ile 385 390 395 400
- Pro Leu Ile Ala Phe Ile Gly Arg Leu Glu Glu Gln Lys Gly Pro Asp 405 410 415
- Val Met Ala Ala Ala Ile Pro Glu Leu Met Gln Glu Asp Val Gln Ile 420 425 430
- Val Leu Leu Gly Thr Gly Lys Lys Phe Glu Lys Leu Leu Lys Ser 435 440 445
- Met Glu Glu Lys Tyr Pro Gly Lys Val Arg Ala Val Val Lys Phe Asn 450 455 460
- Ala Pro Leu Ala His Leu Ile Met Ala Gly Ala Asp Val Leu Ala Val 465 470 475 480
- Pro Ser Arg Phe Glu Pro Cys Gly Leu Ile Gln Leu Gln Gly Met Arg 485 490 495

83

Tyr Gly Thr Pro Cys Ala Cys Ala Ser Thr Gly Gly Leu Val Asp. Thr
500 505 510

Val Ile Glu Gly Lys Thr Gly Phe His Met Gly Arg Leu Ser Val Asp 515 520 525

Cys Lys Val Val Glu Pro Ser Asp Val Lys Lys Val Ala Ala Thr Leu 530 535 540

Lys Arg Ala Ile Lys Val Val Gly Thr Pro Ala Tyr Glu Glu Met Val 545 550 555 560

Arg Asn Cys Met Asn Gln Asp Leu Ser Trp Lys Gly Pro Ala Lys Asn 565 570 575

Trp Glu Asn Val Leu Leu Gly Leu Gly Val Ala Gly Ser Ala Pro Gly 580 585 590

Ile Glu Gly Asp Glu Ile Ala Pro Leu Ala Lys Glu Asn Val Ala Ala 595 600 605

Pro \* 610

- (2) INFORMATION FOR SEQ ID NO:8:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 2007 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: double
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: cDNA to mRNA
  - (iii) HYPOTHETICAL: NO
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: Zea mays
  - (ix) FEATURE:
    - (A) NAME/KEY: CDS
    - (B) LOCATION: 1..2007
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

				Ala					Ala			GAG Glu				4	8
GAC	GCC	GCC	AGG	615	ccc	CGC	GCT	CGG	620 CGC	ААТ	GCG	GTC	TCC	625 AAA	CGG	9	6
												Val				-	
												GCG Ala 655				14	4
ACG	GCC		ACC	GGC	GCC	GCG		TGC	CAG	AAC	GCC	GCA	TTG	GCG	GAC	19	2
Thr	Ala 660	Arg	Thr	Gly	Ala	Ala 665	Ser	Суз	Gln	Asn	Ala 670	Ala	Leu	Ala	Asp		
												CCG Pro				24	0
				Pro					Gln			CCT Pro		Leu		28	8
GAC	АТА	GCA	CCG	695 GAG	ACT	GTC	CTC	CCA	700 GCC	CCG	AAG	CCA	СТG	705	GAA	33	6
Asp	Ile	Ala	Pro 710	Glu	Thr	Val	Leu	Pro 715	Ala	Pro	Lys	Pro	Leu 720	His	Glu		
												CCT Pro 735				38	4
												AAA Lys				43	2
												GTT Val				48	0
GAT					GAA					ATG		CTG Leu			TGT	52	8
GGG	GAG	AAT	GTT	775 ATG	AAC	GTG	ATC	GTG	780 GTG	GCT	GCT	GAA	TGT	785 TCT	CCA	57	6

Gly	Glu	Asn	Val 790	Met	Asn	Val	Ile	Val 795	Val	Ala	Ala	Glu	Сув 800	Ser	Pro	
												GCT Ala 815				624
												GTA Val				672
												AAA Lys				720
												GCA Ala				768
												CAC His				816
												CGC Arg 895				864
												CCA Pro				912
												ATG Met				960
												AGA Arg				1008
												AAC Asn				1056
												GAC Asp				1104

		965					970					975				
ACT	AAC	CTT	CAA	CAT	TTC	GAG	CTG	TAC	GAT	ccc	GTC	GGT	GGC	GAG	CAC	1152
	Asn															
	980					985		-4-			990		1			
GCC	AAC	ATC	TTT	GCC	GCG	TGT	GTT	CTG	AAG	ATG	GCA	GAC	CGG	GTG	GTG	1200
Ala	Asn	Ile	Phe	Ala	Ala	Сув	Val	Leu	Lys	Met	Ala	Asp	Arg	Val	Val	
995					1000	)				1005	5				1010	
ACT	GTC	AGC	CGC	GGC	TAC	CTG	TGG	GAG	CTG	AAG	ACA	GTG	GAA	GGC	GGC	1248
Thr	Val	Ser	Arg	Gly	Tyr	Leu	Trp	Glu	Leu	Lys	Thr	Val	Glu	Gly	Gly	
				1019	5				1020	)				102	5	
TGG	GGC	CTC	CAC	GAC	ATC	ATC	CGT	TCT	AAC	GAC	TGG	AAG	ATC	AAT	GGC	1296
Trp	Gly	Leu	His	Asp	Ile	Ile	Arg	Ser	Asn	Asp	Trp	Lys	Ile	Asn	Gly	
			1030	)				103	5				1040	)		
	CGT															1344
116	Arg		-	Пе	Asp	His			Trp	Asn	Pro	•		Asp	Val	
		104	5				1050	,				105	<b>o</b>			
CAC	CTG	acc	mac	CNG	cca	ma c	200	220	ma c	TCC.	ama	CNC	202	ama	030	1200
	Leu															1392
nrs	1060	-	Ser	изр	Gry	106		Non	TYL	Ser	1070		1111	red	vah	
	1000	,				100.	•				107	•				
GCT	GGA	AAG	CGG	CAG	TGC	AAG	GCG	GCC	CTG	CAG	CGG	GAC	GTG	GGC	CTG	1440
_	Gly															
107	_	•	_		1080	_				108	-	-		-	1090	
GAA	GTG	CGC	GAC	GAC	GTG	CCG	CTG	CTC	GGC	TTC	ATC	GGG	CGT	CTG	GAT	1488
Glu	Val	Arg	Asp	Asp	Val	Pro	Leu	Leu	Gly	Phe	Ile	Gly	Arg	Leu	Asp	
				109	5				110	0				110	5	
GGA	CAG	AAG	GGC	GTG	GAC	ATC	ATC	GGG	GAC	GCG	ATG	CCG	TGG	ATC	GCG	1536
Gly	Gln	Lys	Gly	Val	Asp	Ile	Ile	Gly	Asp	Ala	Met	Pro	Trp	Ile	Ala	
			1110	)				111	5				1120	0		
	CAG															1584
Gly	Gln	-		Gln	Leu	Val			Gly	Thr	Gly			Asp	Leu	
		112	5				1130	O				113	5			
<b></b>										<b></b> -						
	CGA															1632
Glu	Arg		Leu	GIn	HIS			Arg	GLu	His			ràa	val	Arg	
	1140	J				114	•				1150	J				

87

WO 98/14601 PCT/US97/17555

GGG	TGG	GTC	GGG	TTC	TCG	GTC	CTA	ATG	GTG	CAT	CGC	ATC	ACG	CCG	GGC	1680
Gly	Trp	Val	Gly	Phe	Ser	Val	Leu	Met	Val	His	Arg	Ile	Thr	Pro	Gly	
1155	5				1160	)				116	5				1170	
GCC	AGC	GTG	CTG	GTG	ATG	CCC	TCC	CGC	TTC	GCC	GGC	GGG	CTG	AAC	CAG	1728
Ala	Ser	Val	Leu	Val	Met	Pro	Ser	Arg	Phe	Ala	Gly	Gly	Leu	Asn	Gln	
				1179	5				1180					1189	5	
CTC	TAC	GCG	ATG	GCA	TAC	GGC	ACC	GTC	CCT	GTG	GTG	CAC	GCC	GTG	GGC	1776
Leu	Tyr	Ala	Met	Ala	Tyr	Gly	Thr	Val	Pro	Val	Val	His	Ala	Val	Gly	
			1190	)				1199	5				1200	)		
GGG	CTC	AGG	GAC	ACC	GTG	GCG	CCG	TTC	GAC	CCG	TTC	GGC	GAC	GCC	GGG	1824
Gly	Leu	Arg	Asp	Thr	Val	Ala	Pro	Phe	Asp	Pro	Phe	Gly	Asp	Ala	Gly	
		120	5				1210	)				121	5			
						CGC										1872
Leu	_	_	Thr	Phe	Asp	Arg	Ala	Glu	Ala	Asn	Lys	Leu	Ile	Glu	Val	
	1220	ס				1225	5				1230	כ				
						ACG										1920
		His	Cys	Leu		Thr	Tyr	Arg	Asn			Glu	Ser	Trp	-	
1235	•				1240	J				124	•				1250	
N.C.M.	OM C	030	666	000	000	3.000	maa	an a		ama	200	<b></b>	~~~	~~~		1000
						ATG										1968
SEL	Leu	GIII	Ald	125		Met	ser	GTII	1260		ser	Trp	Asp	1269		
				125	,				1200	,				120:	•	
GCT	GAG	CTC	ጥልሮ	GAG	GAC	GTC	CTT	GTC	AAC	TAC	CAC	TOO				2007
						Val										2007
	JIU	Leu	1270		veh	*41	₽e u	1275	-	1 7 1	GIII	тър				
			12/	•				12/	•							

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 669 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ala Glu Ala Glu Ala Gly Gly Lys Asp Ala Pro Pro Glu Arg Ser Gly

1				5					10					15	
Asp	Ala	Ala	Arg 20	Leu	Pro	Arg	Ala	Arg 25	Arg	Asn	Ala	Val	Ser 30	Lys	Arg
Arg	Asp	Pro 35	Leu	Gln	Pro	Val	Gly 40	Arg	Tyr	Gly	Ser	Ala 45	Thr	Gly	Asn
Thr	Ala 50	Arg	Thr	Gly	Ala	Ala 55	Ser	Сув	Gln	Asn	Ala 60	Ala	Leu	Ala	Asp
Val 65	Glu	Ile	Val	Glu	Ile 70	Lys	Ser	Ile	Val	Ala 75	Ala	Pro	Pro	Thr	Ser 80
Ile	Val	Lys	Phe	Pro 85	Gly	Arg	Gly	Leu	Gln 90	Asp	Asp	Pro	Ser	Leu 95	Trp
Asp	Ile	Ala	Pro 100	Glu	Thr	Val	Leu	Pro 105	Ala	Pro	ГÀа	Pro	Leu 110	His	Glu
Ser	Pro	Ala 115	Val	Asp	Gly	Asp	Ser 120	Asn	Gly	Ile	Ala	Pro 125	Pro	Thr	Val
Glu	Pro 130	Leu	Val	Gln	Glu	Ala 135	Thr	Trp	Asp	Phe	Lys 140	ГÀЗ	Tyr	Ile	Gly
Phe 145	Asp	Glu	Pro	Asp	Glu 150	Ala	Lys	Asp	Asp	Ser 155	Arg	Val	Gly	Ala	Asp 160
Asp	Ala	Gly	Ser	Phe 165	Glu	His	Tyr	Gly	Thr 170	Met	Ile	Leu	Gly	Leu 175	Сув
Gly	Glu	Asn	Val 180	Met	Asn	Val	Ile	Val 185	Val	Ala	Ala	Glu	Cys 190	Ser	Pro
Trp	Сув	Lys 195	Thr	Gly	Gly	Leu	Gly 200	Asp	Val	Val	Gly	Ala 205	Leu	Pro	Lys
Ala	Leu 210	Ala	Arg	Arg	Gly	His 215	Arg	Val	Met	Val	Val 220	Val	Pro	Arg	Tyr
Gly 225	Asp	Tyr	Val	Glu	Ala 230	Phe	Asp	Met	Gly	Ile 235	Arg	Lys	Tyr	Tyr	Lys 240
Ala	Ala	Gly	Gln	Asp	Leu	Glu	Val	Asn	Tyr	Phe	His	Ala	Phe	Ile	Asp

				245					250					255	
Gly	Val	Авр	Phe 260	Val	Phe	Ile	Asp	Ala 265	Ser	Phe	Arg	His	Arg 270	Gln	Asp
Asp	Ile	Tyr 275	Gly	Gly	Ser	Arg	Gln 280	Glu	Ile	Met	Lys	Arg 285	Met	Ile	Leu
Phe	Сув 290	Lys	Val	Ala	Val	Glu 295	Val	Pro	Trp	His	Val 300	Pro	Сув	Gly	Gly
Val 305	Сув	Tyr	Gly	Asp	Gly 310	Asn	Leu	Val	Phe	Ile 315	Ala	Met	Asn	Trp	His 320
Thr	Ala	Leu	Leu	Pro 325	Val	Tyr	Leu	Lys	Ala 330	Tyr	Туг	Arg	Asp	His 335	Gly
Leu	Met	Gln	Tyr 340	Thr	Arg	Ser	Val	Leu 345	Val	Ile	His	Asn	Ile 350	Gly	His
Gln	Gly	Arg 355	Gly	Pro	Val	His	Glu 360	Phe	Pro	Tyr	Met	Asp 365	Leu	Leu	Asn
Thr	Asn 370	Leu	Gln	His	Phe	Glu 375	Leu	Tyr	Asp	Pro	Val 380	Gly	Gly	Glu	His
Ala 385	Asn	Ile	Phe	Ala	Ala 390	Сув	Val	Leu	Lys	Met 395	Ala	Asp	Arg	Val	Val 400
Thr	Val	Ser	Arg	Gly 405	Tyr	Leu	Trp	Glu	Leu 410	Lys	Thr	Val	Glu	Gly 415	Gly
Trp	Gly	Leu	His 420	Asp	Ile	Ile	Arg	Ser 425	Asn	Asp	Trp	Lys	Ile 430	Asn	Gly
Ile	Arg	Glu 435	Arg	Ile	Asp	His	Gln 440	Glu	Trp	Asn	Pro	Lys 445	Val	Asp	Val
His	Leu 450	Arg	Ser	Asp	Gly	Tyr 455	Thr	Asn	Tyr	Ser	Leu 460	Glu	Thr	Leu	Asp
Ala 465	Gly	Lys	Arg	Gln	Cys 470	Lys	Ala	Ala	Leu	Gln 475	Arg	yab	Val	Gly	Leu 480
Glu	Val	Arg	Asp	Asp	Val	Pro	Leu	Leu	Gly	Phe	Ile	Gly	Arg	Leu	Asp

90

485 490 495

Gly Gln Lys Gly Val Asp Ile Ile Gly Asp Ala Met Pro Trp Ile Ala 500 505 510

Gly Gln Asp Val Gln Leu Val Met Leu Gly Thr Gly Pro Pro Asp Leu
515 520 525

Glu Arg Met Leu Gln His Leu Glu Arg Glu His Pro Asn Lys Val Arg 530 535 540

Gly Trp Val Gly Phe Ser Val Leu Met Val His Arg Ile Thr Pro Gly 545 550 560

Ala Ser Val Leu Val Met Pro Ser Arg Phe Ala Gly Gly Leu Asn Gln 565 570 575

Leu Tyr Ala Met Ala Tyr Gly Thr Val Pro Val Val His Ala Val Gly 580 585 590

Gly Leu Arg Asp Thr Val Ala Pro Phe Asp Pro Phe Gly Asp Ala Gly
595 600 605

Leu Gly Trp Thr Phe Asp Arg Ala Glu Ala Asn Lys Leu Ile Glu Val 610 615 620

Leu Ser His Cys Leu Asp Thr Tyr Arg Asn Tyr Glu Glu Ser Trp Lys 625 630 635 640

Ser Leu Gln Ala Arg Gly Met Ser Gln Asn Leu Ser Trp Asp His Ala 645 650 655

Ala Glu Leu Tyr Glu Asp Val Leu Val Lys Tyr Gln Trp 660 665

## (2) INFORMATION FOR SEQ ID NO:10:

#### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2097 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: cDNA to mRNA

91

## (iii) HYPOTHETICAL: NO

#### (vi) ORIGINAL SOURCE:

(A) ORGANISM: Zea mays

## (ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..2097

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

АТС	CCG	GGG	GCA	ATC	тст	TCC	TCG	TCG	TCG	GCT	ጥጥጥ	CTC	CTC	CCC	GTC		48
	Pro															•	•0
670		01,			675	-	501	501	001	680		200	Dou	110	685		
0,0					0,5					000					003		
GCG	TCC	TCC	TCG	CCG	CGG	CGC	AGG	CGG	GGC	AGT	GTG	GGT	GCT	GCT	CTG		96
	Ser															•	
				690	5	5	5	5	695			3		700			
CGC	TCG	TAC	GGC	TAC	AGC	GGC	GCG	GAG	CTG	CGG	TTG	CAT	TGG	GCG	CGG	14	44
Arg	Ser	Tyr	Gly	Tyr	Ser	Gly	Ala	Glu	Leu	Arg	Leu	His	Trp	Ala	Arg		
			705					710					715		_		
CGG	GGC	CCG	CCT	CAG	GAT	GGA	GCG	GCG	TCG	GTA	CGC	GCC	GCA	GCG	GCA	19	92
Arg	Gly	Pro	Pro	Gln	Asp	Gly	Ala	Ala	Ser	Val	Arg	Ala	Ala	Ala	Ala		
		720					725					730					
CCG	GCC	GGG	GGC	GAA	AGC	GAG	GAG	GCA	GCG	AAG	AGC	TCC	TCC	TCG	TCC	2	40
Pro	Ala	Gly	Gly	Glu	Ser	Glu	Glu	Ala	Ala	Lys	Ser	Ser	Ser	Ser	Ser		
	735					740					745						
CAG	GCG	GGC	GCT	GTT	CAG	GGC	AGC	ACG	GCC	AAG	GCT	GTG	GAT	TCT	GCT	28	88
Gln	Ala	Gly	Ala	Val	Gln	Gly	Ser	Thr	Ala	Lys	Ala	Val	Asp	Ser	Ala		
750					755					760					765		
TCA	CCT	CCC	AAT	CCT	TTG	ACA	TCT	GCT	CCG	AAG	CAA	AGT	CAG	AGC	GCT	3	36
Ser	Pro	Pro	Asn	Pro	Leu	Thr	Ser	Ala	Pro	Lys	Gln	ser	Gln	Ser	Ala		
				770					775					780			
GCA	ATG	CAA	AAC	GGA	ACG	AGT	GGG	GGC	AGC	AGC	GCG	AGC	ACC	GCC	GCG	38	84
Ala	Met	Gln	Asn	Gly	Thr	Ser	Gly	Gly	Ser	Ser	Ala	Ser	Thr	Ala	Ala		
			785					790					795				
CCG	GTG	TCC	GGA	ccc	AAA	GCT	GAT	CAT	CCA	TCA	GCT	CCT	GTC	ACC	AAG	4:	32

Pro	Val	Ser 800	Gly	Pro	Lys	Ala	Asp 805	His	Pro	Ser	Ala	Pro 810	Val	Thr	Lys		
												GCA Ala				4	180
												GTG Val				5	528
		_	_									GCT Ala				. 5	576
												AAT Asn				6	524
_												AAG Lys 890				6	572
												GCG Ala				7	720
												TAT Tyr				7	768
			_									GGA Gly				8	316
_												GAT Asp				8	364
												ATT Ile 970				9	12
												TGC Cys				9	60

	975					980					985					
GTT	GAG	GTT	CCA	TGG	тат	GCT	CCA	тст	GGC	GGT	АСТ	GTC	тат	CCT	CAT	1008
	Glu															1000
990	014	141		P	995		110	0,0	011	1000		<b>1</b> 41	- 7 -	Gry	1005	
330					,,,					1000	•				1005	
GGC	AAC	TTA	GTT	TTC	ATT	GCT	AAT	GAT	TGG	CAT	ACC	GCA	CTT	CTG	CCT	1056
Gly	Asn	Leu	Val	Phe	Ile	Ala	Asn	Asp	•		Thr	Ala	Leu	Leu	Pro	
				1010	)				1019	5				1020	)	
GTC	TAT	CTA	AAG	GCC	TAT	TAC	CGG	GAC	AAT	GGT	TTG	ATG	CAG	TAT	GCT	1104
Val	Tyr	Leu	Lys	Ala	Tyr	Tyr	Arg	Asp	Asn	Gly	Leu	Met	Gln	Tyr	Ala	
			1025	5				1030	)				103	5		
CGC	TCT	GTG	CTT	GTG	ATA	CAC	AAC	ATT	GCT	CAT	CAG	GGT	CGT	GGC	CCT	1152
Arg	Ser	Val	Leu	Val	Ile	His	Asn	Ile	Ala	His	Gln	Gly	Arg	Gly	Pro	
		1040	)				1045	5				1050	) ·			
GTA	GAC	GAC	TTC	GTC	AAT	TTT	GAC	TTG	CCT	GAA	CAC	TAC	ATC	GAC	CAC	1200
Val	Asp	Asp	Phe	Val	Asn	Phe	Asp	Leu	Pro	Glu	His	Tyr	Ile	Asp	His	
	1055	5				1060	)				106	5				
TTC	AAA	CTG	TAT	GAC	AAC	ATT	GGT	GGG	GAT	CAC	AGC	AAC	GTT	TTT	GCT	1248
Phe	Lys	Leu	Tyr	Asp	Asn	Ile	Gly	Gly	Asp	His	Ser	Asn	Val	Phe	Ala	
107	0				107	5				1080	כ				1085	
GCG	GGG	CTG	AAG	ACG	GCA	GAC	CGG	GTG	GTG	ACC	GTT	AGC	AAT	GGC	TAC	1296
Ala	Gly	Leu	Lys	Thr	Ala	Asp	Arg	Val	Val	Thr	Val	Ser	Asn	Gly	Tyr	
				1090	)				109	5				1100	)	
ATG	TGG	GAG	CTG	AAG	ACT	TCG	GAA	GGC	GGG	TGG	GGC	CTC	CAC	GAC	ATC	1344
Met	Trp	Glu	Leu	Lys	Thr	Ser	Glu	Gly	Gly	Trp	Gly	Leu	His	Asp	Ile	
			1109	5				1110	)				1119	5	•	
ATA	AAC	CAG	AAC	GAC	TGG	AAG	CTG	CAG	GGC	ATC	GTG	AAC	GGC	ATC	GAC	1392
Ile	Asn	Gln	Asn	Asp	Trp	Lys	Leu	Gln	Gly	Ile	Val	Asn	Gly	Ile	Asp	
		1120	כ				112	5				1130	)			
ATG	AGC	GAG	TGG	AAC	CCC	GCT	GTG	GAC	GTG	CAC	CTC	CAC	TCC	GAC	GAC	1440
Met	Ser	Glu	Trp	Asn	Pro	Ala	Val	Asp	Val	His	Leu	His	Ser	Asp	Asp	
	1135	5				1140	)				114	5				
TAC	ACC	AAC	TAC	ACG	TTC	GAG	ACG	CTG	GAC	ACC	GGC	AAG	CGG	CAG	TGC	1488
Tyr	Thr	Asn	Tyr	Thr	Phe	Glu	Thr	Leu	Asp	Thr	Gly	Lys	Arg	Gln	Сув	
115	0				1159	5				1160	)				1165	

AAG GCC GCC C	eu Gln Arg		Leu Gln Val	Arg Asp Asp	Val
	1170		1175	1180	
CCA CTG ATC G	GG TTC ATC	GGG CGG CTG	GAC CAC CAG	AAG GGC GTG	GAC 1584
Pro Leu Ile G	ly Phe Ile	Gly Arg Leu	Asp His Gln	Lys Gly Val	Asp
1	.185	1190	)	1195	
ATC ATC GCC G	אר פרפ אידר	ראר דהה אדר	GCG GGG CAG	GAC GTG CAG	CTC 1632
Ile Ile Ala A		_			
1200	-	1205	•	1210	
GTG ATG CTG G					
Val Met Leu G 1215	ily Thr Gly	arg ala asp	Leu Glu Asp	_	Arg
1215		1220	1225	•	
TTC GAG TCG G	GAG CAC AGC	GAC AAG GTG	CGC GCG TGG	GTG GGG TTC	TCG 1728
Phe Glu Ser G	lu His Ser	Asp Lys Val	Arg Ala Trp	Val Gly Phe	Ser
1230	1235	i	1240		1245
ama aga ama a	100 010 000	NMG 200 000	000 000 000	<b>A M M M M M M M M M M</b>	<b>3</b> 00 1006
GTG CCC CTG G					
var 110 bea 1	1250	ite iii nie	1255	1260	
CCG TCG CGG T	TTC GAG CCG	TGC GGG CTG	AAC CAG CTC	TAC GCC ATG	GCG 1824
Pro Ser Arg P		-		-	Ala
1	1265	127	o	1275	
TAC GGG ACC G	TG CCC GTG	GTG CAC GCC	GTG GGG GGG	CTC CGG GAC	ACG 1872
Tyr Gly Thr V					
1280		1285		1290	
GTG GCG CCG T					
Val Ala Pro F 1295	ene Asp Pro	1300	1305		Pne
		1000	1001		
GAC CGC GCG G	GAG GCG AAC	CGG ATG ATC	GAC GCG CTC	TCG CAC TGC	CTC 1968
Asp Arg Ala G	Slu Ala Asn	Arg Met Ile	Asp Ala Leu	Ser His Cys	Leu
1310	1315		1320		1325
ACC ACG TAC C	יכה אאר ידאר	ANG GAG ACC	TOO COC CCC	TOC AGG GCC	CGC 2016
Thr Thr Tyr A					
	1330	•	1335	1340	•
GGC ATG GCC G	GAG GAC CTC	AGC TGG GAC	CAC GCC GCC	GTG CTG TAT	GAG 2064

95

Gly Met Ala Glu Asp Leu Ser Trp Asp His Ala Ala Val Leu Tyr Glu 1345 1350 1355

GAC GTG CTC GTC AAG GCG AAG TAC CAG TGG TGA
Asp Val Leu Val Lys Ala Lys Tyr Gln Trp \*
1360 1365

2097

- (2) INFORMATION FOR SEQ ID NO:11:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 699 amino acids
    - (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Pro Gly Ala Ile Ser Ser Ser Ser Ala Phe Leu Leu Pro Val

1 5 10 15

Ala Ser Ser Pro Arg Arg Arg Gly Ser Val Gly Ala Ala Leu 20 25 30

Arg Ser Tyr Gly Tyr Ser Gly Ala Glu Leu Arg Leu His Trp Ala Arg
35 40 45

Arg Gly Pro Pro Gln Asp Gly Ala Ala Ser Val Arg Ala Ala Ala Ala 50 55 60

Pro Ala Gly Glu Ser Glu Glu Ala Ala Lys Ser Ser Ser Ser Ser 65 70 75 80

Gln Ala Gly Ala Val Gln Gly Ser Thr Ala Lys Ala Val Asp Ser Ala 85 90 95

Ser Pro Pro Asn Pro Leu Thr Ser Ala Pro Lys Gln Ser Gln Ser Ala 100 105 110

Ala Met Gln Asn Gly Thr Ser Gly Gly Ser Ser Ala Ser Thr Ala Ala 115 120 125

Pro Val Ser Gly Pro Lys Ala Asp His Pro Ser Ala Pro Val Thr Lys 130 135 140

									,	,					
Arg 145	Glu	Ile	Asp	Ala	Ser 150	Ala	Val	Lys	Pro	Glu 155	Pro	Ala	Gly	Asp	Asp 160
Ala	Arg	Pro	Val	Glu 165	Ser	Ile	Gly	Ile	Ala 170	Glu	Pro	Val	Asp	Ala 175	Lys
Ala	Авр	Ala	Ala 180	Pro	Ala	Thr	Asp	Ala 185	Ala	Ala	Ser	Ala	Pro 190	Tyr	Asp
Arg	Glu	Asp 195	Asn	Glu	Pro	Gly	Pro 200	Leu	Ala	Gly	Pro	Asn 205	Val	Met	Asn
Val	Val 210	Val	Val	Ala	Ser	Glu 215	Сув	Ala	Pro	Phe	Cys 220	Lув	Thr	Gly	Gly
Leu 225	Gly	Asp	Val	Val	Gly 230	Ala	Leu	Pro	Lys	Ala 235	Leu	Ala	Arg	Arg	Gly 240
His	Arg	Val	Met	Val 245	Val	Ile	Pro	Arg	Tyr 250	Gly	Glu	Tyr	Ala	Glu 255	Ala
Arg	Asp	Leu	Gly 260	Val	Arg	Arg	Arg	Tyr 265	Lys	Val	Ala	Gly	Gln 270	Asp	Ser
Glu	Val	Thr 275	Tyr	Phe	His	Ser	Tyr 280	Ile	Asp	Gly	Val	Asp 285	Phe	Val	Phe
Val	Glu 290	Ala	Pro	Pro	Phe	Arg 295	His	Arg	His	Asn	Asn 300	Ile	Tyr	Gly	Gly
Glu 305	Arg	Leu	Asp	Ile	Leu 310	Lys	Arg	Met	Ile	Leu 315	Phe	Сув	Lys	Ala	Ala 320
Val	Glu	Val	Pro	Trp 325	Туг	Ala	Pro	Сув	Gly 330	Gly	Thr	Val	Tyr	Gly 335	Asp
Gly	Asn	Leu	Val 340	Phe	Ile	Ala	Asn	Asp 345	Trp	His	Thr	Ala	Leu 350	Leu	Pro
Val	Tyr	Leu 355	Lys	Ala	Tyr	Tyr	Arg 360	Asp	Asn	Gly	Leu	Met 365	Gln	Tyr	Ala

Arg Ser Val Leu Val Ile His Asn Ile Ala His Gln Gly Arg Gly Pro

Val 385	Asp	Asp	Phe	Val	Asn 390	Ph	Aap	Lu	Pro	Glu 395	His	Tyr	Ile	Asp	His 400
Phe	Lys	Leu	Tyr	Asp 405	Asn	Ile	Gly	Gly	Asp 410	His	Ser	Asn	Val	Phe 415	Ala
Ala	Gly	Leu	Lys 420	Thr	Ala	Asp	Arg	Val 425	Val	Thr	Val	Ser	Asn 430	Gly	Tyr
Met	Trp	Glu 435	Leu	Lys	Thr	Ser	Glu 440	Gly	Gly	Trp	Gly	Leu 445	His	Asp	Ile
Ile	Asn 450	Gln	Asn	Asp	Trp	Lys 455	Leu	Gln	Gly	Ile	Val 460	Asn	Gly	Ile	Asp
Met 465	Ser	Glu	Trp	Asn	Pro 470	Ala	Val	Asp	Val	His 475	Leu	His	Ser	Asp	Asp 480
Tyr	Thr	Asn	Tyr	Thr	Phe	Glu	Thr	Leu	Asp	Thr	Gly	Lys	Arg	Gln	Сув
-				485					490					495	
Lys	Ala	Ala	Leu 500	Gln	Arg	Gln	Leu	Gly 505	Leu	Gln	Val	Arg	Asp 510	Asp	Val
Pro	Leu	Ile 515	Gly	Phe	Ile	Gly	Arg 520	Leu	Asp	His	Gln	Lys 525	Gly	Val	Asp
Ile	Ile 530	Ala	Asp	Ala	Ile	His 535	Trp	Ile	Ala	Gly	Gln 540	Asp	Val	Gln	Leu
Val 545	Met	Leu	Gly	Thr	Gly 550	Arg	Ala	Asp	Leu	Glu 555	Asp	Met	Leu	Arg	Arg 560
Phe	Glu	Ser	Glu	His 565	Ser	Asp	Lys	Val	Arg 570	Ala	Trp	Val	Gly	Phe 575	Ser
Val	Pro	Leu	Ala 580	His	Arg	Ile	Thr	Ala 585	Gly	Ala	Asp	Ile	Leu 590	Leu	Met
Pro	Ser	<b>A</b> rg 595	Phe	Glu	Pro	Сув	Gly 600	Leu	Asn	Gln	Leu	Tyr 605	Ala	Met	Ala
Tyr	Gly	Thr	Val	Pro	Val	Val	His	Ala	Val	Gly	Gly	Leu	Arg	Asp	Thr

96

730

									9	3						
Val 625	Ala	Pro	Phe	Asp	Pro 630	Ph	Asn	Asp	Thr	Gly 635	Leu	Gly	Trp	Thr	Phe 640	
Asp	Arg	Ala	Glu		Asn	Arg	Met	Ile	_	Ala	Leu	Ser	His	_	Leu	
Thr	Thr	Tyr	Arg	645 Asn	Tyr	Lys	Glu	Ser	650 Trp	Arg	Ala	Cys	Arg	655 Ala	Arg	
			660					665					670			
Gly	Met	Ala 675	Glu	Asp	Leu	Ser	Trp 680	Asp	His	Ala	Ala	Val 685	Leu	Tyr	Glu	
Asp	Val 690	Leu	Val	Lys	Ala	Lys 695	Tyr	Gln	Trp	*						
(2)	INF	ORMA!	rion	FOR	SEQ	ID I	NO: 1	2:								
	(ii	(1 (0 (1 ) MOI ) HYI ) OR:	A) LI B) TY C) S' D) TO LECU	ENGTI YPE: TRANI OPOLO LE TY ETIC	H: 17 nuc: DEDNI DGY: YPE: AL: 1	752   leic ESS: not cDNA	acio doul relo	pain d ble evant mRN	t							
	(ix	•	ATUR: A) N. B) L	AME/			1752									
	(xi	) SE	QUEN	CE D	ESCR:	IPTI	ON:	SEQ :	ID N	0:12	:					
	Val							GGG Gly			Pro				CCA Pro 715	48

Pro Ala Leu Leu Ala Pro Pro Leu Val Pro Gly Phe Leu Ala Pro Pro

725

	GAG Glu															144
	GGC Gly															192
	ATC Ile 765															240
	GTT Val															288
	GTA Val															336
	GTT Val															384
	ATG Met													-		432
	GCA Ala 845															480
	GGT Gly															528
	TGG Trp															576
	GGA Gly															624
CTC	CTT	TGC	TAT	GCT	GCA	TGT	GAG	GCT	CCT	TTG	ATC	CTT	GAA	TTG	GGA	672

Leu	Leu	Сув 910	Tyr	Ala	Ala	Cys	Glu 915	Ala	Pro	Leu	Il	L u 920	Glu	Leu	Gly	
														TGG		720
GIY		116	Tyr	GIĄ	GIN		Сув	Met	Pne	Val		Asn	Asp	Trp	His	
	925					930					935					
GCC	AGT	CTA	GTG	CCA	GTC	CTT	CTT	GCT	GCA	AAA	TAT	AGA	CCA	TAT	GGT	768
Ala	Ser	Leu	Val	Pro	Val	Leu	Leu	Ala	Ala	Lys	Tyr	Arg	Pro	Tyr	Gly	
940					945					950	-	-		-	955	
GTT	TAT	AAA	GAC	TCC	CGC	AGC	ATT	CTT	GTA	ATA	CAT	AAT	TTA	GCA	CAT	816
Val	Tyr	Lys	qaA	Ser	Arg	Ser	Ile	Leu	Val	Ile	His	Asn	Leu	Ala	His	
				960					965					970		
														CCA		864
Gin	GIÀ	Val		Pro	Ala	Ser	Thr		Pro	Asp	Leu	Gly		Pro	Pro	
			975					980					985			
GAA	TGG	тат	GGA	GCT	СТС	GAG	тсс	СТА	ምጥር	CCT	CAA	ጥርር	GCG	AGG	AGG	912
														Arg		712
		990	1				995					1000		9	9	
CAT	GCC	CTT	GAC	AAG	GGT	GAG	GCA	GTT	ТАД	TTT	ጥጥር	AAA	GGT	CCA	C mm	960
										111				GCA	GII	900
		Leu												Ala		760
							Ala					Lys				960
	Ala					Glu	Ala				Leu	Lys				960
His GTG	Ala 1009	GCA	Asp GAT	Lys CGA	Gly ATC	Glu 1010 GTG	Ala ) ACT	Val GTC	Asn AGT	Phe AAG	Leu 101! GGT	Lys 5 TAT	Gly	Ala TGG	Val GAG	1008
His GTG Val	Ala 1009 ACA Thr	GCA	Asp GAT	Lys CGA	Gly ATC Ile	Glu 1010 GTG Val	Ala ) ACT	Val GTC	Asn AGT	Phe AAG Lys	Leu 101! GGT Gly	Lys 5 TAT	Gly	Ala	Val GAG	
His GTG	Ala 1009 ACA Thr	GCA	Asp GAT	Lys CGA	Gly ATC	Glu 1010 GTG Val	Ala ) ACT	Val GTC	Asn AGT	Phe AAG	Leu 101! GGT Gly	Lys 5 TAT	Gly	Ala TGG	Val GAG	
His GTG Val 1020	Ala 1009 ACA Thr	GCA Ala	Asp GAT Asp	Lys CGA Arg	Gly ATC Ile 1025	Glu 1010 GTG Val	Ala ) ACT Thr	Val GTC Val	Asn AGT Ser	Phe AAG Lys 1030	Leu 101! GGT Gly	Lys 5 TAT Tyr	Gly TCG Ser	Ala TGG Trp	Val GAG Glu 1035	1008
GTG Val 1020	Ala 1005 ACA Thr	GCA Ala ACT	Asp GAT Asp GCT	Lys CGA Arg	ATC Ile 1025	Glu 1010 GTG Val	Ala  ACT Thr	Val GTC Val	Asn AGT Ser	AAG Lys 1030	Leu 101! GGT Gly	TAT Tyr	TCG Ser	Ala TGG Trp	Val GAG Glu 1035 TCC	
GTG Val 1020	Ala 1005 ACA Thr	GCA Ala ACT	Asp GAT Asp GCT	Lys CGA Arg	ATC Ile 1025 GGT Gly	Glu 1010 GTG Val	Ala  ACT Thr	Val GTC Val	Asn AGT Ser	AAG Lys 1030 AAT Asn	Leu 101! GGT Gly	TAT Tyr	TCG Ser	Ala TGG Trp	GAG Glu 1035 TCC Ser	1008
GTG Val 1020	Ala 1005 ACA Thr	GCA Ala ACT	Asp GAT Asp GCT	Lys CGA Arg GAA Glu	ATC Ile 1025 GGT Gly	Glu 1010 GTG Val	Ala  ACT Thr	Val GTC Val	Asn AGT Ser CTC Leu	AAG Lys 1030 AAT Asn	Leu 101! GGT Gly	TAT Tyr	TCG Ser	Ala TGG Trp AGC Ser	GAG Glu 1035 TCC Ser	1008
GTG Val 1020 GTC Val	Ala 1005 ACA Thr ACA	GCA Ala ACT Thr	GAT Asp GCT Ala	CGA Arg GAA Glu 1040	ATC Ile 1025 GGT Gly	Glu 1010 GTG Val GGA GGA	Ala  ACT Thr  CAG Gln	GTC Val GGC Gly	AGT Ser CTC Leu 1045	AAG Lys 1030 AAT Asn	Leu 1019 GGT Gly GAG Glu	TAT Tyr CTC Leu	TCG Ser TTA Leu	Ala TGG Trp AGC Ser	GAG Glu 1035 TCC Ser	1008
GTG Val 1020 GTC Val	Ala 1005 ACA Thr ACA Thr	GCA Ala ACT Thr	GAT Asp GCT Ala	CGA Arg GAA Glu 1040	ATC Ile 1025 GGT Gly	Glu 1010 GTG Val GGA Gly	Ala  ACT Thr  CAG Gln	GTC Val GGC Gly	AGT Ser CTC Leu 1049	AAG Lys 1030 AAT Asn	Leu 1019 GGT Gly GAG Glu	TAT Tyr CTC Leu	TCG Ser TTA Leu	TGG Trp AGC Ser 1050	GAG Glu 1035 TCC Ser	1008 1056
GTG Val 1020 GTC Val	Ala 1005 ACA Thr ACA Thr	GCA Ala ACT Thr	GAT Asp GCT Ala	CGA Arg GAA Glu 1040 TTA Leu	ATC Ile 1025 GGT Gly	Glu 1010 GTG Val GGA Gly	Ala  ACT Thr  CAG Gln	GTC Val GGC Gly	AST SET CTC Leu 1045	AAG Lys 1030 AAT Asn	Leu 1019 GGT Gly GAG Glu	TAT Tyr CTC Leu	TCG Ser TTA Leu	TGG Trp AGC Ser 1050	GAG Glu 1035 TCC Ser	1008 1056
GTG Val 1020 GTC Val	Ala 1005 ACA Thr ACA Thr	GCA Ala ACT Thr	GAT Asp GCT Ala GTA Val	CGA Arg GAA Glu 1040 TTA Leu	ATC Ile 1025 GGT Gly	Glu 1010 GTG Val GGA Gly	Ala  ACT Thr  CAG Gln	GTC Val GGC Gly	AST SET CTC Leu 1045	AAG Lys 1030 AAT Asn	Leu 1019 GGT Gly GAG Glu	TAT Tyr CTC Leu	TCG Ser TTA Leu	TGG Trp AGC Ser 1050	GAG Glu 1035 TCC Ser	1008 1056
GTG Val 1020 GTC Val AGA Arg	ACA Thr ACA Thr AAG Lys	GCA Ala ACT Thr AGT Ser	GAT Asp GCT Ala Val 1055	CGA Arg GAA Glu 1040 TTA Leu	ATC Ile 1025 GGT Gly AAC Asn	Glu 1010 GTG Val GGA Gly GGA Gly	Ala  ACT Thr  CAG Gln  ATT Ile	GTC Val GGC Gly GTA Val 1060	AGT Ser CTC Leu 1045 AAT Asn	AAG Lys 1030 AAT Asn GGA Gly	Leu 1019 GGT Gly ) GAG Glu ATT Ile	TAT Tyr CTC Leu GAC Asp	TCG Ser TTA Leu ATT Ile 1069	TGG Trp AGC Ser 1050 AAT Asn	GAG Glu 1035 TCC Ser GAT Asp	1008 1056
GTG Val 1020 GTC Val AGA Arg	ACA Thr ACA Thr AAG Lys	GCA Ala ACT Thr AGT Ser	GAT Asp GCT Ala Val 1055 GCC Ala	CGA Arg GAA Glu 1040 TTA Leu	ATC Ile 1025 GGT Gly AAC Asn	Glu 1010 GTG Val GGA Gly GGA Gly	Ala  ACT Thr  CAG Gln  ATT Ile  TGT Cys	GTC Val GGC Gly GTA Val 1060	AGT Ser CTC Leu 1045 AAT Asn	AAG Lys 1030 AAT Asn GGA Gly	Leu 1019 GGT Gly ) GAG Glu ATT Ile	TAT Tyr CTC Leu GAC Asp	TCG Ser TTA Leu ATT Ile 1069	TGG Trp AGC Ser 1050 AAT Asn	GAG Glu 1035 TCC Ser GAT Asp	1008 1056 1104
GTG Val 1020 GTC Val AGA Arg	ACA Thr ACA Thr AAG Lys	GCA Ala ACT Thr AGT Ser	GAT Asp GCT Ala Val 1055 GCC Ala	CGA Arg GAA Glu 1040 TTA Leu	ATC Ile 1025 GGT Gly AAC Asn	Glu 1010 GTG Val GGA Gly GGA Gly	Ala  ACT Thr  CAG Gln  ATT Ile	GTC Val GGC Gly GTA Val 1060	AGT Ser CTC Leu 1045 AAT Asn	AAG Lys 1030 AAT Asn GGA Gly	Leu 1019 GGT Gly ) GAG Glu ATT Ile	TAT Tyr CTC Leu GAC Asp	TCG Ser TTA Leu ATT Ile 1069	TGG Trp AGC Ser 1050 AAT Asn	GAG Glu 1035 TCC Ser GAT Asp	1008 1056 1104
GTG Val 1020 GTC Val AGA Arg	ACA Thr ACA Thr AAG Lys	GCA Ala ACT Thr AGT Ser CCT Pro 1070	GAT Asp GCT Ala GTA Val 1055 GCC Ala	CGA Arg GAA Glu 1040 TTA Leu ACA	ATC Ile 1025 GGT Gly AAC Asn GAC	Glu 1010 GTG Val GGA Gly GGA Gly	Ala  ACT Thr  CAG Gln  ATT Ile  TGT Cys 1075	GTC Val GGC Gly GTA Val 1060 ATC Ile	Asn AGT Ser CTC Leu 1049 AAT Asn CCCC Pro	AAG Lys 1030 AAT Asn GGA Gly	Leu 1019 GGT Gly GAG Glu ATT Ile CAT His	TAT Tyr CTC Leu GAC Asp	TCG Ser TTA Leu ATT Ile 1069	TGG Trp AGC Ser 1050 AAT Asn GTT Val	GAG Glu 1035 TCC Ser GAT Asp	1008 1056 1104
GTG Val 1020 GTC Val AGA Arg	Ala 1005 ACA Thr ACA Thr AAG Lys	GCA Ala ACT Thr AGT Ser CCT Pro 1070	GAT Asp GCT Ala 1055 GCC Ala	CGA Arg GAA Glu 1040 TTA Leu S	Gly ATC Ile 1025 GGT Gly AAC Asn GAC Asp	Glu 1010 GTG Val GGA Gly GGA Gly	Ala  ACT Thr  CAG Gln  ATT Ile  TGT Cys 1075	GTC Val GGC Gly GTA Val 1060 ATC Ile	AGT Ser CTC Leu 1049 AAT ASn CCC Pro	AAG Lys 1030 AAT Asn GGA Gly TGT Cys	Leu 1019 GGT Gly GAG Glu ATT Ile CAT His	TAT Tyr CTC Leu GAC Asp TAT Tyr 1080	TCG Ser TTA Leu ATT Ile 1065 TCT Ser	TGG Trp AGC Ser 1050 AAT Asn	GAG Glu 1035 TCC Ser GAT Asp GAT Asp	1008 1056 1104

GGT TTA CCT ATA AGG CCT GAT GTT CCT CTG ATT GGC TTT ATT GGA AGG Gly Leu Pro Ile Arg Pro Asp Val Pro Leu Ile Gly Phe Ile Gly Arg TTG GAT TAT CAG AAA GGC ATT GAT CTC ATT CAA CTT ATC ATA CCA GAT Leu Asp Tyr Gln Lys Gly Ile Asp Leu Ile Gln Leu Ile Ile Pro Asp CTC ATG CGG GAA GAT GTT CAA TTT GTC ATG CTT GGA TCT GGT GAC CCA Leu Met Arg Glu Asp Val Gln Phe Val Met Leu Gly Ser Gly Asp Pro GAG CTT GAA GAT TGG ATG AGA TCT ACA GAG TCG ATC TTC AAG GAT AAA Glu Leu Glu Asp Trp Met Arg Ser Thr Glu Ser Ile Phe Lys Asp Lys TTT CGT GGA TGG GTT GGA TTT AGT GTT CCA GTT TCC CAC CGA ATA ACT Phe Arg Gly Trp Val Gly Phe Ser Val Pro Val Ser His Arg Ile Thr GCC GGC TGC GAT ATA TTG TTA ATG CCA TCC AGA TTC GAA CCT TGT GGT Ala Gly Cys Asp Ile Leu Leu Met Pro Ser Arg Phe Glu Pro Cys Gly CTC AAT CAG CTA TAT GCT ATG CAG TAT GGC ACA GTT CCT GTT GTC CAT Leu Asn Gln Leu Tyr Ala Met Gln Tyr Gly Thr Val Pro Val Val His GCA ACT GGG GGC CTT AGA GAT ACC GTG GAG AAC TTC AAC CCT TTC GGT Ala Thr Gly Gly Leu Arg Asp Thr Val Glu Asn Phe Asn Pro Phe Gly GAG AAT GGA GAG CAG GGT ACA GGG TGG GCA TTC GCA CCC CTA ACC ACA Glu Asn Gly Glu Gln Gly Thr Gly Trp Ala Phe Ala Pro Leu Thr Thr GAA AAC ATG TTT GTG GAC ATT GCG AAC TGC AAT ATC TAC ATA CAG GGA Glu Asn Met Phe Val Asp Ile Ala Asn Cys Asn Ile Tyr Ile Gln Gly ACA CAA GTC CTC CTG GGA AGG GCT AAT GAA GCG AGG CAT GTC AAA AGA Thr Gln Val Leu Leu Gly Arg Ala Asn Glu Ala Arg His Val Lys Arg 

102

CTT CAC GTG GGA CCA TGC CGC TGA Leu His Val Gly Pro Cys Arg \* 1280 1752

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 584 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Cys Val Ala Glu Leu Ser Arg Glu Gly Pro Ala Pro Arg Pro Leu Pro

1 5 10 15

Pro Ala Leu Leu Ala Pro Pro Leu Val Pro Gly Phe Leu Ala Pro Pro 20 25 30

Ala Glu Pro Thr Gly Glu Pro Ala Ser Thr Pro Pro Pro Val Pro Asp
35 40 45

Ala Gly Leu Gly Asp Leu Gly Leu Glu Pro Glu Gly Ile Ala Glu Gly
50 55 60

Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln Asp Ser Glu Ile
65 70 75 80

Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr Gln Ser Ile Val 85 90 95

Phe Val Thr Gly Glu Ala Ser Pro Tyr Ala Lys Ser Gly Gly Leu Gly
100 105 110

Asp Val Cys Gly Ser Leu Pro Val Ala Leu Ala Ala Arg Gly His Arg 115 120 125

Val Met Val Val Met Pro Arg Tyr Leu Asn Gly Thr Ser Asp Lys Asn 130 135 140

Tyr Ala Asn Ala Phe Tyr Thr Glu Lys His Ile Arg Ile Pro Cys Phe 145 150 155 160

Gly	Gly	Glu	His	Glu	Val	Thr	Phe	Phe	His	Glu	Tyr	Arg	Asp	Ser	Val
				165					170					175	

- Asp Trp Val Phe Val Asp His Pro Ser Tyr His Arg Pro Gly Asn Leu 180 185 190
- Tyr Gly Asp Lys Phe Gly Ala Phe Gly Asp Asn Gln Phe Arg Tyr Thr 195 200 205
- Leu Leu Cys Tyr Ala Ala Cys Glu Ala Pro Leu Ile Leu Glu Leu Gly
  210 215 220
- Gly Tyr Ile Tyr Gly Gln Asn Cys Met Phe Val Val Asn Asp Trp His 225 230 235 240
- Ala Ser Leu Val Pro Val Leu Leu Ala Ala Lys Tyr Arg Pro Tyr Gly
  245 250 255
- Val Tyr Lys Asp Ser Arg Ser Ile Leu Val Ile His Asn Leu Ala His 260 265 270
- Gln Gly Val Glu Pro Ala Ser Thr Tyr Pro Asp Leu Gly Leu Pro Pro 275 280 285
- Glu Trp Tyr Gly Ala Leu Glu Trp Val Phe Pro Glu Trp Ala Arg Arg 290 295 300
- His Ala Leu Asp Lys Gly Glu Ala Val Asn Phe Leu Lys Gly Ala Val 305 310 315 320
- Val Thr Ala Asp Arg Ile Val Thr Val Ser Lys Gly Tyr Ser Trp Glu 325 330 335
- Val Thr Thr Ala Glu Gly Gly Gln Gly Leu Asn Glu Leu Leu Ser Ser 340 345 350
- Arg Lys Ser Val Leu Asn Gly Ile Val Asn Gly Ile Asp Ile Asn Asp 355 360 365
- Trp Asn Pro Ala Thr Asp Lys Cys Ile Pro Cys His Tyr Ser Val Asp 370 375 380
- Asp Leu Ser Gly Lys Ala Lys Cys Lys Gly Ala Leu Gln Lys Glu Leu 385 390 395 400

104

Gly Leu Pro Ile Arg Pro Asp Val Pro Leu Ile Gly Phe Ile Gly Arg 405 410 415

Leu Asp Tyr Gln Lys Gly Ile Asp Leu Ile Gln Leu Ile Ile Pro Asp 420 425 430

Leu Met Arg Glu Asp Val Gln Phe Val Met Leu Gly Ser Gly Asp Pro 435 440 445

Glu Leu Glu Asp Trp Met Arg Ser Thr Glu Ser Ile Phe Lys Asp Lys
450 455 460

Phe Arg Gly Trp Val Gly Phe Ser Val Pro Val Ser His Arg Ile Thr 465 470 475 480

Ala Gly Cys Asp Ile Leu Leu Met Pro Ser Arg Phe Glu Pro Cys Gly
485 490 495

Leu Asn Gln Leu Tyr Ala Met Gln Tyr Gly Thr Val Pro Val Val His 500 505 510

Ala Thr Gly Gly Leu Arg Asp Thr Val Glu Asn Phe Asn Pro Phe Gly 515 520 525

Glu Asn Gly Glu Gln Gly Thr Gly Trp Ala Phe Ala Pro Leu Thr Thr 530 535 540

Glu Asn Met Phe Val Asp Ile Ala Asn Cys Asn Ile Tyr Ile Gln Gly 545 550 555 560

Thr Gln Val Leu Leu Gly Arg Ala Asn Glu Ala Arg His Val Lys Arg 565 570 575

Leu His Val Gly Pro Cys Arg \* 580

### (2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2725 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: mRNA

								10	J						
(iii)	НҮР	OTHE	TICA	AL: N	10										
(vi)	ORI			URCE		mays	3								
(ix)	FEA	TURE	:												•
<b>,</b> ,				ŒY:	sig	pept	ide								
	( B	) Lo	CATI	ON:	91	264									
(ix)	FEA	TURE	::												
	(A	) NA	ME/K	ŒY:	mat_	_pept	ide								
	(B	) LO	CATI	ON:	265.	248	37								
(ix)	FEA														
		•	-	EY:			_								
	( B	) LC	CATI	ON:	91.	. 2490	)								
2000020	.ca .	C N C C		ESCRI			_				nmm s c	303 f	nmcc.	NMC N M	
			CGGP	AT TI	rcgc:	CTT	G CGC	GTCGC G GCC C Ala	CTGG G TT(	GGTT	G GT:	r TC	r GG(		c 60 114
AGTTCGAI	rcc G	ATCC	CGGC1	AT TI	rcgc:	PCTT(	G CGC G ATC Met	GTCGC G GCC : Ala B	CTGG G TTC	GGTT C CGC Arc	G GT: g Val	r TC:	r GGC	G GCG / Ala	
AGTTCGAT	CC G	GGG	CGGF CGGCT	AT TI	rcgc: gaagg agg	CCTTC GCGAC GCT	G CGC  Met  -58	GTCGC G GCC E Ala B	CTGG G TTC a Phe CTC	GGTT C CGC Arc	GGC	r TC: l Se:	r GGG	G GCG / Ala GAG	114
GGCCCAGA AGTTCGAT GTG CTC Val Leu -50	CC G	GGG	CGGF CGGCT	AT TI	rcgc: gaagg agg	CCTTC GCGAC GCT	G CGC  Met  -58	GTCGC G GCC E Ala B	CTGG G TTC a Phe CTC	GGTT C CGC Arc	GGC	r TC: l Se:	r GGG	G GCG / Ala GAG	114
AGTTCGAT GTG CTC Val Leu -50 GGT AGT	GGT Gly	GGG Gly GTC	GCC Ala	GTA Val -45	AGG Arg	GCT Ala	G CGC  Met  -58  CCC Pro	GTCGC G GCC E Ala B CGA Arg	CTGG CTC CTC Leu -40	GGTT C CGC ACC ACC Thr	GGC Gly	T TC: L Ser GGC Gly CGG	GGG Gly GGG Gly	GAG Glu -35	114
GTTCGAT GTG CTC Val Leu -50 GGT AGT	GGT Gly	GGG Gly GTC	GCC Ala	GTA Val -45	AGG Arg	GCT Ala	G CGC  Met  -58  CCC Pro	GTCGC G GCC E Ala G G CGA Arg CTC Leu	CTGG CTC CTC Leu -40	GGTT C CGC ACC ACC Thr	GGC Gly	T TC: L Ser GGC Gly CGG	GGG Gly GGT GGT	GAG Glu -35	114
AGTTCGAT GTG CTC Val Leu -50 GGT AGT	GGT Gly	GGG Gly GTC	GCC Ala	GTA Val -45	AGG Arg	GCT Ala	G CGC  Met  -58  CCC Pro	GTCGC G GCC E Ala B CGA Arg	CTGG CTC CTC Leu -40	GGTT C CGC ACC ACC Thr	GGC Gly	T TC: L Ser GGC Gly CGG	GGG Gly GGG Gly	GAG Glu -35	114
GTTCGAT GTG CTC Val Leu -50 GGT AGT Gly Ser	GGT Gly CTA Leu	GGG Gly GTC Val	GCC Ala TTC Phe -30	GTA Val -45 CGG Arg	AGG Arg CAC His	GCT Ala	G CGC  Met  -58  CCC  Pro  GGC  Gly	GTCGC GCC GCC GCC	CTGG CTC Leu -40 TTC Phe	GGTT C CGC GGTT C CGC	GGC Gly ACT Thr	GGC Gly CGG Arg	GGG Gly GGT Gly -20 GCC	GAG GAG Glu -35 GCT Ala	114
GTTCGAT GTG CTC Val Leu -50 GGT AGT Gly Ser	GGT Gly CTA Leu	GGG Gly GTC Val TGT Cys	GCC Ala TTC Phe -30	GTA Val -45 CGG Arg	AGG Arg CAC His	GCT Ala	G CGC Met -58 CCC Pro GGC Gly GGG G1y	GTCGC GCC GCC GCC	CTGG CTC Leu -40 TTC Phe	GGTT C CGC GGTT C CGC	GGC Gly ACT Thr	GGC Gly  CGG Arg	GGG Gly GGT Gly -20 GCC	GAG GAG Glu -35 GCT Ala	114 162 210
GTG CTC Val Leu -50 GGT AGT Gly Ser	GGT Gly CTA Leu	GGG Gly GTC Val	GCC Ala TTC Phe -30	GTA Val -45 CGG Arg	AGG Arg CAC His	GCT Ala	G CGC  Met  -58  CCC  Pro  GGC  Gly	GTCGC GCC GCC GCC	CTGG CTC Leu -40 TTC Phe	GGTT C CGC GGTT C CGC	GGC Gly ACT Thr	GGC Gly CGG Arg	GGG Gly GGT Gly -20 GCC	GAG GAG Glu -35 GCT Ala	114 162 210
AGTTCGAT GTG CTC Val Leu	GGT Gly CTA Leu GGA Gly	GGG Gly GTC Val TGT Cys -15	GCC Ala TTC Phe -30	GTA Val -45 CGG Arg GGG Gly	AGG Arg CAC His	GCT Ala  ACC Thr	G CGC Met -58 CCC Pro GGC Gly GGG Gly -10	GTCGC GCC Ala	CTGG CTC Leu -40 TTC Phe ATG	GGTTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	GGC Gly ACT Thr	GGC Gly  CGG Arg  GCG Ala -5	GGG Gly GGT Gly -20 GCC Ala	GAG GAG Glu -35 GCT Ala GCG Ala	114 162 210
GTG CTC Val Leu -50 GGT AGT Gly Ser CGA GTT Arg Val	GGT Gly CTA Leu GGA Gly	GGG Gly GTC Val TGT Cys -15 GCG	GCC Ala  TTC Phe -30  TCG Ser	GTA Val -45 CGG Arg GGG Gly	AGG Arg CAC His	GCT Ala  ACC Thr  CAC His	G CGC Met -58 CCC Pro GGC Gly GGG Gly -10	GTCGC GCC Ala GGC	CTGG G TTC A Phe CTC Leu -40 TTC Phe ATG Met	GGTT C CGC ACC TTA Leu CGC Arg	GGC Gly ACT Thr	GGC GCG Arg GCG Ala -5	GGG Gly GGT GCC Ala	GAG GAG GLU -35 GCT Ala GCG Ala	114 162 210 258

TCA AGG GCT GAC TCG GCT CAA TTC CAG TCG GAT GAA CTG GAG GTA CCA

Ser Arg Ala Asp Ser Ala Gln Phe Gln Ser Asp Glu Leu Glu Val Pro

														GCT Ala		402
nap	116	Det	Giu	35	1111	1111	Cys	Gly	40	GIY	Val	nia	nap	45	GIII	
GCC	TTG	AAC	AGA	GTT	CGA	GTG	GTC	ccc	CCA	CCA	AGC	GAT	GGA	CAA	AAA	450
Ala	Leu	Asn	Arg 50	Val	Arg	Val	Val	Pro 55	Pro	Pro	Ser	Asp	Gly 60	Gln	Lys	
														CTT		498
Ile	Phe	Gln 65	Ile	Asp	Pro	Met	Leu 70	Gln	Gly	Tyr	ГЛа	Tyr 75	His	Leu	Glu	
TAT	CGG	TAC	AGC	CTC	TAT	AGA	AGA	ATC	CGT	TCA	GAC	ATT	GAT	GAA	CAT	546
Tyr	Arg 80	Tyr	Ser	Leu	Tyr	Arg 85	Arg	Ile	Arg	Ser	Asp 90	Ile	Asp	Glu	His	
GAA	GGA	GGC	TTG	GAA	GCC	TTC	TCC	CGT	AGT	TAT	GAG	AAG	TTT	GGA	TTT	594
	Gly	Gly	Leu	Glu		Phe	Ser	Arg	Ser	-	Glu	Lys	Phe	Gly		
95	ccc	n.c.c	cac	CAA	100	እጥር	n C'n	<b></b>	CCA	105	TICC.	COM	CCT	GGA	110	642
														Gly		642
				115				-	120		-			125		
														AAT		690
Pne	ser	AIG	130	Leu	Vai	GIY	Asp	135	Asn	Asn	Trp	Asp	140	Asn	Ala	
														CTG		738
Asp	Arg	Met 145	Ser	Lys	Asn	Glu	Phe 150	Gly	Val	Trp	Glu	11e 155	Phe	Leu	Pro	
		_		1.2										GTA		786
Asn		Ala	Asp	Gly	Thr		Pro	Ile	Pro	His		Ser	Arg	Val	Lys	
cma	160				~~>	165					170					
														GCC Ala		834
175	ALG	Mec	App	TIIL	180	SEL	GIY	116	гув	185	Ser	116	FIO	Ala	11p	
	220	ma c	mc n	ome		ccc	CCA	CCA	CAA		CCN	mam	CDM	GGG		000
														Gly		882
	~10	-1-	DGL	195	<b></b>			1	200			-11-		205	**6	
TAT	TAT	GAT	CCT	CCT	GAA	GAG	GTA	AAG	TAT	GTG	TTC	AGG	CAT	GCG	CAA	930

Tyr	Tyr	Asp	Pro 210	Pro	Glu	Glu	Val	Lys 215	Tyr	Val	Ph	Arg	His 220	Ala	Gln	
														GGA Gly		978
														GAT Asp		1026
														ATA Ile	-	1074
_														GTA Val 285		1122
														TTG Leu		1170
														ATG Met		1218
														AAT Asn		1266
		_												GGC Gly		1314
														GAA Glu 365		1362
	_						_							TAT Tyr		1410
	_						_							ACT Thr		1458

	385			390			395		
			TTT Phe 405						1506
			GCA Ala						 1554
			CCT Pro						 1602
			GCC Ala						 1650
			ATG Met						 1698
			ACT Thr 485						 1746
_			TTA Leu						 1794
			GGC Gly						1842
			TTC Phe						1890
			GCA Ala						1938
			GGC Gly 565						1986

109

GGA CAT CCT GAA TGG ATA GAT TTT CCA AGA GGT CCG CAA AGA CTT CCA

Gly His Pro Glu Trp Ile Asp Phe Pro Arg Gly Pro Gln Arg Leu Pro

575 580 585 590

AGT GGT AAG TTT ATT CCA GGG AAT AAC AAC AGT TAT GAC AAA TGT CGT 2082 Ser Gly Lys Phe Ile Pro Gly Asn Asn Asn Ser Tyr Asp Lys Cys Arg 595 600 605

CGA AGA TTT GAC CTG GGT GAT GCA GAC TAT CTT AGG TAT CAT GGT ATG 2130
Arg Arg Phe Asp Leu Gly Asp Ala Asp Tyr Leu Arg Tyr His Gly Met 610 615 620

CAA GAG TTT GAT CAG GCA ATG CAA CAT CTT GAG CAA AAA TAT GAA TTC 2178
Gln Glu Phe Asp Gln Ala Met Gln His Leu Glu Gln Lys Tyr Glu Phe
625 630 635

ATG ACA TCT GAT CAC CAG TAT ATT TCC CGG AAA CAT GAG GAG GAT AAG 2226

Met Thr Ser Asp His Gln Tyr Ile Ser Arg Lys His Glu Glu Asp Lys
640 645 650

GTG ATT GTG TTC GAA AAG GGA GAT TTG GTA TTT GTG TTC AAC TTC CAC

Val Ile Val Phe Glu Lys Gly Asp Leu Val Phe Val Phe Asn Phe His

655 660 665 670

TGC AAC AAC AGC TAT TTT GAC TAC CGT ATT GGT TGT CGA AAG CCT GGG

Cys Asn Asn Ser Tyr Phe Asp Tyr Arg Ile Gly Cys Arg Lys Pro Gly

675 680 685

GTG TAT AAG GTG GTC TTG GAC TCC GAC GCT GGA CTA TTT GGT GGA TTT

Val Tyr Lys Val Val Leu Asp Ser Asp Ala Gly Leu Phe Gly Gly Phe

690 695 700

AGC AGG ATC CAT CAC GCA GCC GAG CAC TTC ACC GCC GAC TGT TCG CAT

Ser Arg Ile His His Ala Ala Glu His Phe Thr Ala Asp Cys Ser His

705 710 715

GAT AAT AGG CCA TAT TCA TTC TCG GTT TAT ACA CCA AGC AGA ACA TGT 2466
Asp Asn Arg Pro Tyr Ser Phe Ser Val Tyr Thr Pro Ser Arg Thr Cys
720 725 730

GTC GTC TAT GCT CCA GTG GAG TGA TAGCGGGGTA CTCGTTGCTG CGCGGCATGT 2520

Val Val Tyr Ala Pro Val Glu \*

735 740

GTGGGGCTGT CGATGTGAGG AAAAACCTTC TTCCAAAACC GGCAGATGCA TGCATGCATG 2580

110

CTACAATAAG	GTTCTGATAC	TTTAATCGAT	GCTGGAAAGC	CCATGCATCT	CGCTGCGTTG	2640
TCCTCTCTAT	ATATATAAGA	CCTTCAAGGT	GTCAATTAAA	CATAGAGTTT	TCGTTTTTCG	2700
CTTTCCTAAA	ааааааааа	AAAAA				2725

### (2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 800 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Ala Phe Arg Val Ser Gly Ala Val Leu Gly Gly Ala Val Arg Ala
-58 -55 -50 -45

Pro Arg Leu Thr Gly Gly Gly Glu Gly Ser Leu Val Phe Arg His Thr
-40 -35 -30

Gly Leu Phe Leu Thr Arg Gly Ala Arg Val Gly Cys Ser Gly Thr His -25 -20 -15

Gly Ala Met Arg Ala Ala Ala Ala Arg Lys Ala Val Met Val Pro
-10 -5 1 5

Glu Gly Glu Asn Asp Gly Leu Ala Ser Arg Ala Asp Ser Ala Gln Phe
10 15 20

Gln Ser Asp Glu Leu Glu Val Pro Asp Ile Ser Glu Glu Thr Thr Cys
25 30 35

Gly Ala Gly Val Ala Asp Ala Gln Ala Leu Asn Arg Val Arg Val Val 40 45 50

Pro Pro Pro Ser Asp Gly Gln Lys Ile Phe Gln Ile Asp Pro Met Leu 55 60 65 70

Gln Gly Tyr Lys Tyr His Leu Glu Tyr Arg Tyr Ser Leu Tyr Arg Arg
75 80 85

Ile	Arg	Ser	Asp 90	Ile	Asp	Glu	His	Glu 95	Gly	Gly	Leu	Glu	Ala 100	Phe	Sr
Arg	Ser	Tyr 105	Glu	Lys	Phe	Gly	Phe 110	Asn	Ala	Ser	Ala	Glu 115	Gly	Ile	Thr
Tyr	Arg 120	Glu	Trp	Ala	Pro	Gly 125	Ala	Phe	Ser	Ala	Ala 130	Leu	Val	Gly	Asp
Val 135	Asn	Asn	Trp	Asp	Pro 140	Asn	Ala	Asp	Arg	Met 145	Ser	Lys	Asn	Glu	Phe 150
Gly	Val	Trp	Glu	Ile 155	Phe	Leu	Pro	Asn	Asn 160	Ala	Asp	Gly	Thr	Ser 165	Pro
Ile	Pro	His	Gly 170	Ser	Arg	Val	Lys	Val 175	Arg	Met	Asp	Thr	Pro 180	Ser	Gly
Ile	Lys	Asp 185	Ser	Ile	Pro	Ala	Trp 190	Ile	Lys	Tyr	Ser	Val 195	Gln	Ala	Pro
Gly	Glu 200	Ile	Pro	Tyr	Asp	Gly 205	Ile	Tyr	Tyr	Asp	Pro 210	Pro	Glu	Glu	Va]
Lys 215	Tyr	Val	Phe	Arg	His 220	Ala	Gln	Pro	Lys	Arg 225	Pro	Lys	Ser	Leu	Arg 230
Ile	Tyr	Glu	Thr	His 235	Val	Gly	Met	Ser	Ser 240	Pro	Glu	Pro	Lys	11e 245	Ası
Thr	Tyr	Val	Asn 250	Phe	Arg	Asp	Glu	Val 255	Leu	Pro	Arg	Ile	Lys 260	Lys	Leu
Gly	Tyr	Asn 265	Ala	Val	Gln	Ile	Met 270	Ala	Ile	Gln	Glu	His 275	Ser	Tyr	Туг
Gly	Ser 280	Phe	Gly	Tyr	His	Val 285	Thr	Asn	Phe	Phe	Ala 290	Pro	Ser	Ser	Arg
Phe 295	Gly	Thr	Pro	Glu	Asp 300	Leu	Lys	Ser	Leu	11e 305	Asp	Arg	Ala	His	Glu 310
Leu	GĴΆ	Leu	Leu	Val 315	Leu	Met	Asp	Val	Val 320	His	Ser	His	Ala	Ser 325	Ser

112

Asn	Thr	Leu	330	Gly	Leu	Asn	Gly	Phe 335	Asp	Gly	Thr	Asp	Thr 340	His	Tyr
Phe	His	Ser 345	Gly	Pro	Arg	Gly	His 350	His	Trp	Met	Trp	Авр 355	Ser	Arg	Leu
Phe	Asn 360	Туг	Gly	Asn	Trp	Glu 365	Val	Leu	Arg	Phe	Leu 370	Leu	Ser	Asn	Ala
Arg 375	Trp	Trp	Leu	Glu	Glu 380	Tyr	Lys	Phe	Asp	Gly 385	Phe	Arg	Phe	Asp	Gly 390
Val	Thr	Ser	Met	Met 395	Tyr	Thr	His	His	Gly 400	Leu	Gln	Val	Thr	Phe 405	Thr
Gly	Asn	Phe	Asn 410	Glu	Tyr	Phe	Gly	Phe 415	Ala	Thr	Asp	Val	Asp 420	Ala	Val
Val	Tyr	Leu 425	Met	Leu	Val	Asn	Asp 430	Leu	Ile	His	Gly	Leu 435	Tyr	Pro	Glu
Ala	Val 440	Thr	Ile	Gly	Glu	Asp 445	Val	Ser	Gly	Met	Pro 450	Thr	Phe	Ala	Leu
Pro 455	Val	His	Asp	Gly	Gly 460	Val	Gly	Phe	Asp	Tyr 465	Arg	Met	His	Met	Ala 470
Val	Ala	Asp	Lys	Trp 475	Ile	Asp	Leu	Leu	Lys 480	Gln	Ser	qaA	Glu	Thr 485	Trp
Lys	Met	Gly	Asp 490	Ile	Val	His	Thr	Leu 495	Thr	Asn	Arg	Arg	Trp 500	Leu	Glu

Lys Cys Val Thr Tyr Ala Glu Ser His Asp Gln Ala Leu Val Gly Asp

Lys Thr Ile Ala Phe Trp Leu Met Asp Lys Asp Met Tyr Asp Phe Met

Ala Leu Asp Arg Pro Ser Thr Pro Thr Ile Asp Arg Gly Ile Ala Leu

540 545

His Lys Met Ile Arg Leu Ile Thr Met Gly Leu Gly Glu Gly Tyr

560

565

525 530

510

555

520

113

L u Asn Ph Met Gly Asn Glu Phe Gly His Pro Glu Trp Ile Asp Phe 570 575 580

Pro Arg Gly Pro Gln Arg Leu Pro Ser Gly Lys Phe Ile Pro Gly Asn 585 590 595

Asn Asn Ser Tyr Asp Lys Cys Arg Arg Arg Phe Asp Leu Gly Asp Ala 600 605 610

Asp Tyr Leu Arg Tyr His Gly Met Gln Glu Phe Asp Gln Ala Met Gln 615 620 625 630

His Leu Glu Gln Lys Tyr Glu Phe Met Thr Ser Asp His Gln Tyr Ile
635 640 645

Ser Arg Lys His Glu Glu Asp Lys Val Ile Val Phe Glu Lys Gly Asp 650 655 660

Leu Val Phe Val Phe Asn Phe His Cys Asn Asn Ser Tyr Phe Asp Tyr 665 670 675

Arg Ile Gly Cys Arg Lys Pro Gly Val Tyr Lys Val Val Leu Asp Ser 680 685 690

Asp Ala Gly Leu Phe Gly Gly Phe Ser Arg Ile His His Ala Ala Glu 695 700 705 710

His Phe Thr Ala Asp Cys Ser His Asp Asn Arg Pro Tyr Ser Phe Ser
715 720 725

Val Tyr Thr Pro Ser Arg Thr Cys Val Val Tyr Ala Pro Val Glu \* 730 735 740

## (2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2763 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: mRNA
- (iii) HYPOTHETICAL: NO

	(vi)	ORI	GINA	AL SC	URCE	E:										
		(P	) OF	RGANI	SM:	Zea	mays	3								
	(ix)	FEF	TURE	E :												
		(F	) NA	ME/F	ŒY:	tra	sit_	_pept	ide							
		( E	3) LC	CAT	ON:	2	90									
	(ix)	FE.	TURE	E :												
	•			ME/I	ŒY:	mat	pept	ide								
		( E	3) LC	CAT	ON:	191	.246	57								
	(ix)	FE#	ATURE	E :												
	, ,			AME/I	ŒY:	CDS										
		( E	3) LC	CAT	ON:	22	2470									
				n.			N			2.16						
	(X1)	SEÇ	OENC	JE DI	SCR	LPTIC	ON: 3	SEQ :	TD MO	):16:	•					
G C	rg To	C C	C G	rg To	CG CC	CC TO	CT TO	CC TO	CG C	CG A	CT C	og ci	TT C	CG C	CG	46
L	eu Cy	s Le	eu Va	al Se	er Pi	co Se	er Se	er Se	er P	ro Ti	nr Pi	ro Le	eu Pa	ro P	ro	
-(	53		-6	50				-5	55				-!	50		
	~~~		mam		<b>500</b>	03 m		a								
														GGG Gly		94
	n. g	n. g	-45	nry	561			-40	9		niu	110	-35	Gry	116	
GCG	GGT	GGC	GGC	AAT	GTG	CGC	CTG	AGT	GTG	TTG	TCT	GTC	CAG	TGC	AAG	142
Ala	Gly	_	Gly	Asn	Val	Arg		Ser	Val	Leu	Ser	Val	Gln	Cys	Lys	
		-30					-25					-20				
GCT	CGC	CGG	TCA	GGG	GTG	CGG	AAG	GTC	AAG	AGC	AAA	TTC	GCC	ACT	GCA	190
Ala	Arg	Arg	Ser	Gly	Val	Arg	Lys	Val	Lys	Ser	Lys	Phe	Ala	Thr	Ala	
	-15					-10					-5					
COT	ልርጥ	GTG.	C	CAA	CAT	מממ	<b>እ</b> ርጥ	) TC	CCA	እርጥ	ccc	מממ	ccc	GAT	CTC.	226
														Asp		238
1				5		-1-			10			-,-	V-1	15	•	
														TTC		286
Asp	His	Leu		Ile	Tyr	Asp	Leu	-	Pro	Lys	Leu	Glu		Phe	Lys	
			20					25					30			

GAC CAT TTC AGG TAC CGG ATG AAA AGA TTC CTA GAG CAG AAA GGA TCA

Asp His Phe Arg Tyr Arg Met Lys Arg Phe Leu Glu Gln Lys Gly Ser

ATT	GAA	GAA	AAT	GAG	GGA	AGT	CTT	GAA	TCT	TTT	TCT	AAA	GGC	TAT	TTG	382
Ile	Glu	Glu	Asn	Glu	Gly	Ser	Leu	Glu	Ser	Phe	Ser	Lys	Gly	Tyr	Leu	
	50					55					60					
AAA	TTT	GGG	ATT	AAT	ACA	AAT	GAG	GAT	GGA	ACT	GTA	TAT	CGT	GAA	TGG	430
Lys	Phe	Gly	Ile	Asn	Thr	Asn	Glu	Asp	Gly	Thr	Val	Tyr	Arg	Glu	Trp	
65					70					75					80	
GCA	CCT	GCT	GCG	CAG	GAG	GCA	GAG	CTT	ATT	GGT	GAC	TTC	AAT	GAC	TGG	478
Ala	Pro	Ala	Ala	Gln	Glu	Ala	Glu	Leu	Ile	Gly	Asp	Phe	Asn	Asp	Trp	
				85					90					95	_	
AAT	GGT	GCA	AAC	CAT	AAG	ATG	GAG	AAG	GAT	AAA	TTT	GGT	GTT	TGG	TCG	526
Asn	Gly	Ala	Asn	His	Lys	Met	Glu	Lys	Asp	Lys	Phe	Gly	Val	Trp	Ser	
			100					105	_	-		_	110	_		
ATC	AAA	ATT	GAC	CAT	GTC	AAA	GGG	AAA	CCT	GCC	ATC	CCT	CAC	AAT	TCC	574
Ile	Lys	Ile	Asp	His	Val	Lys	Gly	Lys	Pro	Ala	Ile	Pro	His	Asn	Ser	
	<del>-</del>	115	_			-	120	_				125				
AAG	GTT	AAA	TTT	CGC	TTT	CTA	CAT	GGT	GGA	GTA	TGG	GTT	GAT	CGT	ATT	622
Lys	Val	Lys	Phe	Arg	Phe	Leu	His	Gly	Gly	Val	Trp	Val	Asp	Arg	Ile	
-	130	_		_		135		•	_		140		_	_		
CCA	GCA	TTG	ATT	CGT	TAT	GCG	ACT	GTT	GAT	GCC	TCT	AAA	TTT	GGA	GCT	670
Pro	Ala	Leu	Ile	Arg	Tyr	Ala	Thr	Val	Asp	Ala	Ser	Lys	Phe	Gly	Ala	
145				-	150				_	155		_			160	
CCC	TAT	GAT	GGT	GTT	CAT	TGG	GAT	CCT	CCT	GCT	TCT	GAA	AGG	TAC	ACA	718
Pro	Tyr	Asp	Gly	Val	His	Trp	Asp	Pro	Pro	Ala	Ser	Glu	Arq	Tyr	Thr	
	-	-	-	165		-	-		170				_	175		
																•
TTT	AAG	CAT	ССТ	CGG	CCT	TCA	AAG	CCT	GCT	GCT	CCA	CGT	ATC	TAT	GAA	766
						Ser										, 55
	-		180	_			•	185				_	190	•		
ĠCC	CAT	GTA	GGT	ATG	AGT	GGT	GAA	AAG	CCA	GCA	GTA	AGC	ACA	TAT	AGG	814
Ala	His	Val	Gly	Met	Ser	Gly	Glu	Lys	Pro	Ala	Val	Ser	Thr	Tvr	Ara	
		195	•			•	200	•				205		•	· · · · · ·	
GAA	TTT	GCA	GAC	ААТ	GTG	TTG	CCA	CGC	ATA	CGA	GCA	ААТ	AAC	TAC	אאר	862
	_					Leu										JJ2
-24	210			11911		215		9	-16	9	220			-1-		
	210					213					220					
מים מ	Com	CAC	ምምራ	<b>አ</b> መረግ	CCA	GTT	እ ጥረ	GNC	Chm	TOO	ጥልጥ	ጥልጥ	GCT	ጥረጥ	ጥጥሩ	010
TOM	GII	CAG	116	VIG	GCM	GII	VI G	GAG	CAL	100	INC	111	GCI	101	110	910

Thr																
	Val	Gln	Leu	Met	Ala	Val	Met	Glu	His	Ser	Tyr	Tyr	Ala	Ser	Ph	
225					230					235					240	
GGG	TAC	CAT	GTG	ACA	AAT	TTC	TTT	GCG	GTT	AGC	AGC	AGA	TCA	GGC	ACA	958
Glv	Tyr	His	Val	Thr	Asn	Phe	Phe	Ala	Val	Ser	Ser	Arq	Ser	Gly	Thr	
•	•			245					250					255		
CCA	GAG	GAC	ሮሞሮ	מממ	ጥልጥ	ርሞጥ	стт	GAT	DAG	GCA	ראכ	AGT	TTG	CCT	ጥጥር	1006
																1000
PIO	GIU	Авр		гàя	TYF	Leu	vaı	-	rys	MIG	uis	261	Leu	GIĀ	Leu	
			260					265					270			
													AAT			1054
Arg	Val	Leu	Met	Asp	Val	Val	His	Ser	His	Ala	Ser	Asn	Asn	Val	Thr	
		275					280					285				
GAT	GGT	TTA	AAT	GGC	TAT	GAT	GTT	GGA	CAA	AGC	ACC	CAA	GAG	TCC	TAT	1102
Asp	Gly	Leu	Asn	Gly	Tyr	Asp	Val	Gly	Gln	Ser	Thr	Gln	Glu	Ser	Tyr	
	290					295					300					
TTT	CAT	GCG	GGA	GAT	AGA	GGT	TAT	CAT	AAA	CTT	TGG	GAT	AGT	CGG	CTG	1150
Phe	His	Ala	Glv	Asp	Ara	Glv	Tvr	His	Lvs	Leu	Tro	Asp	Ser	Ara	Leu	
305			1		310	1	-1-		-,-	315				5	320	
-			•		010											
ጥጥር		ጥልጥ	CCT	מממ	TCC	GAG	CTA	$TT\Delta$	AGG	ጥጥጥ	CTT	CTT	ጥርጥ	AAC	CTG	1198
													TCT			1198
				Asn					Arg				TCT Ser	Asn		1198
																1198
Phe	Asn	Tyr	Ala	Asn 325	Trp	Glu	Val	Leu	Arg 330	Phe	Leu	Leu	Ser	Asn 335	Leu	
Phe AGA	Asn	Tyr TGG	Ala TTG	Asn 325 GAT	Trp	Glu	Val ATG	Leu	Arg 330 GAT	Phe	Leu	Leu	Ser	Asn 335 GAT	Leu	1198 1246
Phe AGA	Asn	Tyr TGG	Ala TTG Leu	Asn 325 GAT	Trp	Glu	Val ATG	Leu TTT Phe	Arg 330 GAT	Phe	Leu	Leu	Ser TTT Phe	Asn 335 GAT	Leu	
Phe AGA	Asn	Tyr TGG	Ala TTG	Asn 325 GAT	Trp	Glu	Val ATG	Leu	Arg 330 GAT	Phe	Leu	Leu	Ser	Asn 335 GAT	Leu	
Phe AGA	Asn	Tyr TGG	Ala TTG Leu	Asn 325 GAT	Trp	Glu	Val ATG	Leu TTT Phe	Arg 330 GAT	Phe	Leu	Leu	Ser TTT Phe	Asn 335 GAT	Leu	
Phe AGA Arg	Asn TAT Tyr	Tyr TGG Trp	TTG Leu 340	Asn 325 GAT Asp	Trp GAA Glu	Glu TTC Phe	Val ATG Met	TTT Phe 345	Arg 330 GAT Asp	Phe GGC Gly	Leu TTC Phe	Leu CGA Arg	Ser TTT Phe	Asn 335 GAT Asp	Leu GGA Gly	
Phe AGA Arg	TAT Tyr	Tyr TGG Trp	TTG Leu 340	Asn 325 GAT Asp	Trp GAA Glu TAT	Glu TTC Phe	Val ATG Met	TTT Phe 345	Arg 330 GAT Asp	Phe GGC Gly	TTC Phe	CGA Arg	TTT Phe 350	Asn 335 GAT Asp	Leu GGA Gly	1246
Phe AGA Arg	TAT Tyr	Tyr TGG Trp	TTG Leu 340	Asn 325 GAT Asp	Trp GAA Glu TAT	Glu TTC Phe	Val ATG Met	TTT Phe 345	Arg 330 GAT Asp	Phe GGC Gly	TTC Phe	CGA Arg	TTT Phe 350	Asn 335 GAT Asp	Leu GGA Gly	1246
Phe AGA Arg	TAT Tyr	TGG Trp TCA Ser	TTG Leu 340	Asn 325 GAT Asp	Trp GAA Glu TAT	Glu TTC Phe	ATG Met CAC	TTT Phe 345	Arg 330 GAT Asp	Phe GGC Gly	TTC Phe	CGA Arg GTG Val	TTT Phe 350	Asn 335 GAT Asp	Leu GGA Gly	1246
AGA Arg GTT Val	TAT Tyr ACA Thr	TGG Trp TCA Ser 355	TTG Leu 340 ATG Met	Asn 325 GAT Asp CTG Leu	Trp GAA Glu TAT Tyr	Glu TTC Phe CAT His	ATG Met CAC His 360	TTT Phe 345 CAT	Arg 330 GAT Asp GGT Gly	GGC Gly ATC	TTC Phe AAT Asn	CGA Arg GTG Val 365	TTT Phe 350	Asn 335 GAT Asp TTT Phe	GGA Gly ACT Thr	1246
AGA Arg GTT Val	TAT Tyr ACA Thr	TGG Trp TCA Ser 355	TTG Leu 340 ATG Met	Asn 325 GAT Asp CTG Leu	Trp GAA Glu TAT Tyr	Glu TTC Phe CAT His	ATG Met CAC His 360	TTT Phe 345 CAT His	Arg 330 GAT Asp GGT Gly	GGC Gly ATC Ile	TTC Phe AAT Asn	CGA Arg GTG Val 365	TTT Phe 350 GGG Gly	Asn 335 GAT Asp TTT Phe	GGA Gly ACT Thr	1246 1294
AGA Arg GTT Val	TAT Tyr ACA Thr	TGG Trp TCA Ser 355	TTG Leu 340 ATG Met	Asn 325 GAT Asp CTG Leu	Trp GAA Glu TAT Tyr	Glu TTC Phe CAT His	ATG Met CAC His 360	TTT Phe 345 CAT His	Arg 330 GAT Asp GGT Gly	GGC Gly ATC Ile	TTC Phe AAT Asn	CGA Arg GTG Val 365	TTT Phe 350 GGG Gly	Asn 335 GAT Asp TTT Phe	GGA Gly ACT Thr	1246 1294
AGA Arg GTT Val	TAT Tyr ACA Thr	TGG Trp TCA Ser 355	TTG Leu 340 ATG Met	Asn 325 GAT Asp CTG Leu	Trp GAA Glu TAT Tyr	Glu TTC Phe CAT His	ATG Met CAC His 360	TTT Phe 345 CAT His	Arg 330 GAT Asp GGT Gly	GGC Gly ATC Ile	TTC Phe AAT Asn GCT	CGA Arg GTG Val 365	TTT Phe 350 GGG Gly	Asn 335 GAT Asp TTT Phe	GGA Gly ACT Thr	1246 1294
AGA Arg GTT Val GGA Gly	TAT Tyr ACA Thr AAC Asn 370	Tyr TGG Trp TCA Ser 355 TAC Tyr	TTG Leu 340 ATG Met	Asn 325 GAT Asp CTG Leu GAA Glu	GAA Glu TAT Tyr	TTC Phe CAT His TTC Phe 375	ATG Met CAC His 360 AGT Ser	TTT Phe 345 CAT His	Arg 330 GAT Asp GGT Gly GAC Asp	Phe GGC Gly ATC Ile ACA Thr	TTC Phe  AAT Asn  GCT Ala 380	CGA Arg GTG Val 365 GTG Val	TTT Phe 350 GGG Gly GAT Asp	Asn 335 GAT Asp TTT Phe	GGA Gly ACT Thr GTT Val	1246 1294 1342
AGA Arg GTT Val GGA Gly	TAT Tyr  ACA Thr  AAC Asn 370	TYT TGG Trp TCA Ser 355 TAC Tyr	TTG Leu 340 ATG Met CAG Gln	Asn 325 GAT Asp CTG Leu GAA Glu	GAA Glu TAT Tyr TAT Tyr	TTC Phe CAT His TTC Phe 375	ATG Met CAC His 360 AGT Ser	TTT Phe 345 CAT His	Arg 330 GAT Asp GGT Gly GAC Asp	Phe GGC Gly ATC Ile ACA Thr	TTC Phe  AAT Asn  GCT Ala 380  AAA	CGA Arg GTG Val 365 GTG Val	TTT Phe 350 GGG Gly GAT Asp	Asn 335 GAT Asp TTT Phe GCA Ala	GGA Gly  ACT Thr  GTT Val	1246 1294
AGA Arg GTT Val GGA Gly	TAT Tyr  ACA Thr  AAC Asn 370 TAC Tyr	TYT TGG Trp TCA Ser 355 TAC Tyr	TTG Leu 340 ATG Met CAG Gln	Asn 325 GAT Asp CTG Leu GAA Glu	GAA Glu TAT Tyr TAT Tyr	TTC Phe CAT His TTC Phe 375	ATG Met CAC His 360 AGT Ser	TTT Phe 345 CAT His	Arg 330 GAT Asp GGT Gly GAC Asp	Phe GGC Gly ATC Ile ACA Thr	TTC Phe  AAT Asn  GCT Ala 380  AAA	CGA Arg GTG Val 365 GTG Val	TTT Phe 350 GGG Gly GAT Asp	Asn 335 GAT Asp TTT Phe GCA Ala	GGA Gly ACT Thr GTT Val GAA Glu	1246 1294 1342
AGA Arg GTT Val GGA Gly	TAT Tyr  ACA Thr  AAC Asn 370 TAC Tyr	TYT TGG Trp TCA Ser 355 TAC Tyr	TTG Leu 340 ATG Met CAG Gln	Asn 325 GAT Asp CTG Leu GAA Glu	GAA Glu TAT Tyr TAT Tyr	TTC Phe CAT His TTC Phe 375	ATG Met CAC His 360 AGT Ser	TTT Phe 345 CAT His	Arg 330 GAT Asp GGT Gly GAC Asp	Phe GGC Gly ATC Ile ACA Thr	TTC Phe  AAT Asn  GCT Ala 380  AAA	CGA Arg GTG Val 365 GTG Val	TTT Phe 350 GGG Gly GAT Asp	Asn 335 GAT Asp TTT Phe GCA Ala	GGA Gly  ACT Thr  GTT Val	1246 1294 1342
AGA Arg GTT Val GGA Gly GTT Val 385	TAT Tyr ACA Thr AAC Asn 370 TAC	TYT TGG Trp TCA Ser 355 TAC Tyr ATG Met	TTG Leu 340 ATG Met	Asn 325 GAT Asp CTG Leu GAA Glu CTT Leu	GAA Glu TAT Tyr TAT Tyr GCA Ala 390	Glu TTC Phe CAT His TTC Phe 375 AAC Asn	ATG Met CAC His 360 AGT Ser CAT	TTT Phe 345 CAT His TTG Leu	Arg 330 GAT Asp GGT Gly GAC Asp	Phe GGC Gly ATC Ile ACA Thr CAC His 395	TTC Phe  AAT Asn  GCT Ala 380  AAA Lys	CGA Arg GTG Val 365 GTG Val	TTT Phe 350 GGG Gly GAT Asp	Asn 335 GAT Asp TTT Phe GCA Ala	GGA Gly ACT Thr GTT Val GAA Glu 400	1246 1294 1342 1390
AGA Arg GTT Val GGA Gly GTT Val 385	TAT Tyr  ACA Thr  AAC Asn 370 TAC Tyr	TYT TGG Trp TCA Ser 355 TAC Tyr ATG Met	TTG Leu 340 ATG Met CAG Gln ATG Met	Asn 325 GAT Asp CTG Leu GAA Glu CTT Leu	GAA Glu TAT Tyr TAT Tyr GCA Ala 390 GAA	Glu TTC Phe CAT His TTC Phe 375 AAC Asn	ATG Met CAC His 360 AGT Ser CAT His	TTT Phe 345 CAT His TTG Leu TTA Leu	Arg 330 GAT Asp GGT Gly GAC Asp ATG Met	Phe GGC Gly ATC Ile ACA Thr CAC His 395	TTC Phe  AAT Asn  GCT Ala 380  AAA Lys	CGA Arg GTG Val 365 GTG Val CTC Leu	TTT Phe 350 GGG Gly GAT Asp	Asn 335 GAT Asp TTT Phe GCA Ala CCA Pro	GGA Gly ACT Thr GTT Val GAA Glu 400 CGG	1246 1294 1342

CCA GTT GAT GAA GGT GGG GTT GGG TTT GAC TAT CGC CTG GCA ATG GCT Pro Val Asp Glu Gly Gly Val Gly Phe Asp Tyr Arg Leu Ala Met Ala ATC CCT GAT AGA TGG ATT GAC TAC CTG AAG AAT AAA GAT GAC TCT GAG Ile Pro Asp Arg Trp Ile Asp Tyr Leu Lys Asn Lys Asp Asp Ser Glu TGG TCG ATG GGT GAA ATA GCG CAT ACT TTG ACT AAC AGG AGA TAT ACT Trp Ser Met Gly Glu Ile Ala His Thr Leu Thr Asn Arg Arg Tyr Thr GAA AAA TGC ATC GCA TAT GCT GAG AGC CAT GAT CAG TCT ATT GTT GGC Glu Lys Cys Ile Ala Tyr Ala Glu Ser His Asp Gln Ser Ile Val Gly GAC AAA ACT ATT GCA TTT CTC CTG ATG GAC AAG GAA ATG TAC ACT GGC Asp Lys Thr Ile Ala Phe Leu Leu Met Asp Lys Glu Met Tyr Thr Gly ATG TCA GAC TTG CAG CCT GCT TCA CCT ACA ATT GAT CGA GGG ATT GCA Met Ser Asp Leu Gln Pro Ala Ser Pro Thr Ile Asp Arg Gly Ile Ala CTC CAA AAG ATG ATT CAC TTC ATC ACA ATG GCC CTT GGA GGT GAT GGC Leu Gln Lys Met Ile His Phe Ile Thr Met Ala Leu Gly Gly Asp Gly TAC TTG AAT TTT ATG GGA AAT GAG TTT GGT CAC CCA GAA TGG ATT GAC Tyr Leu Asn Phe Met Gly Asn Glu Phe Gly His Pro Glu Trp Ile Asp TTT CCA AGA GAA GGG AAC AAC TGG AGC TAT GAT AAA TGC AGA CGA CAG Phe Pro Arq Glu Gly Asn Asn Trp Ser Tyr Asp Lys Cys Arg Arg Gln TGG AGC CTT GTG GAC ACT GAT CAC TTG CGG TAC AAG TAC ATG AAT GCG Trp Ser Leu Val Asp Thr Asp His Leu Arg Tyr Lys Tyr Met Asn Ala TTT GAC CAA GCG ATG AAT GCG CTC GAT GAG AGA TTT TCC TTC CTT TCG Phe Asp Gln Ala Met Asn Ala Leu Asp Glu Arg Phe Ser Phe Leu Ser 

TCG	TCA	AAG	CAG	ATC	GTC	AGC	GAC	ATG	AAC	GAT	GAG	GAA	AAG	GTT	ATT	2014
Ser	Ser	Lys	Gln	Ile	Val	Ser	Asp	Met	Asn	Asp	Glu	Glu	Lys	Val	Ile	
		595				•	600					605				
							GTT									2062
Val		Glu	Arg	Gly	Asp		Val	Phe	Val	Phe		Phe	His	Pro	Lys	
	610					615					620					
AAA	АСТ	TAC	GAG	GGC	TAC	AAA	GTG	GGA	TGC	CAT	ጥጥር	CCT	GGG	מממ	TAC	2110
							Val									2110
625		-1-		2	630			2	-3	635			,	-1-	640	
AGA	GTA	GCC	CTG	GAC	TCT	GAT	GCT	CTG	GTC	TTC	GGT	GGA	CAT	GGA	AGA	2158
Arg	Val	Ala	Leu	Asp	Ser	Asp	Ala	Leu	Val	Phe	Gly	Gly	His	Gly	Arg	
				645					650					655		
							TTC									2206
Val	Gly	His	-	Val	Asp	His	Phe		Ser	Pro	Glu	Gly		Pro	Gly	
			660					665					670			
GTG.	ccc	CAA	N C C	220	ጥጥር	D D C	AAC	ccc	ccc	220	· maa	TTC.	222	CTC.	COTO	2254
							Asn									2254
		675					680	•••				685	2,5	,,,,	Deu	
TCT	CCG	CCC	CGC	ACC	TGT	GTG	GCT	TAT	TAC	CGT	GTA	GAC	GAA	GCA	GGG	2302
Ser	Pro	Pro	Arg	Thr	Cys	Val	Ala	Tyr	Tyr	Arg	Val	Asp	Glu	Ala	Gly	
	690					695					700					
							AAA									2350
	Gly	Arg	Arg	Leu		Ala	Lys	Ala	Glu		Gly	Lys	Thr	Ser		
705					710					715					720	
GCA	CAC	N.C.C	እጥር	CAC	CTC	222	GCT	TCC	n C n	COT	n.c.m	ncc.		CAA	CNG	2200
							Ala									2398
	<b>514</b>	JCI	110	725	Vu.	_,5		JCI	730	nzu	Der	Del	Lys	735	veh	
AAG	GAG	GCA	ACG	GCT	GGT	GGC	AAG	AAG	GGA	TGG	AAG	TTT	GCG	CGG	CAG	2446
Lys	Glu	Ala	Thr	Ala	Gly	Gly	Lys	Lys	Gly	Trp	Lys	Phe	Ala	Arg	Gln	
			740					745					750			
CCA	TCC	GAT	CAA	GAT	ACC	AAA	TGA	AGC	CACG	AGT (	CCTT	GTG/	AG G	ACTG	GACTG	2500
Pro	Ser		Gln	Asp	Thr	Lys	*									
		755					760									
													·m-			
GCT	;CCG(	GCG (	CCT	GTTA(	JT AC	TCC.	rgct(	: TAC	CTGG	ACTA	GCC	3CCG(	JTG (	3CGC(	CCTTGG	2560

119

AACGGTCCTT	TCCTGTAGCT	TGCAGGCGAC	TGGTGTCTCA	TCACCGAGCA	GGCAGGCACT	2620
GCTTGTATAG	CTTTTCTAGA	АТААТААТСА	GGGATGGATG	GATGGTGTGT	ATTGGCTATC	2680
TGGCTAGACG	TGCATGTGCC	CAGTTTGTAT	GTACAGGAGC	AGTTCCCGTC	CAGAATAAAA	2740
AAAAACTTGT	TGGGGGGTTT	TTC				2763

- (2) INFORMATION FOR SEQ ID NO:17:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 823 amino acids
    - (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Leu Cys Leu Val Ser Pro Ser Ser Pro Thr Pro Leu Pro Pro Pro -63 -55 -50

Arg Arg Ser Arg Ser His Ala Asp Arg Ala Ala Pro Pro Gly Ile Ala
-45 -40 -35

Gly Gly Asn Val Arg Leu Ser Val Leu Ser Val Gln Cys Lys Ala
-30 -25 -20

Arg Arg Ser Gly Val Arg Lys Val Lys Ser Lys Phe Ala Thr Ala Ala
-15 -5 1

Thr Val Glu Asp Lys Thr Met Ala Thr Ala Lys Gly Asp Val Asp
5 10 15

His Leu Pro Ile Tyr Asp Leu Asp Pro Lys Leu Glu Ile Phe Lys Asp
20 25 30

His Phe Arg Tyr Arg Met Lys Arg Phe Leu Glu Gln Lys Gly Ser Ile  $35 \hspace{1cm} 40 \hspace{1cm} 45$ 

Glu Glu Asn Glu Gly Ser Leu Glu Ser Phe Ser Lys Gly Tyr Leu Lys
50 55 60 65

Phe Gly Ile Asn Thr Asn Glu Asp Gly Thr Val Tyr Arg Glu Trp Ala

				70				•	75					80	
Pro	Ala	Ala	Gln 85	Glu	Ala	Glu	Leu	Ile 90	Gly	Asp	Phe	Asn	Asp 78	Trp	Asn
Gly	Ala	Asn 100	His	Lys	Met	Glu	Lys 105	Asp	Lys	Phe	Gly	Val 110	Trp	Ser	Ile
Lys	Ile 115	Asp	His	Val	Lys	Gly 120	Lys	Pro	Ala	Ile	Pro 125	His	Asn	Ser	Lys
Val 130	Lys	Phe	Arg	Phe	Leu 135	His	Gly	Gly	Val	Trp 140	Val	Asp	Arg	Ile	Pro 145
Ala	Leu	Ile	Arg	Туг 150	Ala	Thr	Val	Asp	Ala 155	Ser	Lys	Phe	Gly	Ala 160	Pro
Tyr	Asp	Gly	Val 165	His	Trp	Asp	Pro	Pro 170	Ala	Ser	Glu	Arg	Tyr 175	Thr	Phe
Lys	His	Pro 180	Arg	Pro	Ser	Lys	Pro 185	Ala	Ala	Pro	Arg	Ile 190	Tyr	Glu	Ala
His	<b>V</b> al 195	Gly	Met	Ser	Gly	Glu 200	Lys	Pro	Ala	Val	Ser 205	Thr	Tyr	Arg	Glu
Phe 210	Ala	Asp	Asn	Val	Leu 215	Pro	Arg	Ile	Arg	Ala 220	Asn	Asn	Tyr	Asn	Thr 225
Val	Gln	Leu	Met	Ala 230	Val	Met	Glu	His	Ser 235	Tyr	Tyr	Ala	Ser	Phe 240	Gly
Tyr	His	Val	Thr 245	Asn	Phe	Phe	Ala	Val 250	Ser	Ser	Arg	Ser	Gly 255	Thr	Pro
Glu	Asp	Leu 260	Lys	туг	Leu	Val	Asp 265	Lys	Ala	His	Ser	Leu 270	Gly	Leu	Arg
Val	Leu 275	Met	Asp	Val	Val	His 280	Ser	His	Ala	Ser	Asn 285	Asn	Val	Thr	Asp
Gly 290	Leu	Asn	Gly	Tyr	Asp 295	Val	Gly	Gln	Ser	Thr 300	Gln	Glu	Ser	Tyr	Phe 305
His	Ala	Gly	Asp	Arg	Gly	Tyr	His	Lys	Leu	Trp	Asp	Ser	Arg	Leu	Phe

				310					315					320	
Asn	Tyr	Ala	Asn 325	Trp	Glu	Val	Leu	Arg 330	Phe	Leu	Leu	Ser	Asn 335	Leu	Arg
Tyr	Trp	Leu 340	Asp	Glu	Phe	Met	Phe 345	Asp	Gly	Phe	Arg	Phe 350	Asp	Gly	Val
Thr	Ser 355	Met	Leu	Tyr	His	His 360	His	Gly	Ile	Asn	Val 365	Gly	Phe	Thr	Gly
Asn 370	Tyr	Gln	Glu	Tyr	Phe 375	Ser	Leu	Asp	Thr	Ala 380	Val	Asp	Ala	Val	Val 385
Tyr	Met	Met	Leu	Ala 390	Asn	His	Leu	Met	His 395	Lys	Leu	Leu	Pro	Glu 400	Ala
Thr	Val	Val	Ala 405	Glu	Asp	Val	Ser	Gly 410	Met	Pro	Val	Leu	Cys 415	Arg	Pro
Val	Asp	Glu 420	Gly	Gly	Val	Gly	Phe 425	Asp	Tyr	Arg	Leu	Ala 430	Met	Ala	Ile
Pro	Asp 435	Arg	Trp	Ile	Asp	Tyr 440	Leu	Lys	Asn	Lys	Asp 445	Asp	Ser	Glu	Trp
Ser 450	Met	Gly	Glu	Ile	Ala 455	His	Thr	Leu	Thr	Asn 460	Arg	Arg	Tyr	Thr	Glu 465
Lys	Сув	Ile	Ala	Tyr 470	Ala	Glu	Ser	His	Asp 475	Gln	Ser	Ile	Val	Gly 480	Asp
Lys	Thr	Ile	Ala 485	Phe	Leu	Leu	Met	Asp 490	Lys	Glu	Met	Tyr	Thr 495	Gly	Met
Ser	Asp	Leu 500	Gln	Pro	Ala	Ser	Pro 505	Thr	Ile	Asp	Arg	Gly 510	Ile	Ala	Leu
Gln	Lys 515	Met	Ile	His	Phe	Ile 520	Thr	Met	Ala	Leu	Gly 525	Gly	Asp	Gly	Tyr
Leu 530	Asn	Phe	Met	Gly	Asn 535	Glu	Phe	Gly	His	Pro 540	Glu	Trp	Ile	Asp	Phe 545
Pro	Arg	Glu	Gly	Asn	Asn	Trp	Ser	Tyr	Asp	Lys	Cys	Arg	Arg	Gln	Trp

122

Ser Leu Val Asp Thr Asp His Leu Arg Tyr Lys Tyr Met Asn Ala Phe
565 570 575

Asp Gln Ala Met Asn Ala Leu Asp Glu Arg Phe Ser Phe Leu Ser Ser 580 585 590

Ser Lys Gln Ile Val Ser Asp Met Asn Asp Glu Glu Lys Val Ile Val 595 600 605

Phe Glu Arg Gly Asp Leu Val Phe Val Phe Asn Phe His Pro Lys Lys 610 615 620 625

Thr Tyr Glu Gly Tyr Lys Val Gly Cys Asp Leu Pro Gly Lys Tyr Arg 630 635 640

Val Ala Leu Asp Ser Asp Ala Leu Val Phe Gly Gly His Gly Arg Val 645 650 655

Gly His Asp Val Asp His Phe Thr Ser Pro Glu Gly Val Pro Gly Val 660 665 670

Pro Glu Thr Asn Phe Asn Asn Arg Pro Asn Ser Phe Lys Val Leu Ser 675 680 685

Pro Pro Arg Thr Cys Val Ala Tyr Tyr Arg Val Asp Glu Ala Gly Ala 690 695 700 705

Gly Arg Arg Leu His Ala Lys Ala Glu Thr Gly Lys Thr Ser Pro Ala 710 715 720

Glu Ser Ile Asp Val Lys Ala Ser Arg Ala Ser Ser Lys Glu Asp Lys
725 730 735

Glu Ala Thr Ala Gly Gly Lys Lys Gly Trp Lys Phe Ala Arg Gln Pro
740 745 750

Ser Asp Gln Asp Thr Lys \*

- (2) INFORMATION FOR SEQ ID NO:18:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 153 base pairs

123

		(E	3) TY	PE:	nucl	.eic	acid	l								
		(0	;) SI	RANE	EDNE	ss:	sing	le								
		( D	) TC	POLC	GY:	not	rele	vant	:							
	(ii)	MOI	ECUI	LE TY	PE:	CDNA	ı to	mRN#	١.							
(	iii)	нуг	POTHE	ETIC#	AL: N	Ю				•						
	(vi)	ORI	GINA	AL SO	URCE	E:										
		( <i>P</i>	A) OF	RGANI	SM:	Zea	maye	3								
	(ix)	FE <i>F</i>	ATURE	S :												
	` '			AME/I	ŒY:	CDS										
		(E	3) LC	CAT	ON:	1	153									
		·				•										
	(xi)	SEÇ	QUENC	CE DI	SCR	PTIC	ON: S	SEQ :	D NO	:18	:					
							GGC									48
Met	Ala	Thr	Pro		Ala	Val	Gly	Ala		сув	Leu	Leu	Leu	775	Arg	
				765					770					//5		
GCC	GCC	TGG	CCG	GCC	GCC	GTC	GGC	GAC	CGG	GCG	CGC	CCG	CGG	AGG	CTC	91
Ala	Ala	Trp	Pro	Ala	Ala	Val	Gly	Asp	Arg	Ala	Arg	Pro	Arg	Arg	Leu	
			780					785					790			
							TGC									14
Gln	Arg		Leu	Arg	Arg	Arg	Cya	Val	Ala	Glu	Leu		Arg	Glu	Gly	
		795					800					805				

153

(2) INFORMATION FOR SEQ ID NO:19:

CCC CAT ATG Pro His Met 810

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 51 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA  Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80										12	:4						
Gln Arg Val Leu Arg Arg Arg Cys Val Ala Glu Leu Ser Arg Glu Gly 35 40 45  Pro His Met 50  (2) INFORMATION FOR SEQ ID NO:20:  (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1620 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant  (ii) MOLECULE TYPE: cDNA to mRNA  (iii) HYPOTHETICAL: NO  (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGC Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA 11e Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG CTT GGA AAG GAG CAA GCT CGA GCT AAA CTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr		Ala	Thr	Pro		Ala	Val	Gly	Ala		Сув	Leu	Leu	Leu		Arg	
Pro His Met 50  (2) INFORMATION FOR SEQ ID NO:20:  (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1620 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant  (ii) MOLECULE TYPE: cDNA to mRNA  (iii) HYPOTHETICAL: NO  (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA 11e Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr	Ala	Ala	Trp		Ala	Ala	Val	Gly		Arg	Ala	Arg	Pro	_	Arg	Leu	
(2) INFORMATION FOR SEQ ID NO:20:  (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1620 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant  (ii) MOLECULE TYPE: cDNA to mRNA  (iii) HYPOTHETICAL: NO  (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr	Gln	Arg		Leu	Arg	Arg	Arg		Val	Ala	Glu	Leu		Arg	Glu	Gly	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 1620 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: double  (D) TOPOLOGY: not relevant  (ii) MOLECULE TYPE: cDNA to mRNA  (iii) HYPOTHETICAL: NO  (ix) FEATURE:  (A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA 11e Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr	Pro		Met														
(A) LENGTH: 1620 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: not relevant  (ii) MOLECULE TYPE: cDNA to mRNA  (iii) HYPOTHETICAL: NO  (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA 1le Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr	(2)	INFO	ORMA:	rion	FOR	SEQ	ID 1	NO: 20	0:								
(iii) HYPOTHETICAL: NO  (ix) FEATURE:  (A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG 48 Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA 1le Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr		(i)	(1 (1	A) LI B) T' C) S'	engti (PE : [Rani	nuc: DEDNI	620 ) leic ESS:	acio doul	pain d ble								
(ix) FEATURE:  (A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG 48 Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA 1le Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAC GAG CAA GCT CGA GCT AAA GTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr		(ii) MOLECULE TYPE: cDNA to mRNA															
(A) NAME/KEY: CDS (B) LOCATION: 11620  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA 96 Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA 144 Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr		(iii) HYPOTHETICAL: NO															
TGC GTC GCG GAG CTG AGC AGG GAG GAC CTC GGT CTC GAA CCT GAA GGG  Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly  55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA  Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln  70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA  Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr		(A) NAME/KEY: CDS															
Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly 55 60 65  ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA  Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr		(xi	) SE(	QUEN	CE DI	ESCR:	IPTI(	ON:	SEQ :	ID N	0:20	:					
ATT GCT GAA GGT TCC ATC GAT AAC ACA GTA GTT GTG GCA AGT GAG CAA  1le Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln  70  75  80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr																	48
Ile Ala Glu Gly Ser Ile Asp Asn Thr Val Val Val Ala Ser Glu Gln 70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr	Cys	Val	Ala		Leu	Ser	Arg	Glu		Leu	Gly	Leu	Glu		Glu	Gly	
70 75 80  GAT TCT GAG ATT GTG GTT GGA AAG GAG CAA GCT CGA GCT AAA GTA ACA Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr																	96
Asp Ser Glu Ile Val Val Gly Lys Glu Gln Ala Arg Ala Lys Val Thr	Ile	Ala		Gly	Ser	Ile	Asp		Thr	Val	Val	Val		Ser	Glu	Gln	
																	144
	Asp		Glu	Ile	Val	Val		Lys	Glu	Gln	Ala		Ala	Lys	Val	Thr	

CAA AGC ATT GTC TTT GTA ACC GGC GAA GCT TCT CCT TAT GCA AAG TCT 192

Gln 100	Ser	Ile	Val	Ph	Val 105	Thr	Gly	Glu	Ala	Ser 110	Pro	Tyr	Ala	Lys	Ser 115	
			_				GGT Gly									240
							GTA Val									288
							GCA Ala 155									336
							CAT His									384
							TTT Phe	_								432
							AAG Lys									480
							TAT Tyr									528
	_						TAT Tyr 235									576
							GTG Val									624
							GAC Asp									672
							GAG Glu									720

	280	285	290
	Glu Trp Tyr Gly	GCT CTG GAG TGG GTA TTG Ala Leu Glu Trp Val Phe 300 30!	Pro Glu
		AAG GGT GAG GCA GTT AA? Lys Gly Glu Ala Val Ası 320	
		CGA ATC GTG ACT GTC AG Arg Ile Val Thr Val Se 335	
		GAA GGT GGA CAG GGC CTG Glu Gly Gly Gln Gly Leo 350	• • • • • • • • • • • • • • • • • • • •
		TTA AAC GGA ATT GTA AA Leu Asn Gly Ile Val Ası 365	
	Trp Asn Pro Ala	ACA GAC AAA TGT ATC CCC Thr Asp Lys Cys Ile Pro 380 38	Cys His
	_	AAG GCC AAA TGT AAA GG Lys Ala Lys Cys Lys Gl 400	
_		AGG CCT GAT GTT CCT CTC Arg Pro Asp Val Pro Let 415	
		AAA GGC ATT GAT CTC AT Lys Gly Ile Asp Leu Ile 430	
		GAT GTT CAA TTT GTC ATG Asp Val Gln Phe Val Met 445	
	Glu Leu Glu Asp	TGG ATG AGA TCT ACA GAG Trp Met Arg Ser Thr Glu 460 46	ı Ser Ile

127

												GTT Val				1296
		470					475					480				
								_				CCA				1344
HIS	485	IIe	Thr	Ala	GIÀ	490	Asp	116	Leu	Leu	мет 495	Pro	ser	Arg	Pne	
CDD	CCT	ጥርጥ	GGT	CTC	ጥልል	CAG	ሮሞል	ጥልጥ	GCT	ልጥር	CAG	TAT	GGC	מיזמ	GTT	1392
												Tyr				1372
500		-1-	4		505					510					515	
								~~~								
												GTG				1440
Pro	vai	vaı	птв	520	Int	GIY	GIY	Leu	525	Asp	Inr	Val	GIU	530	rne	
				320					323					330		
AAC	CCT	TTC	GGT	GAG	AAT	GGA	GAG	CAG	GGT	ACA	GGG	TGG	GCA	TTC	GCA	1488
Asn	Pro	Phe	Gly	Glu	Asn	Gly	Glu	Gln	Gly	Thr	Gly	Trp	Ala	Phe	Ala	
			535					540					545			
ccc	CTA	ACC	ACA	GAA	AAC	ATG	TTT	GTG	GAC	ATT	GCG	AAC	TGC	AAT	ATC	1536
Pro	Leu	Thr	Thr	Glu	Asn	Met	Phe	Val	Asp	Ile	Ala	Asn	Cys	Asn	Ile	
		550					555					560				
TAC	ATA	CAG	GGA	ACA	CAA	GTC	CTC	CTG	GGA	AGG	GCT	AAT	GAA	GCG	AGG	1584
Tyr	Ile	Gln	Gly	Thr	Gln	Val	Leu	Leu	Gly	Arg	Ala	Asn	Glu	Ala	Arg	
	565					570					575					
(1) E	ome			com.	G A G	cmc	007	003	mac	000	ma =					1600
								CCA Pro			TGA *					1620
580	*ul	~y =	ar 9	u	585	*ul	JIY		~y 5	590						

# (2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 540 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Cys Val Ala Glu Leu Ser Arg Glu Asp Leu Gly Leu Glu Pro Glu Gly

1				5					10					15	
Île	Ala	Glu	Gly 20	Ser	Ile	Asp	Asn	Thr 25	Val	Val	Val	Ala	Ser 30	Glu	Glr
Asp	Ser	Glu 35	Ile	Val	Val	Gly	Lys 40	Glu	Gln	Ala	Arg	Ala 45	Lys	Val	Thi
Gln	Ser 50	Ile	Val	Phe	Val	Thr 55	Gly	Glu	Ala	Ser	Pro 60	Tyr	Ala	Lys	Sei
31y 65	Gly	Leu	Gly	Asp	Val 70	Сув	Gly	Ser	Leu	Pro 75	Val	Ala	Leu	Ala	<b>A</b> 1a
Arg	Gly	His	Arg	Val 85	Met	Val	Val	Met	Pro 90	Arg	Tyr	Leu	Asn	Gly 95	Thi
Ser	Asp	Lys	Asn 100	Tyr	Ala	Asn	Ala	Phe 105	Tyr	Thr	Glu	Lys	His 110	Ile	Arq
Ile	Pro	Сув 115	Phe	Gly	Gly	Glu	His 120	Glu	Val	Thr	Phe	Phe 125	His	Glu	Туі
Arg	Asp 130	Ser	Val	Asp	Trp	Val 135	Phe	Val	Asp	His	Pro 140	Ser	Tyr	His	Arg
Pro 145	Gly	Asn	Leu	Tyr	Gly 150	Asp	Lys	Phe	Gly	Ala 155	Phe	Gly	Asp	Asn	Gl:
Phe	Arg	Tyr	Thr	Leu 165	Leu	Cys	Tyr	Ala	Ala 170	Cys	Glu	Ala	Pro	Leu 175	Ile
Leu	Glu	Leu	Gly 180	Gly	Tyr	Ile	Tyr	Gly 185	Gln	Asn	Cys	Met	Phe 190	Val	Va:
Asn	Asp	Trp 195	His	Ala	Ser	Leu	Val 200	Pro	Val	Leu	Leu	Ala 205	Ala	Lys	Ту
Arg	Pro 210	Tyr	Gly	Val	Tyr	Lys 215	Asp	Ser	Arg	Ser	lle 220	Leu	Val	Ile	Hi
Asn 225	Leu	Ala	His	Gln	Gly 230	Val	Glu	Pro	Ala	Ser 235	Thr	Tyr	Pro	Asp	Le:
Gly	Leu	Pro	Pro	Glu	Trp	Tyr	Gly	Ala	Leu	Glu	Trp	Val	Phe	Pro	Glı

				245					250					255	
Trp	Ala	Arg	Arg 260	His	Ala	Leu	Asp	Lys 265	Gly	Glu	Ala	Val	Asn 270	Phe	Leu
ГÀв	Gly	Ala 275	Val	Val	Thr	Ala	Asp 280	Arg	Ile	Val	Thr	Val 285	Ser	Lys	Gly
Tyr	Ser 290	Trp	Glu	Val	Thr	Thr 295	Ala	Glu	Gly	Gly	Gln 300	Gly	Leu	Asn	Glu
Leu 305	Leu	Ser	Ser	Arg	Lys 310	Ser	Val	Leu	Asn	Gly 315	Ile	Val	Asn	Gly	11e 320
Asp	Ile	Asn	Asp	Trp 325	Asn	Pro	Ala	Thr	Asp 330	Lys	Сув	Ile	Pro	Cys 335	His
Tyr	Ser	Val	Asp 340	Asp	Leu	Ser	Gly	Lys 345	Ala	Lys	Cys	Lys	Gly 350	Ala	Leu
Gln	Lys	Glu 355	Leu	Gly	Leu	Pro	11e 360	Arg	Pro	Asp	Val	Pro 365	Leu	Ile	Gly
Phe	Ile 370	Gly	Arg	Leu	Asp	Tyr 375	Gln	Lys	Gly	Ile	Asp 380	Leu	Ile	Gln	Leu
Ile 385	Ile	Pro	Asp	Leu	Met 390	Arg	G <u>l</u> u	Asp	Val	Gln 395	Phe	Val	Met	Leu	Gly 400
Ser	Gly	yab	Pro	Glu 405	Leu	Glu	Asp	Trp	Met 410	Arg	Ser	Thr	Glu	Ser 415	Ile
Phe	Lys	Asp	Lys 420	Phe	Arg	Gly	Trp	Val 425	Gly	Phe	Ser	Val	Pro 430	Val	Ser
His	Arg	Ile 435	Thr	Ala	Gly	Cys	Asp 440	Ile	Leu	Leu	Met	Pro 445	Ser	Arg	Phe
Glu	Pro 450	Cys	Gly	Leu	Asn	Gln 455	Leu	Tyr	Ala	Met	Gln 460	Tyr	Gly	Thr	Val
Pro 465	Val	Val	His	Ala	Thr 470	Gly	Gly	Leu	Arg	Asp 475	Thr	Val	Glu	Asn	Phe 480
Agn	Pro	Phe	Glv	Glu	Asn	G) v	Glu	Gln	Glv	Thr	Glv	Trn	Ala	Phe	Ala

PCT/US97/17555 WO 98/14601

130

485 490 495

Pro Leu Thr Thr Glu Asn Met Phe Val Asp Ile Ala Asn Cys Asn Ile 500 505

Tyr Ile Gln Gly Thr Gln Val Leu Leu Gly Arg Ala Asn Glu Ala Arg 520 525 515

His Val Lys Arg Leu His Val Gly Pro Cys Arg \* 535 530 540

- (2) INFORMATION FOR SEQ ID NO:22:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 30 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: other nucleic acid
    - (A) DESCRIPTION: /desc = "Oligonucleotide"
  - (iii) HYPOTHETICAL: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GTGGATCCAT GGCGACGCCC TCGGCCGTGG

- (2) INFORMATION FOR SEQ ID NO:23:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 35 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: other nucleic acid
    - (A) DESCRIPTION: /desc = "Oligonucleotide"

131	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:	
CTGAATTCCA TATGGGGCCC CTCCCTGCTC AGCTC	35
(2) INFORMATION FOR SEQ ID NO:24:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 36 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
<pre>(ii) MOLECULE TYPE: other nucleic acid     (A) DESCRIPTION: /desc = "Oligonucleotide"</pre>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:	
CTCTGAGCTC AAGCTTGCTA CTTTCTTTCC TTAATG	36
(2) INFORMATION FOR SEQ ID NO:25:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 29 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
<pre>(ii) MOLECULE TYPE: other nucleic acid      (A) DESCRIPTION: /desc = "Oligonucleotide"</pre>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:	
GTCTCCGCGG TGGTGTCCTT GCTTCCTAG	29
(2) INFORMATION FOR SEQ ID NO:26:	

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 base pairs(B) TYPE: nucleic acid

PCT/US97/17555

132

- (C) STRANDEDNESS: doubl
- (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TGCGTCGCGG AGCTGAGCAG GGAGGTCTCC GCGGTGGTGT CCTTGCTTCC TAG

53

- (2) INFORMATION FOR SEQ ID NO:27:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 8 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Cys Val Ala Glu Leu Ser Arg Glu 1 5

- (2) INFORMATION FOR SEQ ID NO:28:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 16 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: double
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: cDNA to mRNA

133

(xi)	SEQUENCE	DESCRIPTION:	SEQ	ΙD	NO:28:
	-		_		

AGAGAGAGA AGAGAG

16

- (2) INFORMATION FOR SEQ ID NO:29:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 36 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: double
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: cDNA to mRNA
  - (iii) HYPOTHETICAL: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

# AAGAAGAAGA AGAAGAAGAA GAAGAAGAAG AAGAAG

36

- (2) INFORMATION FOR SEQ ID NO:30:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 18 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: double
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: cDNA to mRNA
  - (iii) HYPOTHETICAL: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

## ААААААА ААААААА

- (2) INFORMATION FOR SEQ ID NO:31:
  - (i) SEQUENCE CHARACTERISTICS:

134

- (A) LENGTH: 11 bas pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Oligonucleotide"
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

AGATAATGCA G

11

- (2) INFORMATION FOR SEQ ID NO:32:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 10 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: other nucleic acid
    - (A) DESCRIPTION: /desc = "Oligonucleotide"
  - (iii) HYPOTHETICAL: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

AACAATGGCT 10

- (2) INFORMATION FOR SEQ ID NO:33:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 56 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: p ptide

(iii) HYPOTHETICAL: NO

WO 98/14601

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Ala Ser Ser Met Leu Ser Ser Ala Ala Val Ala Thr Arg Thr Asn 1 5 10 15

135

PCT/US97/17555

Pro Ala Gln Ala Ser Met Val Ala Pro Phe Thr Gly Leu Lys Ser Ala 20 25 30

Ala Phe Pro Val Ser Arg Lys Gln Asn Leu Asp Ile Thr Ser Ile Ala 35 40 45

Ser Asn Gly Gly Arg Val Gln Cys 50 55

- (2) INFORMATION FOR SEQ ID NO:34:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 58 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: peptide
  - (iii) HYPOTHETICAL: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Met Ala Pro Thr Val Met Met Ala Ser Ser Ala Thr Ala Thr Arg Thr 1 5 10 15

Asn Pro Ala Gln Ala Ser Ala Val Ala Pro Phe Gln Gly Leu Lys Ser 20 25 30

Thr Ala Ser Leu Pro Val Ala Arg Arg Ser Ser Arg Ser Leu Gly Asn

136

35 40 45

Val Ala Ser Asn Gly Gly Arg Ile Arg Cys
50 55

- (2) INFORMATION FOR SEQ ID NO:35:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 58 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: peptide
  - (iii) HYPOTHETICAL: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Met Ala Gln Ile Leu Ala Pro Ser Thr Gln Trp Gln Met Arg Ile Thr 1 5 10 15

Lys Thr Ser Pro Cys Ala Thr Pro Ile Thr Ser Lys Met Trp Ser Ser 20 25 30

Leu Val Met Lys Gln Thr Lys Lys Val Ala His Ser Ala Lys Phe Arg 35 40 45

Val Met Ala Val Asn Ser Glu Asn Gly Thr 50 55

- (2) INFORMATION FOR SEQ ID NO:36:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 74 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: peptide
  - (iii) HYPOTHETICAL: NO

137

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Met Ala Ala Leu Ala Thr Ser Gln Leu Val Ala Thr Arg Ala Gly His 1 5 10 15

Gly Val Pro Asp Ala Ser Thr Phe Arg Arg Gly Ala Ala Gln Gly Leu 20 25 30

Arg Gly Ala Arg Ala Ser Ala Ala Ala Asp Thr Leu Ser Met Arg Thr
35 40 45

Ser Ala Arg Ala Ala Pro Arg His Gln Gln Ala Arg Arg Gly Gly 50 55 60

Arg Phe Pro Phe Pro Ser Leu Val Val Cys 65 70

- (2) INFORMATION FOR SEQ ID NO:37:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 39 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: not relevant
  - (ii) MOLECULE TYPE: peptide
  - (iii) HYPOTHETICAL: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Met Ala Thr Pro Ser Ala Val Gly Ala Ala Cys Leu Leu Leu Ala Arg

1 5 10 15

Xaa Ala Trp Pro Ala Ala Val Gly Asp Arg Ala Arg Pro Arg Arg Leu 20 25 30

Gln Arg Val Leu Arg Arg Arg

PCT/US97/17555

20

138

### **CLAIMS**

- 1. A hybrid polypeptide comprising:
  - (a) a starch-encapsulating region;
  - (b) a payload polypeptide fused to said starch-encapsulating region.
- The hybrid polypeptide of claim 1 wherein said payload polypeptide consists of not more than three different types of amino acids selected from the group consisting of: Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val.
- 3. The hybrid polypeptide of claim 1 wherein said payload polypeptide is a biologically active polypeptide.
  - 4. The hybrid polypeptide of claim 3 wherein said payload polypeptide is selected from the group consisting of hormones, growth factors, antibodies, peptides, polypeptides, enzyme immunoglobulins, dyes and biologically active fragments thereof.
- 5. The hybrid polypeptide of claim 1 wherein said starch-encapsulating region is the starch-encapsulating region of an enzyme selected from the group consisting of soluble starch synthase I, soluble starch synthase II, soluble starch synthase III, granule-bound starch synthase, branching enzyme I, branching enzyme IIa, branching enzyme IIBb and glucoamylase polypeptides.
  - 6. The hybrid polypeptide of claim 1 comprising a cleavage site between said starchencapsulating region and said payload polypeptide.
    - 7. A recombinant nucleic acid molecule encoding the hybrid polypeptide of claim 1.

8. The recombinant molecule of claim 7 which is a DNA molecule comprising control sequences adapted for expression of said starch-encapsulating region and said payload polypeptide in a bacterial host.

- 9. The recombinant molecule of claim 7 which is a DNA molecule comprising control sequences adapted for expression of said starch-encapsulating region and said payload polypeptide in a plant host.
  - 10. The recombinant molecule of claim 9 wherein said control sequences are adapted for expression of said starch-encapsulating region and said payload polypeptide in a monocot.
- 10 11. The recombinant molecule of claim 9 wherein said control sequences are adapted for expression of said starch-encapsulating region and said payload polypeptide in a dicot.
  - 12. The recombinant molecule of claim 9 wherein said control sequences are adapted for expression of said starch-encapsulating region and said payload polypeptide in an animal host.
- 13. An expression vector comprising the recombinant molecule of claim 7.
  - 14. A cell transformed to comprise the recombinant molecule of claim 7, capable of expressing said DNA molecule.
  - 15. The cell of claim 14 which is a plant cell.
  - 16. A plant regenerated from the cell of claim 15.
- 20 17. A seed from the plant of claim 16 capable of expressing said recombinant molecule.
  - 18. A modified starch derived from cells of claim 14 comprising said payload polypeptide.

- 19. A method of targeting digestion of a payload polypeptide to a selected site in the digestive system of an animal comprising feeding said animal a modified starch of claim 18 comprising said payload polypeptide in a matrix of a starch selected to be digested in the selected site in the digestive tract.
- 5 20. A method of producing a pure payload polypeptide from a hybrid polypeptide of claim 1 comprising:
  - (a) transforming a host organism with DNA encoding said hybrid polypeptide;
  - (b) allowing said hybrid polypeptide to be expressed in said host;
  - (c) isolating said hybrid polypeptide from said host;
- 10 (d) purifying said payload polypeptide from said hybrid polypeptide.




FIG. 1A




FIG. 1B

SUBSTITUTE SHEET (RULE 26)

2/12




FIG. 2A




FIG. 2B

SUBSTITUTE SHEET (RULE 26)

3/12




FIG. 3A




FIG. 3B

**SUBSTITUTE SHEET (RULE 26)** 




FIG. 5

SUBSTITUTE SHEET (RULE 26)




FIG. 6




FIG. 7A





FIG. 7B






FIG. 7D

WO 98/14601 PCT/US97/17555




FIG. 7E




FIG. 7F

WO 98/14601 PCT/US97/17555




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B

## INTERNATIONAL SEARCH REPORT

Inter onal Application No

			31, 11,000	
A. CLASSI IPC 6	IFICATION OF SUBJECT MATTER C12N15/82 C12N9/10 C12N15 C12N1/21 A01H5/00	/54 C12N15/62 C1	201/68	
According to	o International Patent Classification(IPC) or to both national classi	fication and IPC		
B. FIELDS	SEARCHED			
Minimum do IPC 6	ocumentation searched (classification system followed by classification C12N C12Q A01H	ation symbols)		
Documenta	ition searched other than minimumdocumentation to the extent tha	t such documents are included in the field	ds searched	
Electronic d	data base consulted during the international search (name of data	base and, where practical, search terms t	used)	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category '	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.	
X	CHEN, L., ET AL.: "IMPROVED ADSORPTION TO STARCH OF A BETA-GALACTOSIDASE FUSION PROTEIN CONTAINING THE STARCH-BINDING DOMAIN FROM ASPERGILLUS GLUCOAMYLASE" BIOTECHNOLOGY PROGRESS, vol. 7, 1991,		1,3-5,7, 8,13,14, 20	
Y	pages 225-229, XP002056940 see the whole document		6	
X Y	KUSNADI, A.R., ET AL.: "FUNCT STARCH-BINDING DOMAIN OF ASPERG GLUCOAMYLASE I IN ESCHERICHIA C GENE, vol. 127, 1993, pages 193-197, XP002056413 see the whole document	ILLUS	1,3-5,7, 8,13,14, 20	
	<del></del>	-/		
X Furt	her documents are listed in the continuation of box C.	Patent family members are li	sted in annex.	
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publicationdate of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but		or priority date and not in conflict cited to understand the principle invention  "X" document of particular relevance; cannot be considered novel or cinvolve an inventive step when the step of the comment of particular relevance; cannot be considered to involve document is combined with one ments, such combination being in the art.  "8," document member of the same p.	X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  3" document member of the same patent family	
	actual completion of theinternational search	Date of mailing of the internations 10/03/1998	al search report	
	mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (-31-70) 340-3016	Authorized officer Holtorf, S		

1

## INTERNATIONAL SEARCH REPORT

Inter: nal Application No
PCT/US 97/17555

Category Citation of document, with indication, where appropriate, of the relevant passages  X BROEKHUIJSEN M P ET AL: "SECRETION OF HETEROLOGOUS PROTEINS BY ASPERGILLUS NIGER: PRODUCTION OF ACTIVE HUMAN INTERLEUKIN-6 IN A PROTEASE-DEFICIENT MUTANT BY KEX2-LIKE PROCESSING OF A	Relevant to claim No.  1,3-7, 13,14,20
X BROEKHUIJSEN M P ET AL: "SECRETION OF HETEROLOGOUS PROTEINS BY ASPERGILLUS NIGER: PRODUCTION OF ACTIVE HUMAN INTERLEUKIN-6 IN A PROTEASE-DEFICIENT	1,3-7,
HETEROLOGOUS PROTEINS BY ASPERGILLUS NIGER: PRODUCTION OF ACTIVE HUMAN INTERLEUKIN-6 IN A PROTEASE-DEFICIENT	1,3-7, 13,14,20
GLUCOAMYLASE-HI66 FUSION PROTEIN"  JOURNAL OF BIOTECHNOLOGY,  vol. 31, 1993,  pages 135-145, XP002048588	
Y see the whole document	6
A MU-FORSTER, C., ET AL .: "PHYSICAL ASSOCIATION OF STARCH BIOSYNTHETIC ENZYMES WITH STARCH GRANULES OF MAIZE ENDOSPERM" PLANT PHYSIOLOGY, vol. 111, 1996, pages 821-829, XP002056414 see the whole document	1-20
GODDIJN O J M ET AL: "PLANTS AS BIOREACTORS" TRENDS IN BIOTECHNOLOGY, vol. 13, no. 9, 1 September 1995, pages 379-387, XP002005043 see page 384, right-hand column; figure 3	1-20